

STATE OF COLORADO

John W. Hickenlooper, Governor
Christopher E. Urbina, MD, MPH
Executive Director and Chief Medical Officer

Dedicated to protecting and improving the health and environment of the people of Colorado

4300 Cherry Creek Dr. S. Laboratory Services Division
Denver, Colorado 80246-1530 8100 Lowry Blvd.
Phone (303) 692-2000 Denver, Colorado 80230-6928
Located in Glendale, Colorado (303) 692-3090

<http://www.cdphe.state.co.us>



Colorado Department
of Public Health
and Environment

September 22, 2011

Terrence Reis, Deputy Director
Division of Materials Safety and State Agreements
Office of Federal and State Materials and
Environmental Management Programs
U.S. Nuclear Regulatory Commission
T8-E24
Washington, D.C. 20555-0001

Dear Mr. Reis:

Enclosed is a copy of the draft proposed revisions to the Colorado Radiological Health Rules (*Colorado Rules and Regulations Pertaining to Radiation Control*, 6 CCR 1007-1, Part 7, Use of Radionuclides in the Healing Arts). This document has been opened for a 30 day public comment period that began on September 19, 2011. The proposed regulation changes (provided in its entirety) are identified by strike-out text (deletions) and bold text (additions).

The regulatory changes are in response to certain NRC Regulatory Action Tracking System (RATs) changes (Attachment 1). Other changes were made to the regulations based upon programmatic needs which resulted in some additional language being added to Part 7. Further changes were a result of formatting changes to maintain consistency within the document and other Colorado regulatory parts and to correct minor typographical errors. Additionally, as we are uncertain that credit has been given for meeting certain RATs items, we have identified RATs items that are already in effect from the prior revisions of Part 7 in 2005 and 2006.

We believe that the proposed revision satisfies the compatibility and health and safety categories established in the Office of Federal and State Materials and Environmental Management Programs (FSME) Procedure SA-200.

If you have any questions, please feel free to contact me at 303/692-3423 or James Jarvis of my staff at 303/692-3454 or james.jarvis@state.co.us.

Sincerely,

Stephen F. Tarlton, Manager
Radiation Program
Hazardous Materials and Waste Management Division

Enclosures: As stated above

RATs ID	CFR Title	State Section
	ITEMS FOR RATS 2006-1	
2006-1 §35.2	Definitions for: Authorized Medical Physicist; Authorized Nuclear Pharmacist; Authorized User; and Radiation Safety Officer	Section 7.2 NOTE: A part of these RATs items were incorporated into the 2005/2006 revisions of Part 7. Due to the structure of Colorado regulations, these definitions contain equivalent references as they refer to the specific appendix for the applicable requirements. Additionally, each separate appendices of Part 7 includes provisions for experienced authorized persons equivalent to §35.57, the recentness of training requirements contained in §35.59, and also make reference to other appendices, as appropriate.
2006-1 §35.49	Suppliers for sealed sources or devices for medical use.	Section 7.14 – it is recognized that 35.49(b) was not incorporated into Draft 2 of Part 7. This provision will be incorporated into Part 7 prior to final approval.
2006-1 §35.50	Training for Radiation Safety Officer.	Appendix 7A (See 7A1.2(2)(b))
2006-1 §35.51	Training for an Authorized medical physicist.	Appendix 7B (See 7B1.1(2)(b), and 7B2.3)
2006-1 §35.59	Recentness of training.	Appendices A through M. Each appendix incorporates (repeats) a section equivalent to 35.59.
2006-1 §35.100	Use of unsealed byproduct material for uptake, dilution, and excretion studies for which a written directive is not required.	Section 7.30.1.2, and 7.30.2. (Also see Appendix 7D, where sections equivalent to 35.100(b)(2) are referenced.)
2006-1 §35.190	Training for uptake, dilution, and excretion studies.	Section 7.30.2, and Appendix 7D (7D2, 7D3.1(2), and 7D3.2), where sections equivalent to 35.190 (b), (c)(1)(ii), and (c)(2) are referenced.
2006-1 §35.200	Use of unsealed byproduct material for imaging and localization studies for which a written directive is not required.	Section 7.32.1.2, 7.32.2 and Appendix 7E.
2006-1 §35.290	Training for imaging and localization studies.	Section 7.32.2, and Appendix 7E (7E1.1(1), 7E2, 7E3.1(2), and 7E3.2), where sections equivalent to 35.290 are referenced.

2006-1 §35.300	Use of unsealed byproduct material for which a written directive is required.	Section 7.36.1.2, and 7.36.2, 7.36.3, and 7.36.4 (Also see Appendix 7F, 7G, 7H, and 7I).
2006-1 §35.390	Training for use of unsealed byproduct material for which a written directive is required.	Appendix 7F, 7G, 7H, and 7I where sections equivalent to 35.390 are referenced.
2006-1 §35.392	Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries).	Appendix 7G.
2006-1 §35.394	Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries).	Appendix 7H.
2006-1 §35.396	Training for the parenteral administration of unsealed byproduct material requiring a written directive.	Appendix 7I.
2006-1 §35.490	Training for use of manual brachytherapy sources.	Appendix 7K.
2006-1 §35.491	Training for ophthalmic use of strontium-90.	Appendix 7L.
2006-1 §35.491	Training for use of remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.	Appendix 7M.
ITEMS FOR RATS 2007-1		
2007-1 §35.75(a)	Release of individuals containing unsealed byproduct material or implants containing byproduct material	Section 7.26.1.
2007-1 §35.92	Decay-in-storage.	Section 7.29. (Note – the phrase “...or equal to...” was omitted from the current proposed draft, but will be added to this paragraph prior to final approval).
2007-1 §35.190	Training for uptake, dilution, and excretion studies.	Appendix 7D. (Note – the phrase “...and experience...” was omitted from the current proposed draft, but will be added to this paragraph prior to final approval).
2007-1 §35.290	Training for imaging and localization studies.	Appendix 7E. (Note – the phrase “...of training and experience...” was omitted from the current proposed draft, but will be added to paragraph 7E1.1 prior to final approval).
ITEMS FOR RATS 2007-3		
2007-3 §35.11	License required.	Section 7.3
2007-3	Determination of dosages of unsealed byproduct	Sections 7.18.2.2(2), and 7.18.3.

§35.63	material for medical use.	
2007-3 §35.100 (a), and (b)	Use of unsealed byproduct material for uptake, dilution, and excretion studies for which a written directive is not required	Section 7.30.1.
2007-3 §35.200 (a), and (b)	Use of unsealed byproduct material for imaging and localization studies for which a written directive is not required.	Section 7.32.1.
2007-3 §35.204 (a)	Permissible molybdenum-99 concentrations	These requirements are effectively implemented in existing Part 7, Section 7.33.1. which became effective in 2005.
2007-3 §35.300 (a) & (b)	Use of unsealed byproduct material for which a written directive is required	Section 7.36.1.
	ITEMS FOR RATS 2009-1	
2009-1 § 35.50	Training for Radiation Safety Officer	Appendix 7A.
2009-1 § 35.51	Training for an authorized medical physicist.	Appendix 7B
2009-1 § 35.57	Training for experienced Radiation Safety Officer, teletherapy or medical physicist, authorized medical physicist, authorized user, nuclear pharmacist, and authorized nuclear pharmacist.	Appendices A-M.
2009-1 § 35.190	Training for uptake, dilution, and excretion studies.	Appendix 7D (See also RATs 2007-1)
2009-1 § 35.290	Training for imaging and localization studies.	Appendix 7E (See also RATs 2007-1)
2009-1 § 35.390	Training for use of unsealed byproduct material for which a written directive is required.	Appendices 7F, 7G, 7H, and 7I
2009-1 § 35.392	Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries).	Appendix 7G.
2009-1 § 35.394	Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries).	Appendix 7H.
2009-1 § 35.396	Training for the parenteral administration of unsealed byproduct material requiring a written directive.	Appendix 7I.
2009-1 § 35.490	Training for use of manual brachytherapy sources.	Appendix 7K.
2009-1 § 35.690	Training for use of remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.	Appendix 7M.

DRAFT 2 –9/15/2011

DEPARTMENT OF PUBLIC HEALTH AND ENVIRONMENT

Hazardous Materials and Waste Management Division

RADIATION CONTROL - USE OF RADIONUCLIDES IN THE HEALING ARTS

6 CCR 1007-1 Part 07

[Editor's Notes follow the text of the rules at the end of this CCR Document.]

PART 7: USE OF RADIONUCLIDES IN THE HEALING ARTS

USE OF RADIONUCLIDES IN THE HEALING ARTS

7.1 Purpose and Scope.

7.1.1 Authority

Rules and regulations set forth herein are adopted pursuant to the provisions of sections 25-1-108, 25-1.5-101(1)(l), and 25-11-104, CRS.

7.1.2 Basis and Purpose.

A statement of basis and purpose accompanies this part and changes to this part. A copy may be obtained from the Department.

7.1.3 Scope.

This part establishes requirements and provisions for the production, preparation, compounding and use of radionuclides in the healing arts and for issuance of licenses authorizing the medical use of this material. These requirements and provisions provide for the protection of the public health and radiation safety of workers, the general public, patients, and human research subjects. The requirements and provisions of this part are in addition to, and not in substitution for, others in these regulations.

7.1.4 Applicability.

The requirements and provisions of these regulations apply to applicants and licensees subject to this part unless specifically exempted.

7.1.5 Published Material Incorporated by Reference.

Published material incorporated in Part 7 by reference is available in accord with 1.4.

7.2 Definitions.

As used in this part, these terms have the definitions set forth as follows:

~~"Accredited institution" means a teaching facility for nuclear medicine technology or radiation therapy technology whose standards are accepted by the United States Department of Education.~~

"Address of use" means the building(s) identified on the license where radioactive material may be produced, prepared, received, used or stored.

Comment [JJ1]: 8/17/11 - This term was previously used in Appendix 7N, but is no longer used in Part 7 (and was deleted in a prior revision), and is therefore deleted.

DRAFT 2 –9/15/2011

34 "Area of use" means a portion of an address of use that has been set aside for the purpose of
35 producing, preparing, receiving, using, or storing radioactive material.

36 "Authorized medical physicist" (AMP) means an individual who meets the requirements of
37 Appendix 7B.

38 "Authorized nuclear pharmacist" (ANP) means a pharmacist who meets the requirements of
39 Appendix 7C.

40 "Authorized user" (AU) means a physician, dentist, or podiatrist who meets the training and
41 experience requirements for a use of radioactive material specified in the applicable appendix of
42 Appendix 7D through Appendix 7M.

43 "Brachytherapy" means a method of radiation therapy in which plated, embedded, activated, or
44 sealed sources are utilized to deliver a radiation dose at a distance of up to a few centimeters, by
45 surface, intracavitary, intraluminal or interstitial application.

46 "Brachytherapy source" means a radioactive source or a manufacturer-assembled source train or
47 a combination of these sources that is designed to deliver a therapeutic dose within a distance of
48 a few centimeters.

49 "Client" means, for mobile medical service, the person for whom, or in conjunction with whom,
50 medical service is provided.

51 "Client's address" means the address of use for the purpose of providing mobile medical service
52 in accordance with 7.27.

53 "Dedicated –check source" means a radioactive source that is used to assure the consistent
54 response of a radiation detection or measurement device over several months or years.

Comment [JJ2]: JJ 6/22/2011: removal of extra spaces – correction of typographical error.

55 "Dentist" means an individual licensed by a State or Territory of the United States, the District of
56 Columbia or the Commonwealth of Puerto Rico to practice dentistry.

57 "Diagnostic clinical procedures manual" means a collection of written procedures that describes
58 each method (and other instructions and precautions) by which the licensee performs diagnostic
59 clinical procedures; where each diagnostic clinical procedure has been approved by the
60 authorized user and includes the radiopharmaceutical, dosage, and route of administration, or in
61 the case of sealed sources for diagnosis, the procedure.

62 "HDR", see high dose-rate remote afterloader.

63 "High dose-rate remote afterloader" (HDR) means a device that remotely delivers a dose rate in
64 excess of 12 gray (1200 rad) per hour at the treatment site.

65 "LDR", see low dose-rate remote afterloader.

66 "Low dose-rate remote afterloader" (LDR) means a device that remotely delivers a dose rate of
67 less than or equal to 2 gray (200 rad) per hour at the treatment site (at the specified distance).

68 "Management" means the chief executive officer, or other individual having the authority to
69 manage, direct, or administer the licensee's activities, or such person's' delegate(s).

70 "Manual brachytherapy" means a type of therapy in which brachytherapy sources are manually
71 applied or inserted.

DRAFT 2 –9/15/2011

- 72 "MDR", see medium dose-rate remote afterloader".
- 73 "Medical institution" means an organization in which two or more medical disciplines are
74 practiced.
- 75 "Medical use" means, for the purposes of Part 7, the intentional internal or external administration
76 of radioactive material or the radiation from radioactive material to patients or human research
77 subjects under the supervision of an authorized user.
- 78 "Medium dose-rate remote afterloader" (MDR) means a device that remotely delivers a dose rate
79 of greater than 2 gray (200 rad), but less than, or equal to, 12 gray (1200 rad) per hour at the
80 treatment site (at the specified distance).
- 81 "Misadministration" means an event that meets the criteria in 7.21.
- 82 "Mobile medical service" means the transportation of radioactive material to, or its medical use
83 at, the client's address and/or a temporary job site.
- 84 "Nuclear medicine technologist" (NMT) means an individual who meets the requirements of
85 Appendix 7N and who under the supervision of an authorized user prepares or administers
86 radioactive drugs to patients or human research subjects, or performs *in vivo* or *in vitro*
87 measurements for medical purposes.
- 88 "Nuclear medicine technology" means the science and art of *in vivo* and *in vitro* detection and
89 measurement of radioactivity and the administration of radioactive drugs to patients or human
90 research subjects for diagnostic and therapeutic purposes.
- 91 "Output" means the exposure rate, dose rate, or a quantity related in a known manner to these
92 rates, from a brachytherapy source, or a teletherapy, remote afterloader, or gamma stereotactic
93 radiosurgery unit, for a specified set of exposure conditions.
- 94 "Patient intervention" means actions by the patient or human research subject, whether
95 intentional or unintentional, such as dislodging or removing treatment devices or prematurely
96 terminating the administration.
- 97 "PDR", see pulsed dose-rate remote afterloader.
- 98 "Pharmacist" means an individual licensed by a State or Territory of the United States, the District
99 of Columbia or the Commonwealth of Puerto Rico to practice pharmacy. (See also Authorized
100 nuclear pharmacist)
- 101 "Physician" means an individual licensed by a State or Territory of the United States, the District
102 of Columbia or the Commonwealth of Puerto Rico to prescribe drugs in the practice of medicine.
- 103 "Podiatrist" means an individual licensed by a State or Territory of the United States, the District
104 of Columbia or the Commonwealth of Puerto Rico to practice podiatry.
- 105 "Preceptor" means an individual who provides, directs or verifies training and experience required
106 for an individual to become an a radiation safety officer, an authorized user, an authorized
107 medical physicist, an authorized nuclear pharmacist, a nuclear medicine technologist, or a
108 radiation therapy technologist (see appendices 7A through 7O).
- 109 "Prescribed dosage" means the specified activity or range of activity of a radioactive drug as
110 documented in:

DRAFT 2 –9/15/2011

- 111 (1) A written directive as specified in 7.11; or
- 112 (2) Accordance with the directions of the authorized user for procedures performed
- 113 pursuant to 7.30, 7.32, or 7.36.
- 114 "Prescribed dose" means:
- 115 (1) For gamma stereotactic radiosurgery, the total dose as documented in the written
- 116 directive;
- 117 (2) For teletherapy, the total dose and dose per fraction as documented in the written
- 118 directive;
- 119 (3) For manual brachytherapy, either the total source strength and exposure time or the
- 120 total dose, as documented in the written directive; or
- 121 (4) For remote brachytherapy afterloaders, the total dose and dose per fraction as
- 122 documented in the written directive.
- 123 "Pulsed dose-rate remote afterloader" (PDR) means a special type of remote afterloading device
- 124 that uses a single source capable of delivering dose rates (at the specified distance) in the "high
- 125 dose-rate" range, but:
- 126 (1) Is approximately one-tenth of the activity of typical high dose-rate remote afterloader
- 127 sources; and
- 128 (2) Is used to simulate the radiobiology of a low dose rate treatment by inserting the
- 129 source for a given fraction of each hour.
- 130 "Radiation safety officer" (RSO) means, for the purposes of Part 7, an individual who has
- 131 demonstrated sufficient knowledge to apply radiation protection regulations appropriately, who in
- 132 accord with 7.7 has been assigned such responsibility by the licensee, and who meets the
- 133 requirements in Appendix 7A.
- 134 "Radiation therapy technologist" (RTT) means an individual who meets the requirements of
- 135 Appendix 7O and is under the supervision of an authorized user to perform procedures and apply
- 136 radiation emitted from sealed radioactive sources to human beings for therapeutic purposes.
- 137 "Radiation therapy technology" means the science and art of applying radiation emitted from
- 138 sealed radioactive sources to patients or human research subjects for therapeutic purposes.
- 139 "Radioactive drug" means any chemical compound containing radioactive material that may be
- 140 used on or administered to patients or human research subjects as an aid in the diagnosis,
- 141 treatment, or prevention of disease or other abnormal condition.
- 142 "Sealed source" means radioactive material that is permanently bonded or fixed in a capsule or
- 143 matrix designed to prevent release and dispersal of the radioactive material under the most
- 144 severe conditions which are likely to be encountered in normal use and handling.
- 145 "Sealed Source and Device Registry" means the national registry that contains the registration
- 146 certificates maintained by the Nuclear Regulatory Commission, that summarize the radiation
- 147 safety information for the sealed sources and devices and describe the licensing and use
- 148 conditions approved for the product.

DRAFT 2 –9/15/2011

"Stereotactic radiosurgery" means the use of external radiation in conjunction with a stereotactic guidance device to precisely deliver a dose to a treatment site.

"Structured educational program" means an accredited educational program designed to impart particular knowledge and practical education through interrelated studies and supervised training.

"Teletherapy", as used in this part, means a method of radiation therapy in which collimated gamma rays are delivered at a distance from the patient or human research subject.

"Temporary job site", as used in Part 7, means a location where mobile medical services are confined to the mobile unit not at a licensed address of use.

"Therapeutic dosage" means a dosage of unsealed radioactive material that is intended to deliver a radiation dose to a patient or human research subject for palliative or curative treatment.

"Therapeutic dose" means a radiation dose delivered from a sealed source containing radioactive material to a patient or human research subject for palliative or curative treatment.

"Treatment site" means the anatomical description of the tissue intended to receive a radiation dose, as described in a written directive.

"Trunnion" means a support bar sometimes used as a bearing instead of a socket.

"Type of use" means use of radioactive material as specified under 7.30, 7.32, 7.36, 7.40, 7.42, 7.48 or 7.62.

"Unit dosage" means a dosage that:

(1) Is obtained or prepared in accordance with the regulations for uses described in 7.30, 7.32, or 7.36; and

(2) Is to be administered as a single dosage to a patient or human research subject without any further manipulation of the dosage after it is initially prepared.

"Written directive" means an authorized user's written order for the administration of radioactive material or radiation from radioactive material to a specific patient or human research subject, as specified in 7.11.

GENERAL REGULATORY REQUIREMENTS

7.3 License Required.

7.3.1 A person shall manufacture, produce, prepare, acquire, receive, possess, use, or transfer radioactive material for medical use only in accordance with a specific license issued by the Department, an Agreement State or NRC, or as allowed in 7.3.2 or 7.3.3.

7.3.1.1 Unless prohibited by license condition, an individual may receive, possess, use, or transfer radioactive material in accordance with the regulations in this part under the supervision of an authorized user as provided in 7.10.

7.3.1.2 Unless prohibited by license condition, an individual may prepare unsealed radioactive material for medical use in accordance with the regulations in this part under the supervision of an authorized nuclear pharmacist or authorized user as provided in 7.10.

DRAFT 2 –9/15/2011

186 7.3.2 Provisions for **the protection of Human** Research ~~Involving Human~~ Subjects.

Comment [O3]: Section title changed to be consistent with 10 CFR 35.6

187 A licensee may conduct research involving human subjects using radioactive material **provided**
188 ~~that~~**under the following conditions:**

189 7.3.2.1 ~~The~~**For** research ~~is~~ conducted, funded, supported, or regulated by a federal agency
190 which has implemented ~~The f~~**F**ederal ~~p~~**P**olicy for the ~~P~~**P**rotection of ~~h~~**H**uman ~~s~~**S**ubjects
191 ~~(Federal Policy), the licensee shall;~~

192 ~~(1)~~ **Obtain prior informed consent from the human subjects; and**

Comment [JJ4]: Additional clarifying language added to this section is based on feedback of Radioactive Materials Unit staff for consistency with NRC Part 35.6 and SSR G.4.

Whether a research project does or does not involve a federal agency, the requirements are effectively the same. The current language is unclear to the requirements when a federal agency is not involved and is the basis for the proposed change.

193 **(2) Obtain prior review and approval of the research activities by an "Institutional**
194 **Review Board" in accordance with the meaning of these terms as defined and**
195 **described in the Federal Policy; or**

196 **7.3.2.2 For research not conducted, funded, supported, or regulated by a federal agency**
197 **which has implemented the Federal Policy, then:**

198 **(1) The licensee shall apply for and receive a specific amendment to its Department**
199 **license before conducting such research. The amendment request shall include a**
200 **written commitment that the licensee will, before conducting research:**

201 **a. Obtain prior informed consent from the human subjects; and**

Formatted: Indent: Left: 1"

202 **b. Obtain prior review and approval of the research activities by an**
203 **"Institutional Review Board" in accordance with the meaning of these**
204 **terms as defined and described in the Federal Policy;**

205 7.3.2.3 A licensee not authorized pursuant to 3.11 shall apply for and receive approval of a
206 specific amendment to its Department license before conducting such research;

207 ~~7.3.2.3 At a minimum, the licensee shall obtain prior informed consent from the human subjects~~
208 ~~and obtain prior review and approval of the research activities by an "Institutional Review~~
209 ~~Board" in accordance with the meaning of these terms as defined and described in~~
210 ~~federal policy for the protection of human subjects;~~

Comment [JJ5]: This paragraph is deleted as it has been combined into 7.3.2.1, and 7.3.2.2 above.

211 7.3.2.4 The research involving human subjects authorized in 7.3.2.4 shall be conducted using
212 radioactive material authorized for medical use in the license; and

213 7.3.2.5 Nothing in 7.3.2 relieves licensees from complying with the other requirements in Part 7.

214 7.3.3 Nothing in this part relieves the licensee from complying with applicable FDA, other federal, and
215 state requirements governing radioactive drugs or devices.

216 7.3.4 Application for License, Amendment, or Renewal.

217 7.3.4.1 An application shall be signed by the applicant's or licensee's management.

218 7.3.4.2 An application for a **new or renewal** license for medical use of radioactive material as
219 described in 7.30, 7.32, 7.36, 7.40, 7.42, 7.48 or 7.62 must be made by:

Comment [JJ6]: A stakeholder-licensee made the recommendation that we clarify that renewal licenses also require an application and other documents. Other changes to this section are to clarify and to aid in understanding the requirements.

220 (1) Filing an original ~~and one~~ copy of Department Form R-12 **(7C)**, and

Comment [JJ7]: It is proposed that this language requiring a second copy of an application be deleted, since most often it is not needed.

DRAFT 2 –9/15/2011

- (2) Submitting procedures required by **Form R-12 (7C), and** -7.12, 7.15, 7.51, 7.58, 7.59, and 7.61, - as applicable, **and any other procedures applicable to the licensed activities.**

Comment [JJ8]: Additional language added to clarify that other documents pertinent to licensed activities are needed for new or renewal licenses.

7.3.4.3 A request for a license amendment ~~or renewal~~ must be made by:

- (1) Submitting an original **amendment request** ~~and one copy~~ in letter format.

Comment [JJ9]: It is proposed that this language requiring a second copy of an application be deleted, since most often it is not needed.

- (2) Submitting procedures required by 7.12, 7.15, 7.51, 7.58, 7.59, and 7.61, as applicable, **and any other procedures applicable to the licensed activities.**

Comment [JJ10]: Additional language added to clarify that other documents pertinent to licensed activities are needed for license amendments.

7.3.4.4 In addition to the requirements in 7.3.4.2 and 7.3.4.3, an application for a **new** license, **renewal license**, or amendment for medical use of radioactive material as described in 7.62 must also include information regarding any radiation safety aspects of the medical use of the material that is not addressed in 7.1 through 7.29, as well as any specific information on:

- (1) Radiation safety precautions and instructions;
- (2) Training and experience of proposed users;
- (3) Methodology for measurement of dosages or doses to be administered to patients or human research subjects; and
- (4) Calibration, maintenance, and repair of instruments and equipment necessary for radiation safety.

7.3.4.5 The applicant or licensee shall also provide any other information requested by the Department in its review of the application.

7.3.4.6 An applicant that satisfies the requirements specified in 3.11 may apply for a Type A specific license of broad scope.

7.3.5 Mobile Medical Service Administrative Requirements.

7.3.5.1 The Department shall license mobile medical services or clients of such services. The mobile medical service shall be licensed if the service receives, uses or possesses radioactive material. The client of the mobile medical service shall be licensed if the client receives or possesses radioactive material to be used by a mobile medical service.

7.3.5.2 Mobile medical service licensees shall obtain a letter signed by the management of each location where services are rendered that authorizes use of radioactive material at the client's address of use. This letter shall clearly delineate the authority and responsibility of both the client and the mobile medical service. If the client is licensed, the letter shall document procedures for notification, receipt, storage and documentation of transfer of radioactive material delivered to the client's address for use by the mobile medical service.

7.3.5.3 A mobile medical service shall not have radioactive material delivered directly from the manufacturer or the distributor to the client, unless the client has a license allowing possession of the radioactive material. Radioactive material delivered to the client shall be received and handled in conformance with the client's license.

7.3.5.4 A mobile medical service shall inform the client's management who is on site at each client's address of use at the time that radioactive material is being administered.

DRAFT 2 –9/15/2011

- 261 7.3.5.5 A licensee providing mobile medical services shall retain the letter required in 7.3.5.2
262 for 3 years after the last provision of service.
- 263 7.3.5.6 A mobile medical service licensee shall, at a minimum, maintain the following documents
264 on each mobile unit:
- 265 (1) The current operating and emergency procedures;
 - 266 (2) A copy of the license;
 - 267 (3) Copies of the letter required by 7.3.5.2;
 - 268 (4) Current calibration records for each survey instrument and diagnostic equipment or
269 dose delivery device in use; and
 - 270 (5) Survey records covering uses associated with the mobile unit during, at a minimum,
271 the preceding 30 calendar days.
- 272 7.3.5.7 The mobile medical service shall designate and manage each area of use in the client's
273 facility as a restricted area while radioactive material is present. For each location where
274 radioactive materials will be routinely used, the licensee shall provide to the Department:
- 275 (1) A diagram of the location of use, including information about the placement of
276 required postings; and
 - 277 (2) Calculation(s) or survey(s) results that demonstrate compliance with applicable dose
278 limits in 4.14 and 4.15 at the location of use.
- 279 7.3.5.8 The mobile medical service shall ensure that:
- 280 (1) Supervision by an authorized user is in accordance with 7.10.1;
 - 281 (2) Radiation exposures to the client's personnel working in the client facility are:
 - 282 (a) Below the dose limits to members of the public listed in 4.14; or
 - 283 (b) The client's personnel are instructed as described in 10.3 and monitored for
284 exposure in accordance with 4.18 unless the licensee can demonstrate
285 that 4.18 does not apply.
- 286 7.3.5.9 A mobile medical service licensee shall maintain all records required by Parts 4 and 7 of
287 these regulations at a location within the Department's jurisdiction that is:
- 288 (1) A single address of use:
 - 289 (a) Identified as the records retention location; and
 - 290 (b) Staffed at all reasonable hours by individual(s) authorized to provide the
291 Department with access for purposes of inspection; or
 - 292 (2) When no address of use is identified on the license for records retention, the mobile
293 unit:
 - 294 (a) Identified in the license; and

DRAFT 2 –9/15/2011

- 295 (b) Whose current client's address of use and area of use schedule is reported
296 to the Department.
- 297 7.3.6 A licensee possessing a Type A specific license of broad scope for medical use is exempt from:
- 298 7.3.6.1 The provisions of 7.3.4.4 regarding the need to file an amendment to the license for
299 medical uses of radioactive material as described in 7.62;
- 300 7.3.6.2 The provisions of 7.4.2 regarding the need to file an amendment before permitting
301 anyone to work as an authorized user, an authorized nuclear pharmacist or an authorized
302 medical physicist under the license;
- 303 7.3.6.3 The provisions of 7.4.5 regarding additions to or changes in the areas of use at the
304 addresses specified in the license;
- 305 7.3.6.4 The provisions of 7.5.1 regarding notification to the Department for new authorized users,
306 new authorized nuclear pharmacists and new authorized medical physicists;
- 307 7.3.6.5 The provisions of 7.14 regarding suppliers for sealed sources.
- 308 7.3.7 The Department may, upon application of any interested person or upon its own initiative, grant
309 such exemptions from the regulations in Part 7 as it determines are authorized by law and will not
310 endanger life or property or the common defense and security and are otherwise in the public
311 interest.
- 312 **7.4 License Amendments.**
- 313 A licensee shall apply for and shall have received a license amendment before the licensee:
- 314 7.4.1 Receives, prepares, or uses radioactive material for a type of use that is permitted under this part
315 but that is not authorized on the licensee's current license issued pursuant to this part;
- 316 7.4.2 Permits anyone to work as an authorized user, authorized medical physicist, or an authorized
317 nuclear pharmacist under the license in accordance with the training and experience
318 requirements specified in:
- 319 7.4.2.1 The applicable appendix of Appendix 7D through Appendix 7M for an authorized user for
320 a type of use of radioactive material;
- 321 7.4.2.2 Appendix 7B for an authorized medical physicist;
- 322 7.4.2.3 Appendix 7C for an authorized nuclear pharmacist; and
- 323 7.4.3 Changes a Radiation Safety Officer, except as provided in 7.7.6;
- 324 7.4.4 Receives radioactive material in excess of the amount or in a different physical or chemical form
325 than is authorized on the license;
- 326 7.4.5 Adds to or changes the area(s) of use or address(es) of use identified in the application or on the
327 license, except as specified in 7.5.2.4; and
- 328 7.4.6 Changes statements, representations, and procedures which are incorporated into the license; or
- 329 7.4.7 Releases licensed facilities for unrestricted use.

DRAFT 2 –9/15/2011

330 **7.5 Notifications; Maintenance of Records.**

331 7.5.1 A licensee shall provide to the Department required documentation of adequate radiation safety
332 training and experience under Appendix 7B for each authorized medical physicist pursuant to
333 7.4.2, under Appendix 7C for each authorized nuclear pharmacist, and under the applicable
334 appendix of Appendix 7D through Appendix 7M for each individual authorized user.

335 7.5.2 A licensee shall notify the Department in writing within 30 days after:

336 7.5.2.1 An authorized user, authorized medical physicist, authorized nuclear pharmacist, or
337 Radiation Safety Officer permanently discontinues performance of duties under the
338 license or has a name change;

339 7.5.2.2 The licensee's mailing address changes;

340 7.5.2.3 The licensee's name changes, but the name change does not constitute a transfer of
341 control of the license as described in 3.15.2 of these regulations; or

342 7.5.2.4 The licensee has added to or changed the areas where radioactive material is used in
343 accordance with 7.30 and 7.32.

344 **7.5.3 Maintenance of Records.**

345 Each record required by this part must be legible throughout the retention period specified by
346 each Department regulation. The record may be the original, a reproduced copy, or a microform
347 provided that the copy or microform is authenticated by authorized personnel and the microform
348 is capable of producing a clear copy throughout the required retention period. The record may
349 also be stored in electronic media with the capability for producing legible, accurate, and
350 complete records during the required retention period. Records such as letters, drawings, and
351 specifications must include all pertinent information such as stamps, initials, and signatures. The
352 licensee shall maintain adequate safeguards against tampering with and loss of records.

353 **7.6 License Issuance.**

354 7.6.1 The Department shall issue a license for the medical use of radioactive material if:

355 7.6.1.1 The applicant has filed Department Form R-12 in accordance with the instructions in
356 7.3.4;

357 7.6.1.2 The applicant has paid any applicable fee;

358 7.6.1.3 The applicant meets the requirements of Part 3 of these regulations; and

359 7.6.1.4 The Department finds the applicant equipped and committed to observe the safety
360 standards established by the Department in these regulations for the protection of the
361 public health and safety.

362 7.6.2 The Department shall issue a license for mobile services if the applicant:

363 7.6.2.1 Meets the requirements in 7.6.1, and in particular 7.3.5; and

364 7.6.2.2 Assures that individuals to whom radioactive drugs or radiation from implants containing
365 radioactive material will be administered may be released following treatment in
366 accordance with 7.26.

367 **ADDITIONAL OVERALL REQUIREMENTS**

368 **7.7 Authority and Responsibilities for the Radiation Protection Program**

369 7.7.1 In addition to the radiation protection program requirements of 4.5 of these regulations, a licensee's
370 management must approve in writing:

371 7.7.1.1 Requests for license application, renewal, or amendments before submittal to the
372 Department;

373 7.7.1.2 Any individual before allowing that individual to work as an authorized user, authorized
374 nuclear pharmacist or authorized medical physicist; and

375 7.7.1.3 Radiation protection program changes that do not require a license amendment and are
376 permitted under 7.7.

377 7.7.2 A licensee's management shall appoint a Radiation Safety Officer (RSO), who agrees in writing to
378 be responsible for implementing the radiation safety program. The licensee, through the RSO,
379 shall ensure that radiation safety activities are being performed in accordance with approved
380 procedures and regulatory requirements.

381 7.7.3 A licensee shall establish in writing the authority, duties, and responsibilities of the Radiation Safety
382 Officer, and of the Alternate RSO, if required.

383 7.7.4 A licensee shall provide the Radiation Safety Officer sufficient authority, organizational freedom,
384 time, resources, and management prerogative, to:

385 7.7.4.1 Identify radiation safety problems;

386 7.7.4.2 Initiate, recommend, or provide corrective actions;

387 7.7.4.3 Stop unsafe operations; and

388 7.7.4.4 Verify implementation of corrective actions.

389 7.7.5 A licensee shall retain a record of actions taken pursuant to 7.7.1, 7.7.2 and 7.7.3 for 5 years,
390 including:

391 7.7.5.1 A summary of the actions taken (and a signature of licensee management) in accordance
392 with 7.7.1;

393 7.7.5.2 A signed copy of the RSO's agreement (including the signature of the RSO and licensee
394 management) to be responsible for implementing the radiation safety program, as
395 required by 7.7.2; and

396 7.7.5.3 A current copy of the authorities, duties and responsibilities of the RSO as required by
397 7.7.3.

398 7.7.6 For up to sixty days each year, a licensee may permit an authorized user or an individual qualified
399 to be a radiation safety officer to function as a temporary Radiation Safety Officer and to perform
400 the functions of a Radiation Safety Officer, as provided in 7.7.4, provided the licensee takes the
401 actions required in 7.7.2, 7.7.3, 7.7.4 and 7.7.5. A licensee may simultaneously appoint more
402 than one temporary RSO, if needed, to ensure that the licensee has a temporary RSO that
403 satisfies the requirements to be an RSO for each of the different uses of radioactive material
404 permitted by the license.

DRAFT 2 –9/15/2011

405 **7.8 Radiation Safety Committee.**

406 7.8.1 Licensees that are authorized for ~~two~~**one** or more different types of radioactive material use under
407 7.36, 7.42, 7.48, 7.62 or two or more types of units under 7.48 shall establish a Radiation Safety
408 Committee to oversee all uses of radioactive material permitted by the license.

409 7.8.2 The Committee shall:

410 7.8.2.1 Include:

- 411 (1) An authorized user of each type of use permitted by the license;
412 (2) The Radiation Safety Officer
413 (3) A representative of the nursing service
414 (4) A representative of management who is neither an authorized user nor a Radiation
415 Safety Officer; and
416 (5) Other members as the licensee deems appropriate.

417 7.8.2.2 Meet as necessary, but at a minimum shall meet at intervals not to exceed 6 months.

418 7.8.2.3 Maintain minutes of each meeting, including:

- 419 (1) The date of the meeting;
420 (2) Members present;
421 (3) Members absent; and
422 (4) Summary of deliberations and discussions.

423 **7.9 Radiation Protection Program Changes.**

424 7.9.1 A licensee may revise its radiation protection program without Department approval if:

425 7.9.1.1 The revision does not require an amendment under 7.4;

426 7.9.1.2 The revision is in compliance with the regulations and the license;

427 7.9.1.3 The revision has been reviewed and approved by the Radiation Safety Officer, licensee
428 management and licensee's Radiation Safety Committee (if applicable); and

429 7.9.1.4 The affected individuals are instructed on the revised program before the changes are
430 implemented.

431 7.9.2 A licensee shall retain a record of each change for 5 years, including

432 7.9.2.1 A copy of the old and new procedures;

433 7.9.2.2 The effective date of the change; and

434 7.9.2.2 The signature of the licensee management that reviewed and approved the change.

Comment [JJ11]: Radioactive Materials Unit staff believe that Radiation Safety Committees provide a valuable mechanism to review and share radiation safety exposure and related information and are proposing to lower the threshold at which Committee meetings are required. The proposed change is expected to impact only a small number of facilities. This would require a few facilities that do not already hold RSC meetings to hold them 2x per year to review and have oversight of the radiation safety program.

This change would not impact facilities that use only diagnostic radioactive materials (e.g. cardiology only facilities, sentinel node facilities, or smaller programs performing only diagnostic procedures.)

DRAFT 2 –9/15/2011

435 **7.10 Supervision.**

436 7.10.1 A licensee that permits the receipt, possession, use, or transfer of radioactive material by an
437 individual under the supervision of an authorized user as allowed by 7.3.2 shall:

438 7.10.1.1 In addition to the requirements of 10.3 of these regulations, instruct the supervised
439 individual in the licensee's written radiation protection procedures, written directive
440 procedures, regulations of Part 7, and license conditions with respect to the use of
441 radioactive material; and;

442 7.10.1.2 Require the supervised individual to follow the instructions of the supervising authorized
443 user for medical uses of radioactive material, written radiation protection procedures,
444 written directive procedures, regulations of Part 7, and license conditions with respect to
445 the medical use of radioactive material.

446 7.10.2 A licensee that permits the preparation of radioactive material for medical use by an individual
447 under the supervision of an authorized nuclear pharmacist or physician who is an authorized
448 user, as allowed by 7.3.3, shall:

449 7.10.2.1 **In addition to the requirements of 10.3,** instruct the supervised individual in the
450 preparation of radioactive material for medical use, as appropriate to that individual's use
451 of radioactive material; and

452 7.10.2.2 Require the supervised individual to follow the instructions of the supervising authorized
453 user or authorized nuclear pharmacist regarding the preparation of radioactive material
454 for medical use, the written radiation protection procedures, the regulations of Part 7, and
455 license conditions.

456 7.10.3 Unless physical presence as described in other sections of Part 7 is required, a licensee who
457 permits supervised activities under 7.10.1 and 7.10.2 shall require an authorized user to be
458 immediately available ~~(by telephone within ten minutes)~~ to communicate with the supervised
459 individual, ~~and able to be physically present within one hour, unless~~ otherwise authorized by the
460 Department with prior written approval.; and

461 7.10.4 A licensee who permits supervised activities under 7.10.1 and 7.10.2 is responsible for the acts
462 and omissions of the supervising authorized user and supervised individual(s).

463 **7.11 Written Directives.**

464 7.11.1 A written directive must be dated and signed by an authorized user, including the signatory's
465 printed or typed name, prior to administration of:

466 7.11.1.1 I-131 sodium iodide greater than 1.11 MBq (30 µCi), or

467 7.11.1.2 Any therapeutic dosage of radioactive material, or

468 7.11.1.3 Any therapeutic dose of radiation from radioactive material.

469 7.11.2 The written directive must contain the patient or human research subject's name and the
470 following:

471 7.11.2.1 For an administration of a dosage of radioactive drug containing radioactive material,
472 the name of the radioactive drug containing radioactive material, dosage, and route of
473 administration;

Comment [JJ12]: Added language to be consistent with 10 CFR 35.27.

[This change arose as a result of NRC review of 2010 CRCPD SSR Part G.]

NRC Compatibility = H&S

Comment [JJ13]: This proposed change will reduce the regulatory requirements associated with the availability of an authorized user. Over time, Radioactive Materials Unit staff have determined that the current requirement for physical presence within one hour has not been significantly beneficial from a radiation safety perspective.

DRAFT 2 –9/15/2011

474 7.11.2.2 For gamma stereotactic radiosurgery, the total dose, treatment site, and values for the
475 number of target coordinate settings per treatment for each anatomically distinct
476 treatment site;

Comment [JJ14]: Language added consistent with 10 CFR 35.40(b)(3).

[This change arose as a result of NRC review and comments on 2010 CRCPD SSR Draft Part G.]

NRC Compatibility = H&S

477 7.11.2.3 For teletherapy, the total dose, dose per fraction, number of fractions, and treatment
478 site;

479 7.11.2.4 For high dose rate remote afterloading brachytherapy, the radionuclide, treatment site,
480 dose per fraction, number of fractions, and total dose; or

481 7.11.2.5 For all other brachytherapy, including LDR, MDR, and PDR:

482 (1) Prior to implantation: treatment site, the radionuclide, and dose; and

483 (2) After implantation but prior to completion of the procedure: the radioisotope,
484 treatment site, number of sources, and total source strength and exposure time
485 (or the total dose).

486 7.11.3 If, because of the emergent nature of the patient's condition, a delay in order to provide a written
487 directive would jeopardize the patient's health, an oral directive will be acceptable, provided that
488 the information contained in the oral directive is documented as soon as possible in writing in the
489 patient's record and a written directive is prepared within 48 hours of the oral directive.

490 7.11.4 A written revision to an existing written directive may be made provided that the revision is dated
491 and signed by an authorized user prior to the administration of the dosage of radioactive drug
492 containing radioactive material, the brachytherapy dose, the gamma stereotactic radiosurgery
493 dose, the teletherapy dose, or the next fractional dose.

494 7.11.5 If, because of the patient's condition, a delay in order to provide a written revision to an existing
495 written directive would jeopardize the patient's health, an oral revision to an existing written
496 directive will be acceptable, provided that the oral revision is documented as soon as possible in
497 the patient's record and a revised written directive is signed by the authorized user within 48
498 hours of the oral revision.

499 7.11.6 The licensee shall retain a copy of each written directive and/or written revision to an existing
500 written directive for 3 years.

501 **7.12 Procedures for Administrations Requiring a Written Directive.**

502 7.12.1 For any administration requiring a written directive, the licensee shall develop, implement, and
503 maintain written procedures to provide high confidence that:

504 7.12.1.1 The patient's or human research subject's identity is verified before each administration;
505 and

506 7.12.1.2 Each administration is in accordance with the written directive.

507 7.12.2 The procedures required by 7.12.1 must, at a minimum, address the following items that are
508 applicable for the licensee's use of radioactive material:

509 7.12.2.1 Verifying the identity of the patient or human research subject;

510 7.12.2.2 Verifying that the specific details of the administration are in accordance with the
511 treatment plan, if applicable, and the written directive;

DRAFT 2 –9/15/2011

- 512 7.12.2.3 Checking both manual and computer-generated dose calculations; and
- 513 7.12.2.4 Verifying that any computer-generated dose calculations are correctly transferred into
- 514 the consoles of therapeutic medical units authorized by 7.48

515 **7.13 Duties of Authorized User and Authorized Medical Physicist.**

- 516 7.13.1 A licensee shall assure that only authorized users for the type of radioactive material used:
- 517 7.13.1.1 Prescribe the radiopharmaceutical dosage and/or dose to be administered through the
- 518 issuance of a written directive or reference to the diagnostic clinical procedures manual;
- 519 and
- 520 7.13.1.2 Direct, as specified in 7.10 and 7.12, or in license conditions, the administration of
- 521 radioactive material for medical use to patients or human research subjects;
- 522 7.13.1.3 Prepare and administer, or supervise the preparation and administration of radioactive
- 523 material for medical use, in accordance with 7.3.2, 7.3.3 and 7.10;

524 ~~7.13.1.4 Perform the final interpretation of the results of tests, studies, or treatments.~~

525 7.13.2 A licensee shall assure that only authorized medical physicists perform, as applicable:

- 526 **7.13.2.1 Measurements and calculations as described in 7.41;**
- 527 7.13.2.2 Full calibration measurements as described in 7.54, 7.55, and 7.56;
- 528 7.13.2.3 Periodic spot checks as described in 7.58, 7.59 and 7.61; and
- 529 7.13.2.4 Radiation surveys as described in 7.57.

530 **7.14 Suppliers for Sealed Sources or Devices for Medical Use.**

531 For medical use, a licensee shall use only:

- 532 7.14.1 Sealed sources or devices initially manufactured, labeled, packaged, and distributed in
- 533 accordance with a license issued pursuant to these regulation or the equivalent regulations of
- 534 another Agreement State, a Licensing State or the NRC; and
- 535 7.14.2 Teletherapy sources manufactured and distributed in accordance with a license issued pursuant
- 536 to these regulations, or the equivalent regulations of another Agreement State, a Licensing State,
- 537 or the NRC.

538 **SPECIFIC REQUIREMENTS**

539 **7.15 Quality Control of Diagnostic Equipment.**

540 **7.15.1** Each licensee shall establish written quality control procedures for all diagnostic equipment used

541 for radionuclide studies.

542 **7.15.2** As a minimum, quality control procedures and frequencies shall be:

- 543 **7.15.2.1** Those recommended by equipment manufacturers; or
- 544 **7.15.2.2** Procedures which have been approved by the Department.

Comment [JJ15]: This provision is deleted at the recommendation of Radiation Control Program Staff, as it is not consistent with 10 CFR Part 35. This proposed change will no longer require an authorized user to perform the final interpretation of scans and related procedures.

The training requirements for authorized users in the Appendices of this part do not reference interpretation of tests, studies, or treatments or require any specific training related to interpretation. It is believed that retaining this provision may cross, at least in part, into the practice of medicine which is not within the purview of the Department, nor directly radiation safety related.

Comment [JJ16]: This new provision was added at the request of a licensee medical physicist. This does not add any new requirement – it repeats and clarifies/re-states what is already required by 7.41.

Comment [JJ17]: Numbers added to this section for ease of use.

DRAFT 2 –9/15/2011

545 **7.15.3** The licensee shall conduct quality control of diagnostic equipment in accordance with written
546 procedures.

547 **7.15.4 A licensee shall retain a record of each quality control test required by the written quality**
548 **control procedures for 3 years.**

549 **7.16 Possession, Use, and Testing of Instruments to Measure the Activity of Unsealed**
550 **Radioactive Materials.**

551 7.16.1 For direct measurements performed in accordance with 7.18, a licensee shall possess and use
552 instrumentation to measure the activity of unsealed radioactive materials prior to administration to
553 each patient or human research subject.

554 7.16.2 A licensee shall ~~test~~ **calibrate** the instrumentation required in 7.16.1 in accordance with nationally
555 recognized standards or the manufacturer's instructions.

556 7.16.3 **In addition to the calibration** ~~The tests~~ required in 7.16.2, **the licensee** shall at a minimum
557 **include also perform** tests for constancy, linearity, ~~accuracy~~ and geometry dependence, as
558 appropriate to demonstrate proper operation of the ~~instrument~~.

559 7.16.4 A licensee shall retain a record of each instrument ~~test calibration~~ **and test** required by 7.16 for 3
560 years. The record shall include the:

561 7.16.4.1 Model and serial number of the instrument;

562 7.16.4.2 Date of the calibration **and other tests**;

563 7.16.4.3 Results of the calibration **and other tests**; and

564 7.16.4.4 Name of the individual who performed the calibration **and other tests**.

565 **7.17 Calibration of Survey Instruments.**

566 7.17.1 A licensee shall ensure that the survey instruments used to show compliance with Part 4 and Part
567 7 have been calibrated before first use, annually, and following any repair that will affect the
568 calibration.

569 7.17.2 To satisfy the requirements of 7.17.1 the licensee shall:

570 7.17.2.1 Calibrate all required scale readings up to 10 mSv (1 rem) per hour with a radiation
571 source;

572 7.17.2.2 Have each radiation survey instrument calibrated as follows, or by acceptable
573 equivalent methods:

574 (1) At energies appropriate for use and at intervals not to exceed 12 months or after
575 instrument servicing, except for battery changes;

576 (2) For linear scale instruments, at 2 points located approximately one-third and two-
577 thirds of full-scale on each scale;

578 (3) For logarithmic scale instruments, at mid-range of each decade and at 2 points of at
579 least one decade;

Comment [JJ18]: This is a new requirement. This new requirement is added at the suggestion of Radioactive Materials Unit staff. A requirement for performing quality control in accordance with written procedures is less meaningful and effective if there are no requirements related to recordkeeping and is the basis for this added requirement. Only the recordkeeping requirement is new. The timeframe of 3 years is consistent with other recordkeeping requirements of this Part.

Comment [JJ19]: This and subsequent sections changed to be consistent with 10 CFR Part 35.60(b).

[Item identified in NRC comments dated April 1, 2010 SSR Part G draft.]
(Compatibility = H&S)

Comment [JJ20]: Radioactive Materials Unit staff believe that this provision serves as a useful reminder of the tests necessary to maintain instruments that are used for determining the radioactive material dose prior to administration to the patient. Technologists are in the routine habit of performing such activities, and thus it is not considered a new practice. The requirements of this provision reiterate what is already in national standards. Additionally, it was necessary to change the wording of this section to be consistent with 7.16.2 and 7.16.4.

Comment [JJ21]: This and other items in this section changed to be consistent with 10 CFR Part 35.60(c).

Item identified in NRC comments to CRCPD dated April 1, 2010 regarding SSR Part G draft.
(Compatibility = H&S)

Comment [JJ22]: Additional wording is added for clarification and to be consistent with other changes in Section 7.16. (See other prior comments)

DRAFT 2 –9/15/2011

580 (4) For digital instruments, at 3 points between 0.02 and 10 mSv (2 and 1000 mrem) per
581 hour; and

582 (5) For dose rate instruments, so that an accuracy within plus or minus 20 percent of the
583 true radiation dose rate can be demonstrated at each point checked.

584 7.17.2.3 Conspicuously note on the instrument the date of calibration.

585 7.17.3 The licensee shall not use survey instruments if the difference between the indicated exposure
586 rate and the calculated exposure rate is greater than 20 percent.

587 7.17.4 The licensee shall retain a record of each survey instrument calibration required by 7.17 for 3
588 years. The record shall include the:

589 7.17.4.1 Model and serial number of the instrument;

590 7.17.4.2 Date of the calibration;

591 7.17.4.3 Results of the calibration; and

592 7.17.4.4 Name of the individual who performed the calibration.

593 **7.18 Determination of Dosages of Radioactive Material for Medical Use.**

594 7.18.1 A licensee shall determine and record the activity of each dosage prior to medical use.

595 7.18.1.1 For photon-emitting radioactive material, this determination shall be within 30 minutes
596 prior to medical use.

597 7.18.1.2 For all other radioactive material, this determination shall be within the period before
598 medical use that is no greater than 10 percent of the physical half-life of the radioactive
599 material.

600 7.18.2 For a unit dosage, the determination **required** by 7.18.1 shall be made **either** by:

601 **7.18.2.1** direct measurement **of radioactivity**; or

602 **7.18.2.2** **by** a decay correction, based on the measurement made by:

603 **(1)** a manufacturer or preparer licensed pursuant to Part 3 of these regulations or
604 equivalent provisions of another Agreement State, **a Licensing State** or NRC; **or**:

605 **(2) an NRC or Agreement State licensee for use in research in accordance with a**
606 **Radioactive Drug Research Committee-approved protocol or an Investigational New Drug**
607 **(IND) protocol accepted by FDA.**

608 7.18.3 For other than a unit dosage, the determination by 7.18.1 shall be made by direct measurement of
609 radioactivity or by a combination of measurements of radioactivity and mathematical calculations
610 or combination of volumetric measurements and mathematical calculations, based on the
611 measurement made by a manufacturer or preparer licensed pursuant to Part 3 of these
612 regulations or equivalent provisions of another Agreement State, a Licensing State or NRC.

613 7.18.4 Unless otherwise directed by the authorized user, a licensee shall not use a dosage if the dosage
614 differs from the prescribed dosage by more than 20 percent.

Comment [JJ23]: Added for clarity.

Comment [JJ24]: Language added consistent with 10 CFR 35.63.

Comment [O25]: Language added consistent with 10 CFR 35.63.
NRC RATS ID=2007-3; Compatibility = H&S

DRAFT 2 –9/15/2011

- 615 7.18.5 A license shall retain a record of the each dosage determination required by 7.18.1 for 3 years.
616 The record shall contain the:
- 617 7.18.5.1 Name of the radioactive drug;
- 618 7.18.5.2 Patient's or human research subject's name, and identification number if one has been
619 assigned;
- 620 7.18.3.3 Prescribed dosage;
- 621 7.18.3.4 Determined dosage; or a notation that the total activity is less than 1.1 MBq (30 µCi);
- 622 7.18.3.5 Date and time of the dosage determination; and
- 623 7.18.3.6 Name of the individual who determined the dosage.

624 **7.19 Authorization for Calibration, Transmission and Reference Sources.**

625 Any person authorized by 7.3 for medical use of radioactive material may receive, possess, and
626 use the following radioactive material for check, calibration and reference use:

- 627 7.19.1 Sealed sources manufactured and distributed by persons specifically licensed pursuant to Part 3
628 of these regulations or equivalent provisions of the another Agreement State, a Licensing State,
629 or NRC, and that do not exceed 1.1 GBq (30 mCi) each;
- 630 7.19.2 Any radioactive material with a half-life not longer than 120 days or less in individual amounts not
631 to exceed 0.55 GBq (15 mCi);
- 632 7.19.3 Any radioactive material with a half life greater than 120 days in individual amounts not to exceed
633 the smaller of:
- 634 7.19.3.1 7.4 MBq (200 µCi);
- 635 7.19.3.2 1000 times the quantities in [Appendix Part 3 Schedule 3B](#); and
- 636 7.19.4 Technetium-99m in amounts as needed.

Comment [JJ26]: Wording changed to
"Schedule" consistent with April 2011 changes to
Part 3.

637 **7.20 Requirements for Possession of Sealed Sources and Brachytherapy Sources.**

- 638 7.20.1 A licensee in possession of any sealed source or brachytherapy source shall follow the radiation
639 safety and handling instructions supplied by the manufacturer or equivalent instructions approved
640 by the Department and shall maintain the instructions for the duration of source use in a legible
641 form convenient to users.
- 642 7.20.2 A licensee in possession of a sealed source shall test the source for leakage:
- 643 7.20.2.1 In accordance with Part 4 of these regulations; and
- 644 7.20.2.2 At intervals not to exceed 6 months or at intervals approved by the Department, another
645 Agreement State, a Licensing State or the NRC in the Sealed Source and Device
646 Registry.
- 647 **7.20.3 To satisfy the leak test requirements of 7.20, the licensee shall measure the sample so that**
648 **the leak test can detect the presence of 185 Bq (0.005 uCi) of radioactive material in the**
649 **sample.**

Comment [JJ27]: This section revised to be
consistent with 10 CFR 35.67(c). This clarifies that
the measurement method for the leak test must be
capable of measuring 185 Bq.

[This item was identified in NRC comments to
CRCPD dated April 1, 2010 pertaining to SSR Part
G 2010 draft.]

(Compatibility = H&S)

DRAFT 2 –9/15/2011

- 650 | 7.20.43 If the leak test reveals the presence of 0.005 microcurie (185 Bq) or more of removable
651 | contamination, the licensee shall:
- 652 | 7.20.43.1 Immediately withdraw the sealed source from use and store, dispose or cause it to be
653 | repaired in accordance with the requirements of these regulations; and
- 654 | 7.20.43.2 File a written report with the Department within 5 days of receiving the leak test result,
655 | including the model number and serial number, if assigned, of the leaking source, the
656 | radionuclide and its estimated activity, the date and results of the test, and the action
657 | taken.
- 658 | 7.20.54 A licensee in possession of a sealed source or brachytherapy source, except for a gamma
659 | stereotactic radiosurgery source, shall conduct a semi-annual physical inventory of all such
660 | sources. The licensee shall retain each inventory record ~~for~~ 3 years. The inventory records shall
661 | contain the model number of each source, and serial number if one has been assigned, the
662 | identity of each source radionuclide and its estimated activity, the location of each source, and
663 | the name of the individual who performed the inventory.

Comment [JJ28]: Error correction – deletion of extra spaces.

664 | **7.21 Reports and Notifications of Misadministrations.**

- 665 | 7.21.1 Other than events that result from intervention by a patient or human research subject, a licensee
666 | shall report any event in which the administration of radioactive material or radiation from
667 | radioactive material results in:
- 668 | 7.21.1.1 A dose that differs from the prescribed dose by more than 0.05 Sv (5 rem) effective
669 | dose equivalent, 0.5 Sv (50 rem) to an organ or tissue, or 0.5 Sv (50 rem) shallow dose
670 | equivalent to the skin; and either
- 671 | (1) The total dose delivered differs from the prescribed dose by 20 percent or more;
- 672 | (2) The total dosage delivered differs from the prescribed dosage by 20 percent or more
673 | or falls outside the prescribed dosage range; or
- 674 | (3) The fractionated dose delivered differs from the prescribed dose, for a single fraction,
675 | by 50 percent or more.
- 676 | 7.21.1.2 A dose that exceeds 0.05 Sv (5 rem) effective dose equivalent, 0.5 Sv (50 rem) to an
677 | organ or tissue, or 0.5 Sv (50 rem) shallow dose equivalent to the skin from any of the
678 | following:
- 679 | (1) An administration of a wrong radioactive drug;
- 680 | (2) An administration of a radioactive drug containing radioactive material by the wrong
681 | route of administration;
- 682 | (3) An administration of a dose or dosage to the wrong individual or human research
683 | subject;
- 684 | (4) An administration of a dose or dosage delivered by the wrong mode of treatment; or
- 685 | (5) A leaking sealed source.
- 686 | 7.21.1.3 A dose to the skin or an organ or tissue other than the treatment site that exceeds by
687 | 0.5 Sievert (50 rem) to an organ or tissue and 50 percent of the dose expected from the

DRAFT 2 –9/15/2011

688 administration defined in the written directive (excluding, for permanent implants, seeds
689 that were implanted in the correct site but migrated outside the treatment site).

690 7.21.2 A licensee shall report any event resulting from intervention of a patient or human research
691 subject in which the administration of radioactive material or radiation from radioactive material
692 results, or will result in, unintended permanent functional damage to an organ or a physiological
693 system, as determined by a physician.

694 7.21.3 The licensee shall notify the Agency by telephone no later than the next calendar day after
695 discovery of the misadministration.

696 7.21.4 The licensee shall submit a written report to the Agency within 15 days after discovery of the
697 misadministration.

698 7.21.4.1 The written report must include:

- 699 (1) The licensee's name;
700 (2) The name of the prescribing physician;
701 (3) A brief description of the event;
702 (4) Why the event occurred;
703 (5) The effect, if any, on the individual(s) who received the administration;
704 (6) Actions, if any, that have been taken, or are planned, to prevent recurrence;
705 (7) Certification that the licensee notified the individual (or the individual's responsible
706 relative or guardian), and if not, why not.

707 7.21.4.2 The report may not contain the individual's name or any other information that could
708 lead to identification of the individual.

709 7.21.5 The licensee shall provide notification of the misadministration to the referring physician and also
710 notify the individual who is the subject of the misadministration no later than 24 hours after its
711 discovery, unless the referring physician personally informs the licensee either that he or she will
712 inform the individual or that, based on medical judgment, telling the individual would be harmful.
713 The licensee is not required to notify the individual without first consulting the referring physician.
714 If the referring physician or the affected individual cannot be reached within 24 hours, the
715 licensee shall notify the individual as soon as possible thereafter. The licensee may not delay any
716 appropriate medical care for the individual, including any necessary remedial care as a result of
717 the misadministration, because of any delay in notification. To meet the requirements of this
718 paragraph, the notification of the individual who is the subject of the misadministration may be
719 made instead to that individual's responsible relative or guardian. If a verbal notification is made,
720 the licensee shall inform the individual, or appropriate responsible relative or guardian, that a
721 written description of the event can be obtained from the licensee upon request. The licensee
722 shall provide such a written description if requested.

723 7.21.6 Aside from the notification requirement, nothing in this section affects any rights or duties of
724 licensees and physicians in relation to each other, to individuals affected by the
725 misadministration, or to that individual's responsible relatives or guardians.

726 7.21.7 A licensee shall retain a record of a misadministration for 3 years. The record must contain:

DRAFT 2 –9/15/2011

- 727 7.21.7.1 The licensee's name;
- 728 7.21.7.1 Names of the individuals involved;
- 729 7.21.7.1 The social security number or other identification number if one has been assigned, of
730 the individual who is the subject of the misadministration;
- 731 7.21.7.1 A brief description of the event and why it occurred;
- 732 7.21.7.1 The effect, if any, on the individual;
- 733 7.21.7.1 The actions, if any, taken, or planned, to prevent recurrence; and
- 734 7.21.7.1 Whether the licensee notified the individual (or the individual's responsible relative or
735 guardian) and, if not, whether such failure to notify was based on guidance from the
736 referring physician.
- 737 7.21.8 A copy of the record required under 7.21.7 shall be provided to the referring physician if other than
738 the licensee, within 15 days after discovery of the misadministration.
- 739 **7.22 Notification to the Department of Deceased Patients or Human Research Subjects**
740 **Containing Radioactive Material.**
- 741 7.22.1 The licensee shall notify the Department by telephone immediately upon discovery that a patient
742 or human research subject containing radioactive material has died, and it is possible that any
743 individual could receive exposures in excess of 4.14 as a result of the deceased's body.
- 744 7.22.2 The licensee shall submit a written report to the Department within 30 days after discovery that
745 the patient or human research subject referenced in 7.22.1 has died. The written report must
746 include the:
- 747 7.22.2.1 Licensee's name;
- 748 7.22.2.2 Date of death;
- 749 7.22.2.3 Radionuclide, chemical and physical form and calculated activity at time of death; and
- 750 7.22.2.4 Names (or titles) and address(es) of known individuals who might have received
751 exposures exceeding 5 mSv (500 mrem).
- 752 7.22.3 The licensee shall retain a record of each written report required by 7.22 for 3 years.
- 753 **7.23 Report and Notification of a Dose to an Embryo/Fetus or a Nursing Child.**
- 754 7.23.1 A licensee shall report any dose to an embryo/fetus that is greater than 5 mSv (500 mrem) dose
755 equivalent that is a result of an administration of radioactive material or radiation from radioactive
756 material to a pregnant individual unless the dose to the embryo/fetus was specifically approved,
757 in advance, by the authorized user.
- 758 7.23.2 A licensee shall report any dose to a nursing child, that was not specifically approved, in advance,
759 by the authorized user, that is a result of an administration of radioactive material to a breast
760 feeding individual that:
- 761 7.23.2.1 Is greater than 5 millisievert (500 mrem) total effective dose equivalent; or

DRAFT 2 –9/15/2011

- 762 7.23.2.2 Has resulted in unintended permanent functional damage to an organ or a physiological
763 system of the child, as determined by a physician.
- 764 7.23.3 The licensee shall notify by telephone the Agency no later than the next calendar day after
765 discovery of a dose to the embryo/fetus or nursing child that requires a report in 7.23.1 or 7.23.2.
- 766 7.23.4 The licensee shall submit a written report to the Agency within 15 days after discovery of a dose
767 to the embryo/fetus or nursing child that requires a report in 7.23.1 or 7.23.2.
- 768 7.23.4.1 The written report must include:
- 769 (1) The licensee's name;
- 770 (2) The name of the prescribing physician;
- 771 (3) A brief description of the event;
- 772 (4) Why the event occurred;
- 773 (5) The effect on the embryo/fetus or the nursing child;
- 774 (6) What actions, if any, have been taken, or are planned, to prevent recurrence; and
- 775 (7) Certification that the licensee notified the pregnant individual or mother (or the
776 mother's or child's responsible relative or guardian), and if not, why not.
- 777 7.23.4.2 The report must not contain the individual's or child's name or any other information that
778 could lead to identification of the individual or child.
- 779 7.23.5 The licensee shall notify the referring physician and also notify the pregnant individual or mother,
780 both hereafter referred to as the mother, no later than 24 hours after discovery of an event that
781 would require reporting under 7.23.1 or 7.23.2, unless the referring physician personally informs
782 the licensee either that he or she will inform the mother or that, based on medical judgment,
783 telling the mother would be harmful. The licensee is not required to notify the mother without first
784 consulting with the referring physician. If the referring physician or mother cannot be reached
785 within 24 hours, the licensee shall make the appropriate notifications as soon as possible
786 thereafter. The licensee may not delay any appropriate medical care for the embryo/fetus or for
787 the nursing child, including any necessary remedial care as a result of the event, because of any
788 delay in notification. To meet the requirements of this paragraph, the notification may be made to
789 the mother's or child's responsible relative or guardian instead of the mother, when appropriate. If
790 a verbal notification is made, the licensee shall inform the mother, or the mother's or child's
791 responsible relative or guardian, that a written description of the event can be obtained from the
792 licensee upon request. The licensee shall provide such a written description if requested.
- 793 7.23.6 A licensee shall retain a record of a dose to an embryo/fetus or a nursing child for 3 years. The
794 record must contain:
- 795 7.23.6.1 The licensee's name;
- 796 7.23.6.2 Names of all the individuals involved;
- 797 7.23.6.3 Social security number or other identification number if one has been assigned to the
798 pregnant individual or nursing child who is the subject of the event;
- 799 7.23.6.4 A brief description of the event and why it occurred;

DRAFT 2 –9/15/2011

- 800 7.23.6.5 The effect, if any, on the embryo/fetus or nursing child;
- 801 7.23.6.6 The actions, if any, taken, or planned, to prevent recurrence; and
- 802 7.23.6.7 Whether the licensee notified the pregnant individual or mother (or the mother's or
- 803 child's responsible relative or guardian) and, if not, whether such failure to notify was
- 804 based on guidance from the referring physician.
- 805 7.23.7 A copy of the record required under 7.23.6 shall be provided to the referring physician, if other
- 806 than the licensee, within 15 days after discovery of the event.

807 **7.24 Vial Shields and Labels.**

- 808 7.24.1 A licensee shall require each individual preparing or handling a vial that contains a
- 809 radiopharmaceutical to keep the vial in a vial radiation shield.
- 810 7.24.2 Each syringe and vial that contains a radioactive drug shall be labeled to identify the radioactive
- 811 drug, to include the isotope and amount of radioactivity. Each syringe shield and vial shield shall
- 812 also be labeled unless the label on the syringe or vial is visible when shielded.

813 **7.25 Surveys for Contamination and Ambient ~~Radiation Dose~~ Exposure Rate.**

814 **7.25.1 Surveys required by 7.25.2 and 7.25.3 are in addition to surveys required by Part 4.**

815 **7.25.2~~4~~ Daily Survey Requirements**

- 816 **7.25.2.1** ~~Except as provided in 7.25.2, a~~ At the end of each day of use, a licensee shall survey,
- 817 with an **exposure rate** ~~radiation detection~~ instrument, all areas where radioactive drugs
- 818 containing radioactive material requiring a written directive were prepared for use or
- 819 administered.

- 820 **(1) A licensee does not need to perform the surveys required by 7.25.2.1 in**
- 821 **an area where patients or human research subjects are confined when they**
- 822 **cannot be released pursuant to 7.26.**

- 823 **7.25.2.2 At the end of each day of use, a licensee shall survey for removable contamination**
- 824 **all areas where generators and bulk radioactive drugs are prepared for use. An**
- 825 **instrument capable of detecting 2000 dpm of contamination on each wipe sample**
- 826 **shall be used.**

827 **7.25.3~~2~~ Weekly Survey Requirements**

- 828 **7.25.3.1** At least once each week, a licensee shall survey, with a ~~radiation detection~~ **exposure**
- 829 **rate** instrument, all areas where radioactive drugs or radioactive wastes are stored.

- 830 **7.25.3.2 At least once each week, a licensee shall survey for removable contamination in**
- 831 **all areas where radioactive materials other than sealed sources as defined in Part 7**
- 832 **are stored. An instrument capable of detecting 2000 dpm of contamination on**
- 833 **each wipe sample shall be used.**

- 834 **7.25.3** A licensee shall conduct the surveys required by 7.25.1 and 7.25.2 using an instrument capable of
- 835 measuring dose rates as low as 1 µSv (0.1 mrem) per hour.

Comment [JJ29]: Language change based on 10 CFR 35.70 and 2010 Draft SSR G.39. Language pertaining to contamination surveys from 2003 SSR Part G has been retained.

The proposed changes in this section do not change or increase the regulatory requirements for surveys.

Comment [JJ30]: Subsection header added for clarity.

Formatted: Indent: Left: 0.5"

Comment [JJ31]: Language in this section is modified to add clarity and maintain compatibility with 10 CFR 35.70. The more explicit requirements of the current Part 7 are retained.

Formatted: Indent: Left: 1", Tab stops: 1.88", Left + Not at 1.5"

Formatted: Indent: Left: 0.5"

Comment [JJ32]: Subsection header added for clarity.

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Indent: Left: 0.5"

DRAFT 2 –9/15/2011

836 7.25.4 A licensee shall establish ~~dose rate~~-action levels for the surveys required by 7.25.21 and 7.25.23
837 and shall require that the individual performing the survey immediately notify the Radiation Safety
838 Officer if ~~a dose rate exceeds an action level~~s are exceeded.

839 ~~7.25.5 Each day of use a licensee shall survey for removable contamination all areas where generators~~
840 ~~and bulk radioactive drugs are prepared for use.~~

841 ~~7.25.6 Each week the licensee shall perform removable contamination surveys in all areas where~~
842 ~~radioactive materials other than sealed sources as defined in Part 7 are stored.~~

843 ~~7.25.7 For the surveys required by 7.25.5 and 7.25.6, the licensee shall:~~

844 ~~7.25.7.1 Use instrumentation capable of detecting contamination on each wipe sample of 33.3~~
845 ~~Bq (2000 disintegrations per minute);~~

846 ~~7.25.7.2 Establish removable contamination action levels; and~~

847 ~~7.25.7.3 Require that the individual performing the survey immediately notify the Radiation~~
848 ~~Safety Officer if contamination exceeds action levels.~~

849 ~~7.25.8 A licensee does not need to perform the surveys required by 7.25.1 in an area where patients or~~
850 ~~human research subjects are confined when they cannot be released pursuant to 7.26.~~

851 ~~7.25.59~~ A licensee shall retain a record of each survey required by 7.25.1, 7.25.2 and 7.25.36 for 3
852 years. The record must include:

Comment [JJ33]: This section modified for clarity/formatting only.

853 **7.25.5.1** ~~†~~The date of the survey;†

854 **7.25.5.2** ~~†~~The results of the survey;†

Formatted: Not Highlight

855 **7.25.5.3** ~~†~~The instrument used to make the survey (including, if applicable, that the instrument
856 was checked for consistent response with a dedicated check source prior to each daily
857 use);† and

Formatted: Not Highlight

858 **7.25.5.4** ~~†~~The name of the individual who performed the survey.

859 **7.26 Release of Individuals Containing Radioactive Drugs or Implants.**

Comment [JJ34]: The changes to Section 7.26 will reduce the regulatory burden on licensees.

860 7.26.1 A licensee may authorize the release from the licensee's control of any individual who has been
861 administered radioactive drugs or permanent implants containing radioactive material if the total
862 effective dose equivalent to any other individual from exposure to the released individual is not
863 likely to exceed 5 mSv (0.5 rem).¹

Formatted: par2, Indent: Left: 0", Hanging: 0.69", Tab stops: 0.69", Left

Comment [JJ35]: Language from prior 7.26.2.1 plus additional language from 10 CFR 35.75.

864 ¹ Appendix U of U.S. Nuclear Regulatory Commission NUREG-1556, Vol. 9, "Consolidated Guidance About Materials
865 Licenses: Program Specific Guidance About Medical Licenses" describes accepted values and methods for
866 determining doses to other individuals.

Comment [JJ36]: Additional language added consistent with the approach used in 10 CFR Part 35.75 This adds a threshold below which oral and written safety instructions are no longer necessary.

867 7.26.2 ~~Instructions to Individuals:~~A licensee shall provide the released individual or the individual's
868 ~~parent or guardian with instructions, including written instructions on the actions~~
869 ~~recommended to maintain doses to other individuals as low as is reasonably achievable if~~
870 ~~the total effective dose equivalent to any other individual is likely to exceed 1 mSv (0.1~~
871 ~~rem).~~

As a result of the added language, the proposed change reduces the regulatory burden on the licensee. This is a reversal of what is currently written in the regulations, but is consistent with what most other Agreement States and NRC have in their regulations and is consistent with what the Department has had in the past, prior to the 2005 revision of Part 7. The Department has determined that the requirements added in 2005 are likely not significantly justified from a radiation safety standpoint.

872 7.26.2.1 ~~A licensee shall provide the released individual, or the individual's parent or guardian,~~
873 ~~with oral and written safety instructions on actions recommended to maintain doses to~~
874 ~~other individuals as low as is reasonably achievable.~~

DRAFT 2 –9/15/2011

7.26.2.12 If the total effective dose equivalent to a breast-feeding-nursing infant or child could exceed 1 mSv (0.1 rem) assuming there were no interruption in breast-feeding, receive a radiation dose as a result of the release of the patient, the instructions shall also include:

Comment [JJ37]: JJ 6/20/2011: The revised language is consistent with 10 CFR 35.75. The added language places a threshold below which instructions to the patient would not be required.

(1) Guidance on the interruption or discontinuation of breast-feeding; and

(2) Information on the potential consequences, if any, of failure to follow the guidance.

7.26.3 If the total effective dose equivalent to a nursing infant or child could exceed 5 mSv (0.5 rem) from continued breast-feeding, the licensee shall maintain a record that the instructions required by 7.26.2 were provided to a breast-feeding woman.

Formatted: Not Highlight

Formatted: par1, Indent: Left: 0", Tab stops: Not at 1.44"

~~7.26.3 Release of the patient must be approved by an individual listed as an authorized user on the license from the Department who is approved for the type of radioactive material use in the patient being released.~~

Comment [JJ38]: 8/18/2011: New language added to 7.26.3 that is consistent with 10 CFR 35.2075(b) and SSR G (2010 draft).

Formatted: Indent: Left: 0", First line: 0"

7.26.4 The licensee shall maintain a record of the basis for authorizing the release of an individual in accordance with 7.26, if the total effective dose equivalent is calculated by: signed by the authorized user, for 3 years after the date of release, of:

Comment [JJ39]: 8/17/2011: Elimination of this requirement is consistent with 10 CFR Part 35.75 and based on Radioactive Materials Unit staff direction.

~~7.26.4.1 The basis for authorizing the release of an individual~~

Comment [JJ40]: 8/18/2011: New language added to 7.26.4 that is consistent with 10 CFR 35.2075(a) and SSR G (2010 draft).

7.26.4.1 Using the retained activity rather than the administered activity;

Formatted: Not Highlight

7.26.4.2 Using an occupancy factor less than 0.25 at 1 meter;

Formatted: par1

7.26.4.3 Using the biological or effective half-life; and

7.26.4.4 Considering the shielding by tissue; and

~~7.26.4.2 Instructions that were provided to a breast-feeding woman.~~

7.26.5 The records required by 7.26.3 and 7.26.4 must be retained for 3 years after the date of release of the individual.

Formatted: par2, Indent: Left: 0", Hanging: 0.69", Tab stops: 0.69", Left

Comment [JJ41]: Recordkeeping requirement consistent with 10 CFR 35.2075.

7.26.65 Reports of Patient Departure Prior to Authorized Release.

7.26.65.1 The licensee shall notify the Department by telephone immediately upon discovery that a patient or human research subject has departed from the licensee's facility without authorization under 7.26.

7.26.65.2 The licensee shall submit a written report to the Department within 30 days after discovery of the unauthorized departure. The written report must include:

(1) The licensee's name;

(2) The date and time of the unauthorized departure;

(3) The projected date and time when release would have occurred;

(4) The address of the patient's or human research subject's home or anticipated destination following departure;

DRAFT 2 –9/15/2011

- 909 (5) The radionuclide, chemical and physical form and calculated activity at time of
910 release;
- 911 (6) The apparent reason(s) for the departure prior to authorized release; and
- 912 (7) A description of any changes in the licensee's patient release criteria or patient
913 instructions that are designed to avoid a recurrence of such an event.

914 **7.27 Mobile Nuclear Medicine Service Technical Requirements.**

915 A licensee providing mobile nuclear medicine service shall:

- 916 7.27.1 Transport to each client's address of use only syringes or vials containing prepared drugs or
917 radioactive materials that are intended for reconstitution of radioactive drug kits;
- 918 7.27.2 Bring into each client's address of use all radioactive material to be used and, before leaving,
919 remove all unused radioactive material and associated radioactive waste;
- 920 7.27.3 Secure or keep under constant surveillance and immediate control all radioactive material when in
921 transit or at a client's address of use;
- 922 7.27.4 Check instruments used to measure the activity of unsealed radioactive material for proper
923 function before medical use at each client's address or on each day of use, whichever is more
924 frequent. At a minimum, the check for proper function shall include a constancy check;
- 925 7.27.5 Check survey instruments for consistent response with a dedicated check source before use at
926 each client's address;
- 927 7.27.6 Prior to leaving a client's address of use, perform area surveys and survey for removable
928 contamination in all areas of use, to ensure compliance with Part 4 of these regulations; **and**
- 929 ~~7.27.7 Use radioactive gases only in areas of use and under conditions which have been evaluated and~~
930 ~~approved by the Department for compliance with airborne release standards; and~~
- 931 7.27.78 Retain a record of each survey required by 7.27.6 for 3 years. The record must include the date
932 of the survey, the results of the survey, the instrument used to make the survey, and the name of
933 the individual who performed the survey.

Comment [JJ42]: This provision is adequately addressed in Section 7.34 and other provisions and is therefore deleted from section 7.27.

934 **7.28 Storage of Volatiles and Gases.**

- 935 7.28.1 A licensee shall store volatile radioactive materials and radioactive gases in a radiation shield and
936 container.
- 937 7.28.2 A licensee shall store and use a multi-dose container in a properly functioning fume hood.
- 938 7.28.3 A licensee who administers radioactive aerosols or gases shall do so with a system that will keep
939 airborne concentrations within the limits prescribed in Part 4 of these regulations.
- 940 7.28.3.1 The system shall either be directly vented to the atmosphere through an air exhaust or
941 provide for collection and decay or disposal of the aerosol or gas in a shielded container.
- 942 7.28.3.2 A licensee shall check the operation of collection systems monthly. Records of these
943 checks shall be maintained for 3 years.

944 **7.29 Decay-In-Storage.**

DRAFT 2 –9/15/2011

945 7.29.1 A licensee may hold radioactive material with a physical half-life of less than 120 days for decay-
946 in-storage before disposal without regard for its radioactivity if the licensee:

947 7.29.1.1 Monitors radioactive material at the container surface before disposal and determines
948 that its radioactivity cannot be distinguished from the background radiation level with a
949 radiation detection survey instrument set on its most sensitive scale and with no
950 interposed shielding;

951 7.29.1.3 Removes or obliterates all radiation labels, except for material that will be handled as
952 biomedical waste after release; and

953 7.29.1.4 Separates and monitors each generator column individually with all radiation shielding
954 removed to ensure that its contents have decayed to background radiation level before
955 disposal.

956 7.29.2 Records of Decay-in-Storage.

957 For radioactive material disposed in accordance with 7.29.1, the licensee shall retain a record of
958 each disposal for 3 years. The record must include the date of the disposal, the survey instrument
959 used, the background radiation level, the radiation level measured at the surface of each waste
960 container, and the name of the individual who performed the survey.

961 **SPECIFIC REQUIREMENTS FOR THE USE OF RADIOACTIVE MATERIAL FOR UPTAKE, DILUTION,**
962 **AND EXCRETION STUDIES**

963 **7.30 Use of Unsealed Radioactive Material for Uptake, Dilution, and Excretion Studies for which a**
964 **Written Directive is Not Required.**

965 7.30.1 A licensee may use any unsealed radioactive material, in quantities that do not require a written
966 directive, as described in 7.11, for a diagnostic use involving measurements of uptake, dilution, or
967 excretion that ~~is~~:

968 7.30.1.1 ~~Is~~ ~~Ob~~obtained from a manufacturer or preparer licensed pursuant to 3.12.10 or
969 equivalent regulations of another Agreement State, a Licensing State, or NRC; or;

970 7.30.1.2 **Excluding production of PET radioactive material, is P**prepared by an authorized
971 nuclear pharmacist, a physician who is an authorized user and who meets the
972 requirements specified in 7.30.2, or an individual under the supervision of either as
973 specified in 7.10;

974 7.30.1.3 ~~Is~~ ~~Ob~~obtained from and prepared by a Department, Agreement State, Licensing State or
975 NRC licensee for use in research in accordance with a Radioactive Drug Research
976 Committee-approved protocol or an Investigational New Drug (IND) protocol accepted by
977 FDA; or

978 7.30.1.4 ~~Is~~ ~~P~~prepared by the licensee in accordance with a Radioactive Drug Research
979 Committee-approved application or an Investigational New Drug (IND) protocol accepted
980 by FDA for use in research.

981 7.30.2 Authorized User Training For Uptake, Dilution, And Excretion Studies.

982 The licensee shall require an authorized user of an unsealed radioactive material for the uses
983 authorized under 7.30 to meet the requirements of Appendix 7D.

984 **7.31 Possession of Survey Instrument.**

Comment [O43]: Language is added consistent with 10 CFR 35.100(b). Unlike Agreement States, NRC did not previously regulate PET facilities/materials since this material was not considered byproduct material. When NRC began regulating PET materials, they added PET specific provisions. The intent of this provision is that unlike generators used by AU physicians at medical facilities, PET materials cannot be used the same way and must be generated by a facility licensed as a pharmacy/manufacturer. Similarly, a hospital based nuclear pharmacist could not prepare PET materials that is not already licensed as a PET production facility under Part 3.

[RATS 2007-3; Compatibility=H&S]

DRAFT 2 –9/15/2011

985 A licensee authorized to use radioactive material for uptake, dilution, and excretion studies shall
986 possess a portable radiation detection survey instrument capable of detecting dose rates over the
987 range 1.0 μSv (0.1 mrem) per hour to 500 μSv (50 mrem) per hour. The instrument shall be
988 operable and calibrated in accordance with 7.17.

989 **SPECIFIC REQUIREMENTS FOR THE USE OF UNSEALED RADIOACTIVE MATERIAL - WRITTEN**
990 **DIRECTIVE NOT REQUIRED**

991 **7.32 Use of Unsealed Radioactive Material for Imaging and Localization Studies for which a**
992 **Written Directive is Not Required.**

993 7.32.1 A licensee may use, for imaging and localization studies, any radioactive material prepared for
994 medical use, in quantities that do not require a written directive, as described in 7.11, that ~~is~~:

995 7.32.1.1 ~~Is~~ ~~Ob~~obtained from a manufacturer or preparer licensed pursuant to 3.12.10 or
996 equivalent regulations of another Agreement State, a Licensing State, or NRC; or;

997 7.32.1.2 **Excluding production of PET radioactive material, is P**prepared by an authorized
998 nuclear pharmacist, a physician who is an authorized user and who meets the
999 requirements specified in 7.32.2, or an individual under the supervision of either as
1000 specified in 7.10.;

1001 7.32.1.3 ~~Is~~ ~~Ob~~obtained from and prepared by a Department, Agreement State, Licensing State or
1002 NRC licensee for use in research in accordance with a Radioactive Drug Research
1003 Committee-approved protocol or an Investigational New Drug (IND) protocol accepted by
1004 FDA; or

1005 7.32.1.4 ~~Is~~ ~~P~~prepared by the licensee in accordance with a Radioactive Drug Research
1006 Committee-approved application or an Investigational New Drug (IND) protocol accepted
1007 by FDA for use in research.

1008 7.32.2 Authorized User Training for Imaging and Localization Studies for which a Written Directive is Not
1009 Required.

1010 The licensee shall require an authorized user of an unsealed radioactive material for the uses
1011 authorized under 7.32 to meet the requirements of Appendix 7E.

1012 **7.33 Radionuclide Contaminants.**

1013 7.33.1 A licensee shall not administer to humans a radioactive drug containing:

1014 7.33.1.1 More than 0.15 kBq of molybdenum-99 per MBq of technetium-99m (0.15 μCi of ^{99}Mo
1015 per mCi of $^{99\text{m}}\text{Tc}$).

1016 7.33.1.2 More than 0.02 kBq of strontium-82 per MBq of rubidium-82 chloride injection (0.02 μCi
1017 of ^{82}Sr per mCi of ^{82}Rb chloride);

1018 7.33.1.3 More than 0.2 kBq of strontium-85 per MBq of rubidium-82 chloride injection (0.2 μCi of
1019 ^{85}Sr per mCi of ^{82}Rb).

1020 7.33.2 To demonstrate compliance with 7.33.1, the licensee preparing radioactive drugs from
1021 radionuclide generators shall measure the concentration of radionuclide contaminant in:

1022 7.33.2.1 ~~The first~~**Each** eluate after receipt of a molybdenum-99/technetium-99m generator;

Comment [JJ44]: Language is added consistent with 10 CFR 35.200(b).

Unlike Agreement States, NRC did not previously regulate PET facilities/materials since this material was not considered byproduct material. When NRC began regulating PET materials, they added PET specific provisions. The intent of this provision is that unlike generators used by AU physicians at medical facilities, PET materials cannot be used the same way and must be generated by a facility licensed as a pharmacy/manufacture. Similarly, a hospital based nuclear pharmacist could not prepare PET materials that is not already licensed as a PET production facility under Part 3.

[RATS 2007-3; Compatibility=H&S]

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Comment [JJ45]: Current Part 35 indicates that only the first eluate be evaluated. However, NRC is reconsidering this currently during proposed rulemaking for 10 CFR 35, and as a result of recent generator breakthrough incidents. Although this rulemaking process is in its early stages and proposed language has not been finalized, the general industry consensus participating in NRC stakeholder meetings is that most licensees using generators are evaluating each eluate, and is consistent with generator manufacturer recommendations.

The revision to Part 7 prior to 2005 required each eluate be tested. The proposed change returns to this approach.

DRAFT 2 –9/15/2011

1023 7.33.2.2 Each eluate or extract, **before the first patient use of the day**, as appropriate for other
1024 than molybdenum-99/technetium-99m generator systems.

Comment [JJ46]: Clarification language added consistent with 10 CFR 35.204(c).

See NRC RATs 2007-3; 35.35.204, 30.34g.
(Compatibility=D)

1025 7.33.3 Records of Radionuclide Purity.

1026 A licensee who must measure radionuclide contaminant concentration shall retain a record of
1027 each radionuclide contaminant test for 3 years. The record shall include, for each measured
1028 elution of radionuclide used to prepare a radioactive drug, the ratio of the measures expressed as
1029 kBq of contaminant per MBq of desired radionuclide ($\mu\text{Ci}/\text{mCi}$), the time and date of the test, and
1030 the name of the individual who made the measurement.

1031 7.33.4 Immediate Report.

1032 A licensee shall report immediately to the Department each occurrence of radionuclide
1033 contaminant concentration exceeding a limit specified in 7.33.1.

1034 **7.34 Aerosols and Gases.**

1035 Provided the conditions of 7.28 are met, a licensee shall use radioactive aerosols or gases only if
1036 specific application is made to and approved by the Department.

1037 **7.35 Radiation Detection Capability.**

1038 A licensee authorized to use radioactive material pursuant to 7.32, 7.36, or 7.42 shall possess
1039 portable radiation detection survey instrumentation capable of detecting dose rates over the
1040 range 1.0 μSv (0.1 mrem) per hour to 500 μSv (50 mrem) per hour and over the range of 10 μSv
1041 (1 mrem) per hour to 10 mSv (1 rem) per hour. Each instrument shall be operable and calibrated
1042 in accordance with 7.17.

1043 **SPECIFIC REQUIREMENTS FOR THE USE OF UNSEALED RADIOACTIVE MATERIAL - WRITTEN**
1044 **DIRECTIVE REQUIRED**

1045 **7.36 Use of Unsealed Radioactive Material for Which A Written Directive Is Required.**

1046 7.36.1 A licensee may use any unsealed radioactive material for diagnostic or therapeutic medical use
1047 for which a written directive is required that ~~has been~~:

1048 7.36.1.1 ~~Is~~ ~~Ob~~ obtained from a manufacturer or preparer licensed pursuant to 3.12.10 or
1049 equivalent regulations of another Agreement State, a Licensing State, or NRC; or

1050 7.36.1.2 **Excluding production of PET radioactive material**, ~~is~~ ~~P~~ prepared by an authorized
1051 nuclear pharmacist, a physician who is an authorized user and who meets the
1052 requirements specified in 7.36.2, 7.36.3 or 7.36.4, ~~—~~ or an individual under the
1053 supervision of either as specified in 7.10;

1054 7.36.1.3 ~~Is~~ ~~Ob~~ obtained from and prepared by a Department, Agreement State, Licensing State or
1055 NRC licensee for use in research in accordance with a Radioactive Drug Research
1056 Committee-approved protocol or an Investigational New Drug (IND) protocol accepted by
1057 FDA; or

1058 7.36.1.4 ~~Is~~ ~~P~~ prepared by the licensee in accordance with a Radioactive Drug Research
1059 Committee-approved application or an Investigational New Drug (IND) protocol accepted
1060 by FDA for use in research.

Comment [JJ47]: Language is added consistent with 10 CFR 35.300(b).

Unlike Agreement States, NRC did not previously regulate PET facilities/materials since this material was not considered byproduct material. When NRC began regulating PET materials, they added PET specific provisions. The intent of this provision is that unlike generators used by AU physicians at medical facilities, PET materials cannot be used the same way and must be generated by a facility licensed as a pharmacy/manufacturer. Similarly, a hospital based nuclear pharmacist could not prepare PET materials that is not already licensed as a PET production facility under Part 3.

[RATs 2007-3; Compatibility=H&S]

DRAFT 2 –9/15/2011

- 1061 7.36.2 Authorized User Training For Use Of Any Unsealed Radioactive Material For Diagnostic Or
1062 Therapeutic Medical Use For Which A Written Directive Is Required.
- 1063 The licensee shall require an authorized user of an unsealed radioactive material for diagnostic or
1064 therapeutic medical use for which a written directive is required under 7.36 to meet the
1065 requirements of Appendix 7F.
- 1066 7.36.3 Authorized User Training For Oral Administration Of $< / = 1.22 \text{ GBq } ^{131} \text{ I}$ (33 mCi) Sodium Iodide
1067 Requiring A Written Directive.
- 1068 The licensee shall require an authorized user of an unsealed radioactive material for oral
1069 administration of $< / = 1.22 \text{ GBq } ^{131} \text{ I}$ (33 mCi) sodium iodide requiring a written directive under
1070 7.36 to meet the requirements of Appendix 7G.
- 1071 7.36.4 Authorized User Training For Oral Administration Of $> 1.22 \text{ GBq } ^{131} \text{ I}$ (33 mCi) Sodium Iodide
1072 Requiring A Written Directive.
- 1073 The licensee shall require an authorized user of an unsealed radioactive material for oral
1074 administration of $> 1.22 \text{ GBq } ^{131} \text{ I}$ (33 mCi) sodium iodide requiring a written directive under
1075 7.36 to meet the requirements of Appendix 7H.
- 1076 7.36.5 Authorized User Training For Parenteral Administration Requiring A Written Directive.
- 1077 The licensee shall require an authorized user of an unsealed radioactive material for parenteral
1078 administration requiring a written directive under 7.36 to meet the requirements of Appendix 7I.
- 1079 **7.37 Safety Instruction.**
- 1080 In addition to the requirements of Part 10 of these regulations:
- 1081 7.37.1 The licensee shall provide radiation safety instruction, initially and at least annually, to personnel
1082 caring for patients or human research subjects that have received therapy with a radioactive drug,
1083 and cannot be released in accordance with 7.26.
- 1084 7.37.2 The instruction required by 7.37.1 shall be appropriate for the duties of the personnel and include:
- 1085 7.37.2.1 Patient or human research subject control;
- 1086 7.37.2.2 Visitor control, to include the following;
- 1087 (1) Routine visitation to hospitalized individuals in accordance with Part 4 of these
1088 regulations;
- 1089 (2) Contamination control;
- 1090 (3) Waste control; and
- 1091 (4) Notification of the RSO, or his or her designee, and the authorized user if the patient
1092 or the human research subject dies or has a medical emergency.
- 1093 7.37.3 A licensee shall keep a record of individuals receiving instruction required by 7.37.1 and maintain
1094 such records for 3 years. The record shall include a list of the topics covered, the date of
1095 instruction, the names(s) of the attendee(s), and the name(s) of the individual(s) who gave the
1096 instruction.

DRAFT 2 –9/15/2011

1097 **7.38 Safety Precautions.**

1098 7.38.1 For each patient or human research subject receiving radiopharmaceutical therapy and
1099 hospitalized for compliance with 7.26, a licensee shall:

1100 7.38.1.1 Quarter the patient or the human research subject either in:

1101 (1) A private room with a private sanitary facility; or

1102 (2) A room, with a private sanitary facility, with another individual who also has received
1103 similar radiopharmaceutical therapy and who cannot be released in accordance
1104 with 7.26; and

1105 7.38.1.2 Visibly post the patient's or the human research subject's door with a "Caution:
1106 Radioactive Material" sign and note on the door or on the patient's or the human research
1107 subject's chart where and how long visitors may stay in the patient's or the human
1108 research subject's room;

1109 7.38.1.3 Either monitor material and items removed from the patient's or the human research
1110 subject's room to determine that their radioactivity cannot be distinguished from the
1111 natural background radiation level with a radiation detection survey instrument set on its
1112 most sensitive scale and with no interposed shielding, or handle such materials and items
1113 as radioactive waste.

1114 7.38.2 A licensee shall notify the RSO , or his or her designee, and the authorized user immediately if
1115 the hospitalized patient dies or has a medical emergency and notify the Department as required
1116 by 7.39.

1117 **7.39 Emergency Notification.**

1118 The licensee shall notify the Department in accordance with 7.22 if it is possible that any
1119 individual could receive exposures in excess of 4.14 as a result of a deceased's body.

1120 **SPECIFIC REQUIREMENTS FOR THE USE OF SEALED SOURCES FOR DIAGNOSIS**

1121 **7.40 Use of Sealed Sources for Diagnosis.**

1122 7.40.1 A licensee shall use for diagnostic medical uses only sealed sources:

1123 7.40.1.1 Approved in the Sealed Source and Device Registry; and

1124 7.40.1.2 Handled in accordance with the manufacturer's radiation safety and handling
1125 instructions:

1126 7.40.2 Authorized User Training For Use Of Sealed Sources For Diagnosis.

1127 The licensee shall require an authorized user under 7.40 to meet the requirements of Appendix
1128 7J.

1129 **SPECIFIC REQUIREMENTS FOR THE USE OF SEALED SOURCES FOR MANUAL**
1130 **BRACHYTHERAPY**

1131 **7.41 Calibration Measurements of Brachytherapy Sealed Sources.**

DRAFT 2 –9/15/2011

- 1132 7.41.1 Prior to the first medical use of a brachytherapy sealed source on or after October 25, 2005, a
1133 licensee shall perform the following:
- 1134 7.41.1.1 Determine the source output or activity using a dosimetry system that meets the
1135 requirements of 7.53;
- 1136 7.41.1.2 Determine source positioning accuracy within applicators; and
- 1137 7.41.1.3 Use published protocols accepted by nationally recognized bodies to meet the
1138 requirements of 7.41.1.1 and 7.41.1.2.
- 1139 7.41.2 A licensee may use measurements provided by the source manufacturer or by a calibration
1140 laboratory accredited by the American Association of Physicists in Medicine that are made in
1141 accordance with 7.41.1.
- 1142 7.41.3 A licensee shall mathematically correct the outputs or activities determined in 7.41.1 for physical
1143 decay at intervals consistent with 1.0 percent physical decay.
- 1144 7.41.4 An authorized medical physicist shall perform or review the measurements and calculations made
1145 pursuant to 7.41.1, 7.41.2, or 7.41.3.
- 1146 7.41.5 Only an authorized medical physicist shall calculate the activity of each strontium-90 source that is
1147 used to determine the treatment times for ophthalmic treatments. The actual source output shall
1148 consider decay based on the activity determined in accordance with paragraphs 7.41.1, 7.41.2, or
1149 7.41.3.
- 1150 7.41.6 A licensee shall retain a record of each calibration on brachytherapy sources required by 7.41.1
1151 for 3 years after the last use of the source. The record must include the date of the calibration; the
1152 manufacturer's name, model number, and serial number for the source and the instruments used
1153 to calibrate the source; the source output or activity; source positioning accuracy within
1154 applicators; and the signature of the authorized medical physicist.
- 1155 7.41.7 A licensee shall retain a record of decay calculations required by 7.41.5 for the life of the source.
1156 The record must include the date and initial activity of the source as determined under 7.41, and
1157 for each decay calculation, the date, the source activity and the signature of the authorized
1158 medical physicist.
- 1159 **7.42 Use of Sealed Sources For Manual Brachytherapy.**
- 1160 7.42.1 A licensee shall use for manual brachytherapy only sealed sources:
- 1161 7.42.1.1 Approved in the Sealed Source and Device Registry; or
- 1162 7.42.1.2 In research in accordance with an effective Investigational Device Exemption (IDE)
1163 application accepted by the FDA provided the requirements of 7.14.1 are met.
- 1164 7.42.2 Authorized User Training For Use Of Sealed Sources For Manual Brachytherapy.
- 1165 The licensee shall require an authorized user under 7.42 to meet the requirements of Appendix
1166 7K.
- 1167 7.42.3 Authorized User Training For Use Of Strontium-90 Sealed Sources For Ophthalmic Uses.
- 1168 The licensee shall require an authorized user of strontium-90 sealed sources for ophthalmic uses
1169 under 7.42 to meet the requirements of Appendix 7L.

DRAFT 2 –9/15/2011

1170 **7.43 Safety Instruction.**

1171 7.43.1 The licensee shall provide radiation safety instruction, initially and at least annually, to personnel
1172 caring for patients or human research subjects that are undergoing implant therapy and cannot
1173 be released in accordance with 7.26.

1174 7.43.2 The instruction required by 7.43.1 shall be commensurate with the duties of the personnel and
1175 include:

1176 7.43.2.1 Size and appearance of the brachytherapy sources;

1177 7.43.2.2 Safe handling and shielding instructions in case of a dislodged source;

1178 7.43.2.3 Patient or human research subject control;

1179 7.43.2.4 Visitor control, including both;

1180 (1) Routine visitation to hospitalized individuals in accordance with 4.14.1.1; and

1181 (2) Visitation authorized in accordance with 4.14.3; and

1182 7.43.2.5 Notification of the RSO, or his or her designee, and the authorized user if the patient or
1183 the human research subject dies or has a medical emergency .

1184 7.43.3 A licensee shall keep a record of individuals receiving instruction required by 7.43.1 and maintain
1185 such records for 3 years. The record shall include a list of the topics covered, the date of
1186 instruction, the names(s) of the attendee(s), and the name(s) of the individual(s) who gave the
1187 instruction.

1188 **7.44 Safety Precautions.**

1189 7.44.1 For each patient or the human research subject that is receiving brachytherapy and cannot be
1190 released in accordance with 7.26, a licensee shall:

1191 7.44.1.1 Not place the patient or the human research subject in the same room with a patient
1192 who is not receiving radiation therapy;

1193 7.44.1.2 Visibly post the patient's or human research subject's door with a "Caution:
1194 Radioactive Material" sign and note on the door or on the patient's or human research
1195 subject's chart where and how long visitors may stay in the patient's or human research
1196 subject's room.

1197 7.44.2 A licensee shall have emergency response equipment available near each treatment room to
1198 respond to a source that inadvertently becomes:

1199 7.44.2.1 Dislodged from the patient; or

1200 7.44.2.2 Lodged within the patient following removal of the source applicators.

1201 7.44.3 A licensee shall notify the RSO , or his or her designee, and the authorized user immediately if
1202 the hospitalized patient dies or has a medical emergency and notify the Department as required
1203 by 7.39.

1204 **7.45 Brachytherapy Sources Inventory.**

DRAFT 2 –9/15/2011

- 1205 7.45.1 A licensee shall maintain accountability at all times for all brachytherapy sources in storage or
1206 use.
- 1207 7.45.2 Promptly after removing brachytherapy sources from a patient, a licensee shall return
1208 brachytherapy sources to a secure storage area and count or otherwise verify the number
1209 returned to ensure that all sources taken from the storage area have been returned.
- 1210 7.45.3 A licensee shall maintain a record of brachytherapy source accountability for 3 years.
- 1211 7.45.3.1 For temporary implants, the record must include the number and activity of sources:
- 1212 (1) Removed from storage, the time and date they were removed from storage, the
1213 name of the individual who removed them from storage, and the location of use;
1214 and
- 1215 (2) Not implanted, the time and date they were returned to storage, and the name of the
1216 individual who returned them to storage.
- 1217 7.45.3.2 For permanent implants, the record must include the number and activity of sources:
- 1218 (1) Removed from storage, the date they were removed from storage, and the name of
1219 the individual who removed them from storage;
- 1220 (2) Returned to storage, the date they were returned to storage, and the name of the
1221 individual who returned them to storage; and
- 1222 (3) Permanently implanted in the patient or human research subject.
- 1223 **7.46 Surveys After Source Implant and Removal.**
- 1224 7.46.1 Immediately after implanting sources in a patient or a human research subject, the licensee shall
1225 perform a survey to locate and account for all sources that have not been implanted.
- 1226 7.46.2 Immediately after removing the last temporary implant source from a patient or a human research
1227 subject, the licensee shall perform a radiation survey of the patient with a radiation detection
1228 survey instrument to confirm that all sources have been removed. The licensee shall not release
1229 from confinement for medical care a patient treated by temporary implant until all sources have
1230 been removed.
- 1231 7.46.3 A licensee shall maintain a record of patient surveys which demonstrate compliance with 7.46.1
1232 and 7.6.2 for 3 years. Each record shall include the date and results of the survey, the survey
1233 instrument used, and the name of the individual who made the survey.
- 1234 **7.47 Therapy-related Computer Systems.**
- 1235 7.47.1 The licensee shall perform acceptance testing on the treatment planning system in accordance
1236 with published protocols accepted by nationally recognized bodies.
- 1237 7.47.2 At a minimum, the acceptance testing required by 7.47.1 shall include, as applicable, verification
1238 of:
- 1239 7.47.2.1 The source-specific input parameters required by the dose calculation algorithm;
- 1240 7.47.2.1 The accuracy of dose, dwell time, and treatment time calculations at representative
1241 points;

DRAFT 2 –9/15/2011

- 1242 7.47.2.1 The accuracy of isodose plots and graphic displays; and
- 1243 7.47.2.1 The accuracy of the software used to determine radioactive source positions from
- 1244 radiographic images.
- 1245 **SPECIFIC REQUIREMENTS FOR PHOTON-EMITTING REMOTE AFTERLOADER UNITS,**
- 1246 **TELETHERAPY UNITS, AND GAMMA STEREOTACTIC RADIOSURGERY UNITS**
- 1247 **7.48 Use of a Sealed Source in a Remote Afterloader Unit, Teletherapy Unit, or Gamma**
- 1248 **Stereotactic Radiosurgery Unit.**
- 1249 7.48.1 A licensee shall use sealed sources in remote afterloader units, teletherapy units, or gamma
- 1250 stereotactic radiosurgery units for therapeutic medical uses:
- 1251 7.48.1.1 Approved in the Sealed Source and Device Registry; and
- 1252 7.48.1.2 In research in accordance with an ~~effective~~ **active** Investigational Device Exemption
- 1253 (IDE) application accepted by the FDA provided the requirements of 7.14.1 are met.
- 1254 7.48.2 Authorized User Training For Use of a Remote Afterloader Unit, Teletherapy Unit, or Gamma
- 1255 Stereotactic Radiosurgery Unit.
- 1256 The licensee shall require an authorized user under 7.48 to meet the requirements of Appendix
- 1257 7M.
- 1258 **7.49 Installation, Maintenance, Adjustment, and Repair.**
- 1259 7.49.1 Only a person specifically licensed by the Department, another Agreement State, or the NRC shall
- 1260 install, maintain, adjust, or repair a remote afterloader unit, teletherapy unit, or gamma
- 1261 stereotactic radiosurgery unit that involves work on the source(s) shielding, the source(s) driving
- 1262 unit, or other electronic or mechanical component that could expose the source(s), reduce the
- 1263 shielding around the source(s), or compromise the radiation safety of the unit or the source(s).
- 1264 7.49.2 Except for low dose-rate remote afterloader units, only a person specifically licensed by the
- 1265 Department, another Agreement State, a Licensing State, or the NRC shall install, replace,
- 1266 relocate, or remove a sealed source or source contained in other remote afterloader units,
- 1267 teletherapy units, or gamma stereotactic radiosurgery units.
- 1268 7.49.3 For a low dose-rate remote afterloader unit, only a person specifically licensed by the Department,
- 1269 another Agreement State, a Licensing State, or the NRC, or an authorized medical physicist shall
- 1270 install, replace, relocate, or remove a sealed source(s) contained in the unit.
- 1271 7.49.4 A licensee shall retain a record of the installation, maintenance, adjustment and repair done on
- 1272 remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units for 3 years.
- 1273 The record shall include the date, description of the service, and name(s) of the individual(s) who
- 1274 performed the work.
- 1275 **7.50 Surveys of Patients and Human Research Subjects Treated with a Remote Afterloader Unit.**
- 1276 7.50.1 Before releasing a patient or a human research subject from licensee control, a licensee shall
- 1277 make a survey of the patient or the human research subject and the remote afterloader unit with a
- 1278 portable radiation detection survey instrument to confirm that the source(s) has been removed
- 1279 from the patient or human research subject and returned to the safe, shielded position.

Comment [JJ48]: Changed wording for clarification to be consistent with 10 CFR 35.600.

[Change arose as a result of NRC review of draft SSR G in 2010.]

NRC Compatibility = C

DRAFT 2 –9/15/2011

Comment [JJ49]: Change to correct error in repeat numbering.

1280 7.50.24 A licensee shall maintain a record of patient surveys which demonstrate compliance with 7.50.1
1281 for 3 years. Each record shall include the date and results of the survey, the survey instrument
1282 used, and the name of the individual who made the survey.

1283 **7.51 Safety Procedures and Instructions for a Remote Afterloader Unit, Teletherapy Unit, or**
1284 **Gamma Stereotactic Radiosurgery Unit.**

1285 7.51.1 A licensee shall:

1286 7.51.1.1 Secure the unit, the console, the console keys, and the treatment room when not in use
1287 or unattended;

1288 7.51.1.2 Permit only individuals approved by the authorized user, RSO, or authorized medical
1289 physicist to be present in the treatment room during treatment with the source(s), if such
1290 presence is necessary and justified;

1291 7.51.1.3 Prevent dual operation of more than one radiation producing device in a treatment
1292 room, if applicable; and

1293 7.51.1.4 Develop, implement, and maintain written procedures for responding to an abnormal
1294 situation when the operator is unable to place the source(s) in the shielded position, or
1295 remove the patient or human research subject from the radiation field with controls from
1296 outside the treatment room. This procedure must include:

1297 (1) Instructions for responding to equipment failures and the names of the individuals
1298 responsible for implementing corrective actions;

1299 (2) The process for restricting access to and posting of the treatment area to minimize
1300 the risk of inadvertent exposure; and

1301 (3) The names and telephone numbers of the authorized users, the authorized medical
1302 physicist, and the RSO to be contacted if the unit or console operates
1303 abnormally.

1304 7.51.2 A copy of the procedures required by 7.51.1.4 shall be physically located at the unit console.

1305 7.51.3 A licensee shall conspicuously post instructions at the unit console to inform the operator of the
1306 names and telephone numbers of the authorized users, the authorized medical physicist, and the
1307 RSO to be contacted if the unit or console operates abnormally.

1308 7.51.4 A licensee shall provide instruction, initially and at least annually, to all individuals who operate a
1309 unit, as appropriate to the individual's assigned duties, in:

1310 7.51.4.1 The procedures identified in 7.51.1.4; and

1311 7.51.4.2 The operating procedures for the unit.

1312 7.51.5 A licensee shall ensure that operators, authorized medical physicists, and authorized users
1313 participate in drills of the emergency procedures, initially and at least annually.

1314 7.51.6 A licensee shall keep a record of individuals receiving instruction required by 7.51.4 and maintain
1315 such records for 3 years. The record shall include a list of the topics covered, the date of
1316 instruction, the names(s) of the attendee(s), and the name(s) of the individual(s) who gave the
1317 instruction.

DRAFT 2 –9/15/2011

1318 **7.52 Doors, Interlocks, and Warning Systems.**

1319 7.52.1 A licensee shall control access to the treatment room by a door at each entrance.

1320 7.52.2 A licensee shall equip each entrance to the treatment room with an electrical interlock system that
1321 shall:

1322 7.52.2.1 Prevent the operator from initiating the treatment cycle unless each treatment room
1323 entrance door is closed;

1324 7.52.2.2 Cause the source(s) to be shielded promptly when an entrance door is opened; and

1325 7.52.2.3 Prevent the source(s) from being exposed following an interlock interruption until all
1326 treatment room entrance doors are closed and the source(s)' on/off control is reset at the
1327 console.

1328 7.52.3 A licensee shall require any individual entering the treatment room to assure, through the use of
1329 appropriate radiation monitors, that radiation levels have returned to ambient levels.

1330 7.52.4 Except for low-dose remote afterloader units, a licensee shall construct or equip each treatment
1331 room with viewing and intercom systems to permit continuous observation of the patient or the
1332 human research subject from the treatment console during irradiation.

1333 7.52.5 For licensed activities where sources are placed within the patient's or human research subject's
1334 body, a licensee shall only conduct treatments which allow for expeditious removal of a
1335 decoupled or jammed source.

1336 7.52.6 In addition to the requirements specified in 7.52.1 through 7.52.5, a licensee shall:

1337 7.52.6.1 For low dose-rate, medium dose-rate, and pulsed dose-rate remote afterloader units,
1338 require:

1339 (1) An authorized medical physicist and either an authorized user or a physician, under
1340 the supervision of an authorized user, who has been trained in the operation and
1341 emergency response for the unit, to be physically present during the initiation of
1342 all patient treatments involving the unit; and

1343 (2) An authorized medical physicist and either an authorized user or an individual, under
1344 the supervision of an authorized user, who has been trained to remove the
1345 source applicator(s) in the event of an emergency involving the unit, to be
1346 immediately available during continuation of all patient treatments involving the
1347 unit.

1348 7.52.6.2 For high dose-rate remote afterloader units, require:

1349 (1) An authorized user and an authorized medical physicist to be physically present
1350 during the initiation of all patient treatments involving the unit; and

1351 (2) An authorized medical physicist and either an authorized user or a physician, under
1352 the supervision of an authorized user, who has been trained in the operation and
1353 emergency response for the unit, to be physically present during continuation of
1354 all patient treatments involving the unit.

DRAFT 2 –9/15/2011

- 1355 7.52.6.3 For gamma stereotactic radiosurgery units, require an authorized user and an
1356 authorized medical physicist to be physically present throughout all patient treatments
1357 involving the unit.
- 1358 7.52.6.4 If a patient or research subject suffers a medical emergency during radiation therapy:
- 1359 (1) Cease the therapy immediately;
- 1360 (2) Remove the source(s); and
- 1361 (3) Provide appropriate care to the patient or research subject.
- 1362 7.52.6.5 If the patient expires during treatment, remove the source(s) before further actions are
1363 taken.
- 1364 7.52.6.6 Notify the RSO, or his or her designee, and an authorized user as soon as possible, if
1365 the patient or human research subject has a medical emergency and, immediately, if the
1366 patient dies.
- 1367 7.52.7 A licensee shall have emergency response equipment available near each treatment room, to
1368 respond to a situation in which a source inadvertently:
- 1369 7.52.7.1 Remains in the unshielded position; or
- 1370 7.52.7.2 Lodges within the patient following completion of the treatment.
- 1371 **7.53 Dosimetry Equipment.**
- 1372 7.53.1 Except for low dose-rate remote afterloader sources where the source output or activity is
1373 determined by the manufacturer, a licensee shall have a calibrated dosimetry system available for
1374 use. To satisfy this requirement, one of the following two conditions shall be met:
- 1375 7.53.1.1 The system shall have been calibrated using a system or source traceable to the
1376 National Institute of Standards and Technology and published protocols accepted by
1377 nationally recognized bodies, or by a calibration laboratory accredited by the American
1378 Association of Physicists in Medicine. The calibration shall have been performed within
1379 the previous 2 years and after any servicing that may have affected system calibration; or
- 1380 7.53.1.2 The system shall have been calibrated within the previous 4 years; 18 to 30 months
1381 after that calibration, the system shall have been intercompared with another dosimetry
1382 system that was calibrated within the past 24 months by the National Institute of
1383 Standards and Technology or by a calibration laboratory accredited by the American
1384 Association of Physicists in Medicine. The results of the intercomparison must have
1385 indicated that the calibration factor of the licensee's system had not changed by more
1386 than 2 percent. The licensee shall not use the intercomparison result to change the
1387 calibration factor. When intercomparing dosimetry systems to be used for calibrating
1388 sealed sources for therapeutic units, the licensee shall use a comparable unit with beam
1389 attenuators or collimators, as applicable, and sources of the same radionuclide as the
1390 source used at the licensee's facility.
- 1391 7.53.2 The licensee shall have available for use a dosimetry system for spot-check output
1392 measurements. To meet this requirement, the system may be compared with a system that has
1393 been calibrated in accordance with 7.53.1. This comparison shall have been performed within
1394 the previous year and after each servicing that may have affected system calibration. The spot-
1395 check system may be the same system used to meet the requirement in 7.53.1.

DRAFT 2 –9/15/2011

- 1396 7.53.3 The licensee shall maintain a record of each calibration, intercomparison, and comparison for the
1397 duration of the license. For each calibration, intercomparison, or comparison, the record shall
1398 include:
- 1399 7.53.3.1 The date;
- 1400 7.53.3.2 The manufacturer's name, the model numbers and serial numbers of the instruments
1401 that were calibrated, intercompared, or compared as required by 7.53.1 and 7.53.2;
- 1402 7.53.3.3 The correction factor that were determined from the calibration or comparison or the
1403 apparent correction factor that was determined from an intercomparison;
- 1404 7.53.3.4 The names of the individuals who performed the calibration, intercomparison, or
1405 comparison.
- 1406 **7.54 Full Calibration Measurements on Teletherapy Units.**
- 1407 7.54.1 A licensee authorized to use a teletherapy unit for medical use shall perform full calibration
1408 measurements on each teletherapy unit:
- 1409 7.54.1.1 Before the first medical use of the unit;
- 1410 7.54.1.2 Before medical use under the following conditions:
- 1411 (1) Whenever spot-check measurements indicate that the output differs by more than 5
1412 percent from the output obtained at the last full calibration corrected
1413 mathematically for radioactive decay;
- 1414 (2) Following replacement of the source or following reinstallation of the teletherapy unit
1415 in a new location; and
- 1416 (3) Following any repair of the teletherapy unit that includes removal of the source or
1417 major repair of the components associated with the source exposure assembly;
1418 and
- 1419 7.54.1.3 At intervals not exceeding 1 year.
- 1420 7.54.2 To satisfy the requirement of 7.54.1, full calibration measurements shall include determination of:
- 1421 7.54.2.1 The output within +/- 3 percent for the range of field sizes and for the distance or range
1422 of distances used for medical use;
- 1423 7.54.2.2 The coincidence of the radiation field and the field indicated by the light beam localizing
1424 device;
- 1425 7.54.2.3 The uniformity of the radiation field and its dependence on the orientation of the useful
1426 beam;
- 1427 7.54.2.4 Timer accuracy, constancy, and linearity;
- 1428 7.54.2.5 "On off" error; and
- 1429 7.54.2.6 The accuracy of all distance measuring and localization devices in medical use.

DRAFT 2 –9/15/2011

- 1430 7.54.3 A licensee shall use the dosimetry system described in 7.53 to measure the output for one set of
1431 exposure conditions. The remaining radiation measurements required in 7.54.2.1 may then be
1432 made using a dosimetry system that indicates relative dose rates.
- 1433 7.54.4 A licensee shall make full calibration measurements required by 7.54.1 in accordance with
1434 published protocols accepted by nationally recognized bodies.
- 1435 7.54.5 A licensee shall correct mathematically the outputs determined in 7.54.2.1 for physical decay for
1436 intervals not exceeding 1 month for cobalt 60, 6 months for cesium 137, or at intervals consistent
1437 with 1 percent decay for all other nuclides.
- 1438 7.54.6 Full calibration measurements required by 7.54.1 and physical decay corrections required by
1439 7.54.5 shall be performed by the authorized medical physicist.
- 1440 7.54.7 A licensee shall maintain a record of each calibration for the duration of the license. The record
1441 shall include:
- 1442 7.54.7.1 The date of the calibration;
- 1443 7.54.7.2 The manufacturer's name, model number, and serial number for the teletherapy unit,
1444 source(s), and instruments used to calibrate the teletherapy unit;
- 1445 7.54.7.3 The results and assessments of the full calibrations; and
- 1446 7.54.7.4 The signature of the authorized medical physicist who performed the full calibration.
- 1447 **7.55 Full Calibration Measurements on Remote Afterloader Units.**
- 1448 7.55.1 A licensee authorized to use a remote afterloader unit for medical use shall perform full calibration
1449 measurements on each unit:
- 1450 7.55.1.1 Before the first medical use of the unit;
- 1451 7.55.1.2 Before medical use under the following conditions:
- 1452 (1) Following replacement of the source or following reinstallation of the unit in a new
1453 location outside the facility; and
- 1454 (2) Following any repair of the unit that includes removal of the source or major repair of
1455 the components associated with the source exposure assembly; and
- 1456 7.55.1.3 At intervals not exceeding one (1) calendar quarter for high dose-rate, medium dose-
1457 rate, and pulsed dose-rate remote afterloader units with sources whose half-life exceeds
1458 75 days; and
- 1459 7.55.1.4 At intervals not exceeding 1 year for low dose-rate remote afterloader units.
- 1460 7.55.2 To satisfy the requirement of 7.55.1, full calibration measurements must include, as applicable,
1461 determination of:
- 1462 7.55.2.1 The output within +/- 5 percent;
- 1463 7.55.2.2 Source positioning accuracy to within +/- 1 millimeter;
- 1464 7.55.2.3 Source retraction with backup battery upon power failure;

DRAFT 2 –9/15/2011

- 1465 7.55.2.4 Length of the source transfer tubes;
- 1466 7.55.2.5 Timer accuracy and linearity over the typical range of use;
- 1467 7.55.2.6 Length of the applicators; and
- 1468 7.55.2.7 Function of the source transfer tubes, applicators, and transfer tube-applicator
1469 interfaces.
- 1470 7.55.3 In addition to the requirements for full calibrations for low dose-rate remote afterloader units in
1471 7.55.2, a licensee shall perform an autoradiograph of the source(s) to verify inventory and
1472 source(s) arrangement at intervals not exceeding one quarter.
- 1473 7.55.4 A licensee shall use the dosimetry system described in 7.53 to measure the output.
- 1474 7.55.5 A licensee shall make full calibration measurements required by 7.55.1 of this section in
1475 accordance with published protocols accepted by nationally recognized bodies.
- 1476 7.55.6 For low dose-rate remote afterloader units, a licensee may use measurements provided by the
1477 source manufacturer that are made in accordance with 7.55.1 through 7.55.5.
- 1478 7.55.7 A licensee shall mathematically correct the outputs determined in 7.55.2.1 for physical decay at
1479 intervals consistent with 1 percent physical decay.
- 1480 7.55.8 Full calibration measurements required by 7.55.1 and physical decay corrections required by
1481 7.55.7 must be performed by the authorized medical physicist.
- 1482 7.55.9 A licensee shall retain a record of each calibration for the duration of the license. The record
1483 shall include:
- 1484 7. 55.9.1 The date of the calibration;
- 1485 7. 55.9.2 The manufacturer's name, model number, and serial number for the remote afterloader
1486 unit, source(s), and instruments used to calibrate the remote afterloader unit;
- 1487 7. 55.9.3 The results and assessments of the full calibrations;
- 1488 7. 55.9.4 The results of the autoradiograph required for low dose-rate remote afterloader units;
1489 and
- 1490 7. 55.9.5 The signature of the authorized medical physicist who performed the full calibration.
- 1491 **7.56 Full Calibration Measurements on Gamma Stereotactic Radiosurgery Units.**
- 1492 7.56.1 A licensee authorized to use a gamma stereotactic radiosurgery unit for medical use shall perform
1493 full calibration measurements on each unit:
- 1494 7.56.1.1 Before the first medical use of the unit;
- 1495 7.56.1.2 Before medical use under the following conditions:
- 1496 (1) Whenever spot-check measurements indicate that the output differs by more than 5
1497 percent from the output obtained at the last full calibration corrected
1498 mathematically for radioactive decay;

DRAFT 2 –9/15/2011

- 1499 (2) Following replacement of the sources or following reinstallation of the gamma
1500 stereotactic radiosurgery unit in a new location; and
- 1501 (3) Following any repair of the gamma stereotactic radiosurgery unit that includes
1502 removal of the sources or major repair of the components associated with the
1503 source assembly; and
- 1504 7.56.1.3 At intervals not exceeding 1 year, with the exception that relative helmet factors need
1505 only be determined before the first medical use of a helmet and following any damage to
1506 a helmet.
- 1507 7.56.2 To satisfy the requirement of 7.56.1, full calibration measurements must include determination of:
- 1508 7.56.2.1 The output within +/-3 percent;
- 1509 7.56.2.2 Relative helmet factors;
- 1510 7.56.2.3 Isocenter coincidence;
- 1511 7.56.2.4 Timer accuracy and linearity over the range of use;
- 1512 7.56.2.5 On-off error;
- 1513 7.56.2.6 Trunnion centricity;
- 1514 7.56.2.7 Treatment table retraction mechanism, using backup battery power or hydraulic
1515 backups with the unit off;
- 1516 7.56.2.8 Helmet microswitches;
- 1517 7.56.2.9 Emergency timing circuits; and
- 1518 7.56.2.10 Stereotactic frames and localizing devices (trunnions).
- 1519 7.56.3 A licensee shall use the dosimetry system described in 7.53 to measure the output for one set of
1520 exposure conditions. The remaining radiation measurements required in 7.56.2.1 may be made
1521 using a dosimetry system that indicates relative dose rates.
- 1522 7.56.4 A licensee shall make full calibration measurements required by 7.56.1 in accordance with
1523 published protocols accepted by nationally recognized bodies.
- 1524 7.56.5 A licensee shall mathematically correct the outputs determined in 7.56.2.1 at intervals not
1525 exceeding 1 month for cobalt-60 and at intervals consistent with 1 percent physical decay for all
1526 other radionuclides.
- 1527 7.56.6 Full calibration measurements required by 7.56.1 and physical decay corrections required by
1528 7.56.5 must be performed by the authorized medical physicist.
- 1529 7.56.7 A licensee shall retain a record of each calibration for the duration of the license. The record
1530 shall include:
- 1531 7. 56.7.1 The date of the calibration;

DRAFT 2 –9/15/2011

1532 7. 56.7.2 The manufacturer's name, model number, and serial number for the gamma
1533 stereotactic radiosurgery unit, source(s), and instruments used to calibrate the gamma
1534 stereotactic radiosurgery unit;

1535 7. 56.7.3 The results and assessments of the full calibrations;

1536 7. 56.7.4 The signature of the authorized medical physicist who performed the full calibration.

1537 **7.57 Radiation Surveys of Therapeutic Treatment Units.**

1538 7.57.1 A licensee authorized to use radioactive material in remote afterloader units, teletherapy units,
1539 and gamma stereotactic radiosurgery units shall possess a portable radiation detection survey
1540 instrument capable of detecting dose rates over the range of 1 μ Sv (0.1 mrem) per hour to 500
1541 μ Sv (50 mrem) per hour, and a portable radiation measurement survey instrument capable of
1542 measuring dose rates over the range of 10 μ Sv (1 mrem) per hour to 10 mSv (1 rem) per hour.
1543 The instruments shall be operable and calibrated in accordance with 7.17.

1544 7.57.2 In addition to the survey requirements in Part 4 of these regulations, a person licensed pursuant to
1545 Part 7 shall make surveys to ensure that the maximum radiation levels and average radiation
1546 levels from the surface of the main source safe with the source(s) in the shielded position does
1547 not exceed the levels stated in the Sealed Source and Device Registry.

1548 7.57.3 The licensee shall make the survey required by 7.57.2 at installation of a new source and
1549 following repairs to the source(s) shielding, the source(s) driving unit, or other electronic or
1550 mechanical component that could expose the source, reduce the shielding around the source(s),
1551 or compromise the radiation safety of the unit or the source(s).

1552 7.57.4 A licensee shall retain a record of the radiation surveys required by 7.57.2 for the duration of use
1553 of the unit. The record must include:

1554 7.57.4.1 The date of the measurements;

1555 7.57.4.2 The manufacturer's name, model number and serial number of the treatment unit,
1556 source, and instrument used to measure radiation levels;

1557 7.57.4.3 Each dose rate measured around the source while the unit is in the off position and the
1558 average of all measurements; and

1559 7.57.4.4 The signature of the authorized medical physicist who performed the test.

1560 **7.58 Periodic Spot Checks for Teletherapy Units.**

1561 7.58.1 A licensee authorized to use teletherapy units for medical use shall perform output spot checks on
1562 each teletherapy unit once in each calendar month, including determination of:

1563 7.58.1.1 Timer accuracy and timer linearity over the range of use;

1564 7.58.1.2 "On off" error;

1565 7.58.1.3 The coincidence of the radiation field and the field indicated by the light beam localizing
1566 device;

1567 7.58.1.4 The accuracy of all distance measuring and localization devices used for medical use;

DRAFT 2 –9/15/2011

- 1568 7.58.1.5 The output for one typical set of operating conditions measured with the dosimetry
1569 system described in 7.53; and
- 1570 7.58.1.6 The difference between the measurement made in 7.58.1.5 and the anticipated output,
1571 expressed as a percentage of the anticipated output (i.e., the value obtained at last full
1572 calibration corrected mathematically for physical decay).
- 1573 7.58.2 A licensee shall perform spot checks required by 7.58.1 in accordance with procedures
1574 established by the authorized medical physicist. That individual need not actually perform the
1575 output spot-check measurements.
- 1576 7.58.3 A licensee shall have the authorized medical physicist review the results of each spot check within
1577 15 days. The authorized medical physicist shall promptly notify the licensee in writing of the
1578 results of each spot check.
- 1579 7.58.4 A licensee authorized to use a teletherapy unit for medical use shall perform safety spot checks of
1580 each teletherapy facility once in each calendar month and after each source installation to assure
1581 proper operation of:
- 1582 7.58.4.1 Electrical interlocks at each teletherapy room entrance;
- 1583 7.58.4.2 Electrical or mechanical stops installed for the purpose of limiting use of the primary
1584 beam of radiation restriction of source housing angulation or elevation, carriage or stand
1585 travel, and operation of the beam "on off" mechanism;
- 1586 7.58.4.3 Source exposure indicator lights on the teletherapy unit, on the control console, and in
1587 the facility;
- 1588 7.58.4.4 Viewing and intercom systems;
- 1589 7.58.4.5 Treatment room doors from inside and outside the treatment room; and
- 1590 7.58.4.6 Electrically assisted treatment room doors with the teletherapy unit electrical power
1591 turned "off".
- 1592 7.58.5 If the results of the checks required in 7.58.4 indicate the malfunction of any system, a licensee
1593 shall lock the control console in the "off" position and not use the unit except as may be
1594 necessary to repair, replace, or check the malfunctioning system.
- 1595 7.58.6 A licensee shall maintain a record of each spot check required by 7.58.1 and 7.58.5 for 3 years.
1596 The record shall include:
- 1597 7.58.6.1 The date of the spot check;
- 1598 7.58.6.2 The manufacturer's name, model number, and serial number for the teletherapy unit,
1599 source, and instrument used to measure the output of the teletherapy unit;
- 1600 7.58.6.3 An assessment of timer linearity and constancy;
- 1601 7.58.6.4 The calculated "on off" error;
- 1602 7.58.6.5 A determination of the coincidence of the radiation field and the field indicated by the
1603 light beam localizing device
- 1604 7.58.6.6 The determined accuracy of each distance measuring or localization device;

DRAFT 2 –9/15/2011

- 1605 7.58.6.7 The difference between the anticipated output and the measured output;
- 1606 7.58.6.8 Notations indicating the operability of each entrance door electrical interlock, each
- 1607 electrical or mechanical stop, each source exposure indicator light, and the viewing and
- 1608 intercom system and doors; and
- 1609 7.58.6.9 The name of the individual who performed the periodic spot check and the signature of
- 1610 the authorized medical physicist who reviewed the record of the spot check.

1611 **7.59 Periodic Spot Checks for Remote Afterloader Units.**

- 1612 7.59.1 A licensee authorized to use remote afterloader units for medical use shall perform spot checks of
- 1613 each remote afterloader facility and on each unit:
- 1614 7.59.1.1 At the beginning of each day of use of a high dose-rate, medium dose-rate or pulsed
- 1615 dose-rate remote afterloader unit;
- 1616 7.59.1.2 Prior to each patient treatment with a low dose-rate remote afterloader unit; and
- 1617 7.59.1.3 After each source installation.
- 1618 7.59.2 The licensee shall have the authorized medical physicist establish written procedures for
- 1619 performing the spot checks required in 7.59.1 The authorized medical physicist need not actually
- 1620 perform the spot-check measurements.
- 1621 7.59.3 A licensee shall have the authorized medical physicist review the results of each spot check within
- 1622 15 days. The authorized medical physicist shall notify the licensee as soon as possible in writing
- 1623 of the results of each spot check.
- 1624 7.59.4 To satisfy the requirements of 7.59.1, spot checks must, at a minimum, assure proper operation
- 1625 of:

1626 **7.59.4.1 Emergency response equipment;**

1627 **7.59.4.2 Viewing and intercom systems in each high dose-rate, medium dose-rate and**

1628 **pulsed dose-rate remote afterloader facility;**

1629 **7.59.4.3 Radiation monitors used to indicate the source position;**

1630 **7.59.4.4 Electrical interlocks at each remote afterloader unit room entrance;**

1631 **7.59.4.5 Source exposure indicator lights on the remote afterloader unit, on the control console,**

1632 **and in the facility;**

1633 ~~7.59.4.3 Viewing and intercom systems in each high dose-rate, medium dose-rate and pulsed~~

1634 ~~dose-rate remote afterloader facility;~~

1635 ~~7.59.4.4 Emergency response equipment;~~

1636 ~~7.59.4.5 Radiation monitors used to indicate the source position;~~

1637 7.59.4.6 Timer accuracy;

1638 7.59.4.7 Clock (date and time) in the unit's computer; and

Comment [JJ50]: This section was re-ordered based on the recommendation of Radioactive Materials Unit staff to list the required tests in a safer order or sequence. Although not required, some licensees perform the tests in the order shown in the regulations.
There is no change in content or requirements in this section.

DRAFT 2 –9/15/2011

- 1639 7.59.4.8 Decayed source(s) activity in the unit's computer.
- 1640 7.59.5 If the results of the checks required in 7.59.4 indicate the malfunction of any system, a licensee
1641 shall lock the control console in the off position and not use the unit except as may be necessary
1642 to repair, replace, or check the malfunctioning system.
- 1643 7.59.6 A licensee shall retain a record of each check required by 7.59.4 for 3 years. The record must
1644 include, as applicable:
- 1645 7.59.6.1 The date of the spot check;
- 1646 7.59.6.2 The manufacturer's name, model number, and serial number for the remote afterloader
1647 unit and source;
- 1648 7.59.6.3 An assessment of timer accuracy;
- 1649 7.59.6.4 Notations indicating the operability of each entrance door electrical interlock, radiation
1650 monitors, source exposure indicator lights, viewing and intercom systems, and clock and
1651 decayed source activity in the unit's computer; and
- 1652 7.59.6.5 The name of the individual who performed the periodic spot check and the signature of
1653 the authorized medical physicist who reviewed the record of the spot check.
- 1654 **7.60 Additional Technical Requirements for Mobile Remote Afterloader Units.**
- 1655 7.60.1 A licensee providing mobile remote afterloader service shall:
- 1656 7.60.1.1 Check survey instruments for consistent response before medical use at each address
1657 of use or on each day of use, whichever is more frequent; and
- 1658 7.60.1.2 Account for all sources before departure from a client's address of use.
- 1659 7.60.2 In addition to the periodic spot checks required by 7.59, a licensee authorized to use mobile
1660 afterloaders for medical use shall perform checks on each remote afterloader unit before use at
1661 each address of use. At a minimum, checks must be made to verify the operation of:
- 1662 7.60.2.1 Electrical interlocks on treatment area access points;
- 1663 7.60.2.2 Source exposure indicator lights on the remote afterloader unit, on the control console,
1664 and in the facility;
- 1665 7.60.2.3 Viewing and intercom systems;
- 1666 7.60.2.4 Applicators, source transfer tubes, and transfer tube-applicator interfaces;
- 1667 7.60.2.5 Radiation monitors used to indicate room exposures;
- 1668 7.60.2.6 Source positioning (accuracy); and
- 1669 7.60.2.7 Radiation monitors used to indicate whether the source has returned to a safe shielded
1670 position.
- 1671 7.60.3 In addition to the requirements for checks in 7.60.2, a licensee shall ensure overall proper
1672 operation of the remote afterloader unit by conducting a simulated cycle of treatment before use
1673 at each address of use.

DRAFT 2 –9/15/2011

1674 7.60.4 If the results of the checks required in 7.60.2 indicate the malfunction of any system, a licensee
1675 shall lock the control console in the off position and not use the unit except as may be necessary
1676 to repair, replace, or check the malfunctioning system.

1677 7.60.5 A licensee shall retain a record of each check required by 7.60.2 for 3 years. The record must
1678 include:

1679 7.60.5.1 The date of the check;

1680 7.60.5.2 The manufacturer's name, model number, and serial number of the remote afterloader
1681 unit;

1682 7.60.5.3 Notations accounting for all sources before the licensee departs from a facility;

1683 7.60.5.4 Notations indicating the operability of each entrance door electrical interlock, radiation
1684 monitors, source exposure indicator lights, viewing and intercom system, applicators and
1685 source transfer tubes, and source positioning accuracy; and

1686 7.60.5.5 The signature of the individual who performed the check.

1687 **7.61 Periodic Spot Checks for Gamma Stereotactic Radiosurgery Units.**

1688 7.61.1 A licensee authorized to use a gamma stereotactic radiosurgery unit for medical use shall perform
1689 spot checks of each gamma stereotactic radiosurgery facility and on each unit:

1690 7.61.1.1 Monthly;

1691 7.61.1.2 At the beginning of each day of use; and

1692 7.61.1.3 After each source installation.

1693 7.61.2 The licensee shall have the authorized medical physicist:

1694 7.61.2.1 Establish written procedures for performing the spot checks required in 7.61.1; and

1695 7.61.2.2 Review the results of each spot check required by 7.61.1.1 within 15 days of the check.
1696 The authorized medical physicist need not actually perform the spot-check
1697 measurements. The authorized medical physicist shall notify the licensee as soon as
1698 possible, in writing, of the results of the spot check.

1699 7.61.3 To satisfy the requirements of 7.61.1.1 spot checks must, at a minimum:

1700 7.61.3.1 Assure proper operation of:

1701 (1) Treatment table retraction mechanism, using backup battery power or hydraulic
1702 backups with the unit off;

1703 (2) Helmet microswitches;

1704 (3) Emergency timing circuits; and

1705 (4) Stereotactic frames and localizing devices (trunnions).

1706 7.61.3.2 Determine:

DRAFT 2 –9/15/2011

- 1707 (1) The output for one typical set of operating conditions measured with the dosimetry
1708 system described in 7.53.2;
- 1709 (2) The difference between the measurement made in 7.61.3.2(1) and the anticipated
1710 output, expressed as a percentage of the anticipated output (i.e., the value
1711 obtained at last full calibration corrected mathematically for physical decay);
- 1712 (3) Source output against computer calculation;
- 1713 (4) Timer accuracy and linearity over the range of use;
- 1714 (5) On-off error; and
- 1715 (6) Trunnion centricity.
- 1716 7.61.4 To satisfy the requirements of 7.61.1.2 and 7.61.1.3, spot checks must assure proper operation
1717 of:
- 1718 7.61.4.1 Electrical interlocks at each gamma stereotactic radiosurgery room entrance;
- 1719 7.61.4.2 Source exposure indicator lights on the gamma stereotactic radiosurgery unit, on the
1720 control console, and in the facility;
- 1721 7.61.4.3 Viewing and intercom systems;
- 1722 7.61.4.4 Timer termination;
- 1723 7.61.4.5 Radiation monitors used to indicate room exposures; and
- 1724 7.61.4.6 Emergency off buttons.
- 1725 7.61.5 A licensee shall arrange for prompt repair of any system identified in 7.61.3 that is not operating
1726 properly.
- 1727 7.61.6 If the results of the checks required in 7.61.4 indicate the malfunction of any system, a licensee
1728 shall lock the control console in the off position and not use the unit except as may be necessary
1729 to repair, replace, or check the malfunctioning system.
- 1730 7.61.7 A licensee shall retain a record of each check required by 7.61.3 and 7.61.4 for 3 years. The
1731 record must include:
- 1732 7.61.7.1 The date of the spot check;
- 1733 7.61.7.2 The manufacturer's name, model number, and serial number for the gamma stereotactic
1734 radiosurgery unit and the instrument used to measure the output of the unit;
- 1735 7.61.7.3 An assessment of timer linearity and accuracy;
- 1736 7.61.7.4 The calculated on-off error;
- 1737 7.61.7.5 A determination of trunnion centricity;
- 1738 7.61.7.6 The difference between the anticipated output and the measured output;
- 1739 7.61.7.7 An assessment of source output against computer calculations;

DRAFT 2 –9/15/2011

1740 7.61.7.8 Notations indicating the operability of radiation monitors, helmet microswitches,
1741 emergency timing circuits, emergency off buttons, electrical interlocks, source exposure
1742 indicator lights, viewing and intercom systems, timer termination, treatment table
1743 retraction mechanism, and stereotactic frames and localizing devices (trunnions); and

1744 7.61.7.9 The name of the individual who performed the periodic spot check and the signature of
1745 the authorized medical physicist who reviewed the record of the spot check.

1746 **7.62 Other Medical Uses of Radioactive Material or Radiation From Radioactive Material.**

1747 7.62.1 A licensee may use radioactive material or a radiation source approved for medical use that is not
1748 specifically addressed in Part 7 if:

1749 7.62.1.1 The applicant or licensee has submitted the information required by 7.3.4.2, 7.3.4.3, and
1750 7.3.4.4; and

1751 7.62.1.2 The applicant or licensee has received written approval from the an Agreement State,
1752 Licensing State, or NRC in a license and uses the material in accordance with the
1753 regulations and specific conditions that the Agreement State, Licensing State, or NRC
1754 considers necessary for the medical use of the material.

1755 **7.63 Five Year Inspection.**

1756 7.63.1 A licensee shall have each teletherapy unit and gamma stereotactic radiosurgery unit fully
1757 inspected and serviced during source replacement or at intervals not to exceed 5 years,
1758 whichever comes first, to assure proper functioning of the source exposure mechanism.

1759 7.63.2 This inspection and servicing shall only be performed by persons specifically licensed to do so by
1760 the Department, another Agreement State, a Licensing State, or the NRC.

1761 7.63.3 A licensee shall keep a record of the inspection and servicing for the duration of the license. The
1762 record shall contain:

1763 7.63.3.1 The inspector's radioactive materials license number;

1764 7.63.3.2 The date of inspection;

1765 7.63.3.3 The manufacturer's name and model number and serial number of both the treatment
1766 unit and source;

1767 7.63.3.4 A list of components inspected and serviced;

1768 7.63.3.5 A list of components inspected and serviced, and the type of service;

1769 7.63.3.6 A list of components replaced; and

1770 7.63.3.7 The signature of the inspector.
1771

**PART 7, APPENDIX 7A: TRAINING FOR RADIATION SAFETY OFFICER (RSO)-ADEQUATE
RADIATION SAFETY TRAINING AND EXPERIENCE**

The licensee shall require the individual fulfilling the responsibilities of the Radiation Safety Officer (RSO) as provided in 7.7 to be an individual who:

7A1 ~~Has provided:~~ Is certified by a specialty board whose certification process has been recognized by NRC or an Agreement State and who meets the requirements in paragraphs 7A4 and 7A5 of this Appendix. NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>. To have its certification process recognized, a specialty board shall require all candidates for certification to:

7A1.1 ~~(1) Evidence of current certification in health physics or medical physics by a recognized specialty board (see 7A5); and~~ Hold a bachelor's or graduate degree from an accredited college or university in physical science or engineering or biological science with a minimum of 20 college credits in physical science;

and

(2) Have 5 or more years of professional experience in health physics, provided:

(a) At least 3 years are in applied health physics;

and

(b) Graduate training may substitute for no more than 2 years of the required 5 years of experience;

and

(3) Pass an examination administered by diplomates of the specialty board, which evaluates knowledge and competence in radiation physics and instrumentation, radiation protection, mathematics pertaining to the use and measurement of radioactivity, radiation biology, and radiation dosimetry;

or

7A1.2 ~~(1)~~ Hold a master's or doctor's degree in physics, medical physics, other physical science, engineering, or applied mathematics from an accredited college or university;

and

(2) Have 2 years of full-time practical training and/or supervised experience in medical physics that is:

(a) Under the supervision of a medical physicist who is certified in medical physics by a specialty board recognized by an Agreement State or NRC;

or

Comment [JJ51]: NOTE TO READER: THIS AND APPENDICES B THROUGH M HAVE BEEN REVISED TO FOLLOW THE SEQUENCE AND CURRENT REQUIREMENTS CONTAINED IN 10 CFR PART 35.

ALSO NOTE THAT IN 10 CFR PART 35, SECTIONS 35.57 (EXPERIENCED INDIVIDUALS) AND 35.59 (RECENTNESS OF TRAINING) ARE STAND-ALONE SECTIONS WHEREAS IN THIS PART 7, SIMILAR PROVISIONS APPEAR AND ARE REPEATED IN EACH APPENDIX.

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: par2

Formatted: Indent: Hanging: 1"

Formatted: par2

Formatted: Font: Not Italic

DRAFT 2 –9/15/2011

(b) In clinical nuclear medicine facilities providing diagnostic and / or therapeutic services under the general supervision of physicians who meet the requirements for Authorized Users in 7A7, Appendix 7F or Appendix 7G;

Comment [JJ52]: Original references not consistent with references made in 10 CFR 35.50(a)(2)(ii)(B).

and

Formatted: Indent: Hanging: 1"

(3) Pass an examination administered by diplomates of the specialty board that assesses knowledge and competence in clinical diagnostic radiological or nuclear medicine physics and in radiation safety.

Formatted: par3

Formatted: Font: Not Italic

~~7A1.2 Written attestation(s), signed by a preceptor RSO, that the individual has achieved a level of radiation safety knowledge sufficient to function independently as an RSO for a medical use licensee;~~

~~(1) Each preceptor RSO supervising the training required by Appendix 7A shall meet the requirements for an RSO for the type(s) of use for which the individual is seeking authorization; and~~

~~7A1.3 Evidence of documented experience with the radiation safety aspects of the type(s) of use or similar type(s) of use of radioactive material for which the individual is seeking to have RSO responsibilities.~~

~~(1) For a new type of use under 7.62, acceptable training under 7A2.2 is sufficient, unless the Department determines otherwise;~~

Formatted: Indent: Hanging: 0.5"

or

7A2 Has satisfied the following criteria:

~~7A2.1 Has provided written attestation(s), signed by a preceptor RSO, that the individual has completed a structured educational program~~ **consisting of that includes:**

(1) 200 hours of classroom and laboratory training in the following areas:

- (a) Radiation physics and instrumentation;
- (b) Radiation protection;
- (c) Mathematics pertaining to the use and measurement of radioactivity;
- (d) Radiation biology; and
- (e) Radiation dosimetry;

and

Formatted: Indent: Hanging: 1"

(2) 1 year of full-time radiation safety experience, under the supervision of **the individual identified as** an RSO **or Alternate RSO**, ~~authorized medical physicist, authorized nuclear pharmacist, or authorized user, as appropriate,~~ on an Agreement State or NRC license **or permit issued by a NRC master material licensee** that authorizes similar type(s) of use of radioactive material, involving the following:

- (a) Shipping, receiving, and performing related radiation surveys;

DRAFT 2 –9/15/2011

- 1845 (b) Using and performing checks for proper operation of dose calibrators, survey
1846 meters, and, if appropriate, instruments used to measure radionuclides;
- 1847 (c) Securing and controlling radioactive material;
- 1848 (d) Using administrative controls to avoid mistakes in the administration of
1849 radioactive material;
- 1850 (e) Using procedures to prevent or minimize radioactive contamination and using
1851 proper decontamination procedures;
- 1852 (f) Using emergency procedures to control radioactive material; and
- 1853 (g) Disposing of radioactive material; ~~and~~

1854 or

1855 **7A3 Meets the following requirements:**

1856 **7A3.1 Is a medical physicist who has been certified by a specialty board whose**
1857 **certification process has been recognized by the NRC or an Agreement State**
1858 **under Appendix 7B1 and has experience in radiation safety for similar types of use**
1859 **of radioactive material for which the licensee is seeking the approval of the**
1860 **individual as Radiation Safety Officer and who meets the requirements in 7A4 and**
1861 **7A5.**

1862 or

1863 **7A3.2 Is an authorized user, authorized medical physicist, or authorized nuclear**
1864 **pharmacist identified on the licensee's license and has experience with the**
1865 **radiation safety aspects of similar types of use of radioactive materials for which**
1866 **the individual has RSO responsibilities;**

1867 and

1868 **7A4 Has provided written attestation(s), signed by a preceptor RSO, that the individual has**
1869 **satisfactorily completed the requirements in 7A5 and in 7A1.1(1) and 7A1.1(2) or 7A1.2(1)**
1870 **and 7A1.2(2) or 7A2.1 or 7A3.1 or 7A3.2, and has achieved a level of radiation safety**
1871 **knowledge sufficient to function independently as an RSO for a medical use licensee;**

1872 and

1873 **7A5 7A2.2 Has experiential training in the radiation safety, regulatory issues, and emergency procedures**
1874 **for the type(s) of use for which the licensee is seeking approval. This training**
1875 **requirement may be satisfied by completing for example, training that is supervised**
1876 **by an RSO, Alternate RSO, authorized medical physicist, authorized nuclear pharmacist,**
1877 **or authorized user, as appropriate, who is authorized on an Agreement State or NRC**
1878 **license that authorizes similar for the type(s) of use of radioactive material for which the**
1879 **licensee is seeking approval. and**

1880 **7A2.3 Has provided written attestation(s), signed by a preceptor RSO, that the individual has**
1881 **achieved a level of radiation safety knowledge sufficient to function independently as an**
1882 **RSO for a medical use licensee;**

1883 or

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.5"

Formatted: Font: 10 pt

Formatted: Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.5"

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0"

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Indent: Hanging: 1"

DRAFT 2 –9/15/2011

7A3 Has demonstrated adequate prior experience as:

~~7A3.1 An experienced medical physicist who has provided written attestation(s), signed by a preceptor RSO, that the medical physicist:~~

~~(1) Is certified by a specialty board whose certification process has been recognized under 7A5.2; and~~

~~(2) Has satisfied 7A1.2, 7A2.2 and 7A2.3;~~

~~or~~

~~7A3.2 An authorized user, authorized medical physicist, or authorized nuclear pharmacist who:~~

~~(1) Is identified on the licensee's current license; and~~

~~(2) Has satisfied 7A1.2, 7A2.2 and 7A2.3;~~

~~or~~

and

7A6 Meets the following recentness of training requirements:

7A6.1 The training and experience required by Appendix 7A shall have been obtained within the 7 years preceding the date of license application or amendment request;

or

7A6.2 The individual must have had related, documented continuing education and experience since the required training and experience was obtained.

or

7A7 Meets the following requirements for an experienced Radiation Safety Officer:

~~7A7.13.3 An individual identified as a Radiation Safety Officer on a license issued by the NRC or Agreement State, a permit issued under an NRC or Agreement State broad scope license before October 25, 2005, are not required to comply with the training requirements of 7A1 through 7A6. experienced RSO who was identified before October 25, 2005 (and thus need not comply with 7A1, 7A2.1 or 7A2.2) either on:~~

~~(1) An Agreement State or NRC license that authorizes medical use; or~~

~~(2) A permit issued by an Agreement State or NRC broad scope licensee that authorizes medical use; or on~~

~~(3) An equivalent permit or license recognized by the Department for similar types and uses of radioactive material.~~

7A7.2 Individuals not required to comply with the training requirements of 7A1 through 7A6 may serve as preceptors for, and supervisors of, applicants seeking authorization on licenses for the same uses for which these individuals are authorized.

Comment [JJ53]: JJ 6/20/2011: Changes to 7A4 requested by staff (JG) to clarify requirement and make language consistent w/NRC.

Comment [JJ54]: JJ 6/21/2011: The term "or amendment request" is added for clarity, since many additions of RSO's occur during license amendment requests as well as during license applications.

Formatted: par3, Indent: Left: 0.5"

Formatted: Not Highlight

Formatted: par3, Indent: Left: 1", Tab stops: 0.88", Left

Formatted: Not Highlight

Comment [JJ55]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: Not Bold

DRAFT 2 –9/15/2011

- 1918 ~~7A4. Training and experience required by Appendix 7A, shall have been obtained:~~
- 1919 ~~7A4.1 Within the 7 years preceding the date of license application; or~~
- 1920 ~~7A4.2 Through documented subsequent continuing education and experience.~~
- 1921 ~~7A5—To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by~~
- 1922 ~~NRC at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>) a specialty~~
- 1923 ~~board shall require that each candidate for certification:~~
- 1924 ~~7A5.1 With a health physics background:~~
- 1925 ~~(1) Hold a bachelor's or graduate degree from an accredited college or university in~~
- 1926 ~~physical science or engineering or biological science with a minimum of 20~~
- 1927 ~~college credits in physical science; and~~
- 1928 ~~(2) Have 5 or more years of professional experience in health physics; provided:~~
- 1929 ~~(a) At least 3 years are in applied health physics; and~~
- 1930 ~~(b) Graduate training may be substituted for no more than 2 years of the~~
- 1931 ~~required 5 years of experience; and~~
- 1932 ~~(3) Pass an examination administered by diplomates of the specialty board that~~
- 1933 ~~evaluates knowledge and competence in radiation physics and instrumentation,~~
- 1934 ~~radiation protection, mathematics pertaining to the use and measurement of~~
- 1935 ~~radioactivity, radiation biology, and radiation dosimetry;~~
- 1936 ~~7A5.2 With a medical physics background:~~
- 1937 ~~(1) Hold a master's or doctor's degree in physics, medical physics, other physical~~
- 1938 ~~science, engineering, or applied mathematics from an accredited college or~~
- 1939 ~~university; and~~
- 1940 ~~(2) Have 2 years of full-time practical training and/or supervised experience in medical~~
- 1941 ~~physics;~~
- 1942 ~~(a) Under the supervision of a medical physicist who is certified in medical~~
- 1943 ~~physics by a specialty board recognized by an Agreement State or NRC;~~
- 1944 ~~or~~
- 1945 ~~(b) In clinical nuclear medicine facilities providing diagnostic and / or therapeutic~~
- 1946 ~~services under the general supervision of physicians who meet the~~
- 1947 ~~requirements of Appendix 7E or Appendix 7G; and~~
- 1948 ~~(3) Pass an examination administered by diplomates of the specialty board that~~
- 1949 ~~assesses knowledge and competence in clinical diagnostic radiological or~~
- 1950 ~~nuclear medicine physics and in radiation safety.~~
- 1951
- 1952

Comment [JJ56]: JJ 6/20/2011: Changes to 7A4 requested by staff (JG) to clarify requirement and make language consistent w/NRC.

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Comment [JJ57]: JJ 6/27/2011: Original references not consistent with references made in 10 CFR 35.50(a)(2)(ii)(B).

Formatted: par3

PART 7, APPENDIX 7B: TRAINING FOR AUTHORIZED MEDICAL PHYSICIST (AMP)-ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE

The licensee shall require each authorized medical physicist to be an individual who:

7B1 ~~Has provided:~~ **Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agreement State and who meets the requirements in paragraph 7B2.3 and 7B3 of this Appendix. NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>.**

7B1.1 To have its certification process recognized, a specialty board shall require all candidates for certification to:

(1) Hold a master's or doctor's degree in physics, medical physics, other physical science, engineering, or applied mathematics from an accredited college or university;

and

(2) Have 2 years of full-time practical training and/or supervised experience in medical physics:

(a) Under the supervision of a medical physicist who is certified in medical physics by a specialty board recognized by an Agreement State or NRC;

or

(b) In clinical radiation facilities providing high energy, external beam therapy (photons and electrons with energies greater than or equal to 1 million electron volts) and brachytherapy services under the direction of physicians who meet the requirements for authorized users in 7B5, Appendix 7K or Appendix 7M;

and

(3) Pass an examination administered by diplomates of the specialty board, that assesses knowledge and competence in clinical radiation therapy, radiation safety, calibration, quality assurance and treatment planning for external beam therapy, brachytherapy, and stereotactic radiosurgery;

Evidence of current certification by a recognized specialty board (see 7B5); and

7B1.2 Written attestation(s), signed by a preceptor medical physicist, that the individual has achieved a level of competency sufficient to function independently as an authorized medical physicist for each type of therapeutic medical unit for which the individual is requesting authorized medical physicist status;

(1) Each preceptor medical physicist supervising the training required by Appendix 7B shall meet the requirements for an authorized medical physicist for the type(s) of use for which the individual is seeking authorization;

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Indent: Left: 1.5", Hanging: 0.5", Numbered + Level: 1 + Numbering Style: a, b, c, ... + Start at: 1 + Alignment: Left + Aligned at: 1" + Indent at: 1.25", Tab stops: 2", Left

Formatted: Indent: Left: 1.5"

Formatted: Indent: Left: 1.5", Hanging: 0.5", Numbered + Level: 1 + Numbering Style: a, b, c, ... + Start at: 1 + Alignment: Left + Aligned at: 1" + Indent at: 1.25"

Formatted: Indent: Left: 0.5"

DRAFT 2 –9/15/2011

- 1991 (2) The Department may, upon application or upon its own initiative, accept as being
1992 adequate:
- 1993 (a) Documentation that the equivalent component of an Agreement State or
1994 NRC requirement has been met; or
- 1995 (b) Equivalent approval by another state or agency; and
- 1996 7B1.3 Written attestation(s), signed by a preceptor medical physicist, that the individual has
1997 adequate training for the type(s) of use for which authorization is sought:
- 1998 (1) Including:
- 1999 (a) Hands on device operation;
- 2000 (b) Safety procedures;
- 2001 (c) Clinical use; and
- 2002 (d) Treatment planning system operation; and
- 2003 (2) Provided by either:
- 2004 (a) Satisfactorily completing a vendor training program; or
- 2005 (b) Being supervised by an authorized medical physicist authorized for the
2006 type(s) of use for which the individual is seeking authorization; and
- 2007 or
- 2008 7B2 Has **satisfied the following criteria** provided written attestation(s), signed by a preceptor medical
2009 physicist, that the individual:
- 2010 7B2.1 Holds a master's or doctor's degree in physics, medical physics, other physical science,
2011 engineering, or applied mathematics from an accredited college or university;
- 2012 **and**
- 2013 7B2.2 Has ~~satisfactorily~~ completed ~~21~~ years of **full-time** training **in medical physics** and **an**
2014 **additional year of full-time** work experience **under the supervision of an individual**
2015 **who meets the requirements for an authorized medical physicist for the type(s) of**
2016 **use for which the individual is seeking authorization.**
- 2017 (1) **The training and work experience of 7B2.2 must be that:**
- 2018 (1) Include one year of full time training in medical physics; and
- 2019 (2) Include an additional year of full time practical experience;
- 2020 (3) ~~Are c~~Conducted in clinical radiation facilities that provide high-energy, external beam
2021 **therapy** (photons or electrons **with energies greater than or equal to** ~~1~~ **1**
2022 MeV) ~~therapy~~ and brachytherapy services **and must include;**
- 2023 (4) ~~And include:~~

Formatted: Indent: Hanging: 0.5"

Formatted: Tab stops: 4.82", Left + Not at 1" + 1.5"

Comment [JJ58]: The change from 2 years to 1 year is consistent with recent changes to 10 CFR 35.51.

Formatted: par2

DRAFT 2 –9/15/2011

- 2024 (a) Performing sealed source leak tests and inventories;
- 2025 (b) Performing decay corrections;
- 2026 (c) Performing full calibration and periodic spot checks of external beam
2027 treatment units, stereotactic radiosurgery units, and remote afterloading
2028 units as applicable;
- 2029 and
- 2030 (d) Conducting radiation surveys around external beam treatment units,
2031 stereotactic radiosurgery units, and remote afterloading units as
2032 applicable;

2033 and

2034 7B2.3 Has obtained written attestation that the individual has satisfactorily completed the
2035 requirements in:

2036 (1) 7B3 and 7B1.1(1) and 7B1.1(2);

2037 or

2038 (2) 7B2 and 7B3;

2039 and

2040 (3) Has achieved a level of competency sufficient to function independently as an
2041 authorized medical physicist for each type of therapeutic medical unit for
2042 which the individual is requesting authorized medical physicist status. The
2043 written attestation must be signed by a preceptor authorized medical physicist
2044 who meets the requirements in this Appendix (7B), 7B5, or equivalent NRC or
2045 Agreement State requirements for an authorized medical physicist for each
2046 type of therapeutic medical unit for which the individual is requesting
2047 authorized medical physicist status;

2048 and

2049 Has also satisfied 7B1.1 and 7B1.2.

2050 or

2051 7B3 Has met the following requirements:

2052 7B3.1 Has training for the type(s) of use for which authorization is sought that includes:

2053 (1) Hands-on device operation,

2054 (2) Safety procedures,

2055 (3) Clinical use,

2056 and

2057 (4) The operation of a treatment planning system.

Formatted: Indent: Hanging: 1.5"

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25", Tab stops: 1.25", Left + Not at 1.5"

Formatted: Indent: Left: 1", Hanging: 0.25",
Tab stops: 1.25", Left + Not at 1.5"

Formatted: Font: 10 pt, Not Highlight

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25", Tab stops: 1.25", Left + Not at 1.5"

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Indent: Left: 1", Hanging: 0.25",
Tab stops: 1.25", Left + Not at 1.5"

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25", Tab stops: 1.25", Left + Not at 1.5"

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Indent: Hanging: 1"

Formatted: par2

Formatted: Indent: Left: 0"

Formatted: Indent: Left: 1"

7B3.2 The training required by 7B3.1 may be satisfied by:

(1) Satisfactorily completing a training program provided by the vendor;

or

Through training supervised by an authorized medical physicist authorized for the type(s) of use for which the individual is seeking authorization.

and

7B4 Meets the following recentness of training requirements:

7B4.1 Training and experience required by Appendix 7B shall have been obtained within the 7 years preceding the date of license application or amendment request;

or

7B4.2 The individual must have had related, documented, continuing education and experience since the required training and experience was obtained.

or

7B53 Meets the following requirements for an experienced authorized medical physicist: Has demonstrated adequate prior experience as:

7B35.1 An individual identified as an authorized medical physicist on a license issued by the NRC or Agreement State, a permit issued under an NRC or Agreement State broad scope license before October 25, 2005, are not required to comply with the training requirements of 7B1 through 7B4. authorized medical physicist identified on a current license or permit, either on:

(1) A specific medical license or equivalent permit issued by the Department, another Agreement State, a Licensing State, or NRC; or

(2) A permit issued by a Department, Agreement State, Licensing State, or NRC specific medical use licensee of broad scope that is authorized to permit the use of radioactive material;

or

7B3.2 An experienced medical physicist who was identified before October 25, 2005 (and thus need not comply with the training and experience requirements of 7B1 or 7B2) either on:

(1) An NRC or Agreement State license; or

(2) A permit issued under an NRC or Agreement State broad scope license that authorizes medical use;

or

7B35.23 An experienced medical physicist who has demonstrated to the Department experience in the type(s) of use for which the individual is requesting authorized medical physicist

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25"

Formatted: Indent: Left: 1"

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25"

Formatted: par1, Indent: Left: 0"

Formatted: Indent: Left: 0", Hanging: 0.5"

Comment [JJ59]: JJ 6/21/2011: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Indent: Hanging: 1"

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

2092 status (and thus need not comply with the specific training and experience requirements
2093 of 7B1 ~~through~~ 7B42):

2094 (1) Having been certified before October 25, 2005 by the American Board of Radiology
2095 in:

2096 (a) Therapeutic radiological physics;

2097 (b) Roentgen ray and gamma ray physics;

2098 (c) X-ray and radium physics;

2099 or

2100 (d) Radiological physics;

2101 or

2102 (2) Having been certified before October 25, 2005 by the American Board of Medical
2103 Physics in radiation oncology physics;

2104 and

2105 (3) And having ~~Has~~ sufficient work experience that includes the tasks listed in 7.13.2
2106 and/or other sections of these regulations related to medical physics, as
2107 applicable (having also satisfied 7B2.1 and being trained in therapeutic
2108 radiological physics).

2109 **7B5.3 Individuals not required to comply with the training requirements of 7B1 through**
2110 **7B4 may serve as preceptors for, and supervisors of, applicants seeking**
2111 **authorization on licenses for the same uses for which these individuals are**
2112 **authorized.**

2113 ~~7B4 Training and experience required by Appendix 7B shall have been obtained:~~

2114 ~~7B4.1 Within the 7 years preceding the date of license application; or~~

2115 ~~7B4.2 Through documented subsequent continuing education and experience.~~

2116 ~~7B5 To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by~~
2117 ~~NRC at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>), a specialty~~
2118 ~~board shall require that each candidate for certification:~~

2119 ~~7B5.1 Hold a master's or doctor's degree in physics, medical physics, other physical science,~~
2120 ~~engineering, or applied mathematics from an accredited college or university; and~~

2121 ~~7B5.2 Have 2 years of full-time practical training and/or supervised experience in medical~~
2122 ~~physics;~~

2123 ~~(1) Under the supervision of a medical physicist who is certified in medical physics by a~~
2124 ~~specialty board recognized by an Agreement State or NRC; or~~

2125 ~~(2) In clinical radiation facilities providing high energy, external beam therapy and~~
2126 ~~brachytherapy services under the direction of physicians who meet the~~
2127 ~~requirements for authorized users in Appendix 7K or Appendix 7M; and~~

Formatted: Font: 10 pt

Comment [O60]: NOTE: The certifications referenced in this section (which are not being changed) do not appear in Part 35. However, the certifications referenced in this section are believed to have been placed in Part 7 to address the concern that prior to the 2005 Part 7 revision, the term "authorized medical physicist" did not appear in regulation or on radioactive materials licenses.

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Indent: Hanging: 1"

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: par3, Indent: Left: 1", Tab stops: 0.31", Left

Comment [JJ61]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

Formatted: Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: Not Bold

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

2128 |
2129 |
2130 |
2131 |
2132 |

7B5.3 Pass an examination administered by diplomates of the specialty board, that
assesses knowledge and competence in clinical radiation therapy, radiation
safety, calibration, quality assurance and treatment planning for external beam
therapy, brachytherapy, and stereotactic radiosurgery.

DRAFT 2 –9/15/2011

**PART 7, APPENDIX 7C: TRAINING FOR AUTHORIZED NUCLEAR PHARMACIST (ANP)
ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE**

The licensee shall require each authorized nuclear pharmacist to be a pharmacist who has a current active Colorado State Board of Pharmacy license and who:

Formatted: Font: 10 pt

7C1 ~~Has provided:~~ **Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agreement State and who meets the requirements in paragraph 7C2.2 of this Appendix. NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>.**

Formatted: Font: 10 pt

7C1.1 To have its certification process recognized, a specialty board shall require all candidates for certification to:

Formatted: Font: 10 pt

(1) Have graduated from a pharmacy program accredited by the American Council on Pharmaceutical Education (ACPE) or have passed the Foreign Pharmacy Graduate Examination Committee (FPGEC) examination;

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25", Tab stops: 1.25", Left + Not at 1.5"

(2) Hold a current, active license to practice pharmacy;

(3) Provide evidence of having acquired at least 4000 hours of training/experience in nuclear pharmacy practice (academic training may be substituted for no more than 2000 hours of the required training and experience);

and

Formatted: Indent: Left: 1", Hanging: 0.25"

(4) Pass an examination, in nuclear pharmacy administered by diplomates of the specialty board, which assesses knowledge and competency in procurement, compounding, quality assurance, dispensing, distribution, health and safety, radiation safety, provision of information and consultation, monitoring patient outcomes, and research and development.

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25", Tab stops: 1.25", Left + Not at 1.5"

Evidence of:

(1) Current Board of Pharmaceutical Specialties Certification as a Nuclear Pharmacist; or

Formatted: par2

(2) Current certification by a recognized specialty board (see 7C5); and

7C1.2 Written attestation(s), signed by a preceptor nuclear pharmacist, that the individual has achieved a level of competency sufficient to function independently as a nuclear pharmacist;

(1) Each preceptor nuclear pharmacist supervising the experiential training required by Appendix 7C shall meet the requirements for an authorized nuclear pharmacist;

Formatted: par2

or

7C2 **Has satisfied the following criteria:**

7C2.1 ~~Has provided written attestation(s), signed by a preceptor nuclear pharmacist, that the individual has~~ **completed 700 hours in a structured educational program that includes:**

(1) 200 hours of classroom and laboratory training in the following areas:

DRAFT 2 –9/15/2011

- 2169 (a) Radiation physics and instrumentation;
2170 (b) Radiation protection;
2171 (c) Mathematics pertaining to the use and measurement of radioactivity;
2172 (d) Chemistry of radioactive material for medical use; and
2173 (e) Radiation biology;
2174 and
2175 (2) Supervised practical experience in nuclear pharmacy involving:
2176 (a) Shipping, receiving, and performing related radiation surveys;
2177 (b) Using and performing checks for proper operation of instruments to
2178 determine the activity of dosages, survey meters, and, if appropriate,
2179 instruments used to measure alpha- or beta-emitting radionuclides;
2180 (c) Calculating, assaying, and safely preparing dosages for patients or human
2181 research subjects;
2182 (d) Using administrative controls to avoid misadministrations in the
2183 administration of radioactive material;
2184 and
2185 (e) Using procedures to prevent or minimize radioactive contamination and using
2186 proper decontamination procedures;

Formatted: Indent: Left: 0", First line: 0"

- 2187 and
2188 7C2.2 Has provided written attestation(s), signed by a preceptor **authorized** nuclear pharmacist,
2189 that the individual has **satisfactorily completed the requirements in 7C1.1(1),**
2190 **7C1.1(2), and 7C1.1(3) or 7C2, and has** achieved a level of competency sufficient to
2191 function independently as **an authorized** nuclear pharmacist.

Formatted: Indent: Hanging: 1.5"

2192 and

Formatted: Indent: Hanging: 0.5"

2193 **7C3 Meets the following recentness of training requirements:**

2194 **7C3.1 The training and experience required by Appendix 7C shall have been obtained**
2195 **within the 7 years preceding the date of license application or amendment request;**

2196 or

Comment [JJ62]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

2197 **7C3.2 The individual must have had related, documented, continuing education and**
2198 **experience since the required training and experience was obtained.**

Formatted: Indent: Hanging: 0.5"

2199 or

2200 **7C43 Meets the following requirements for an experienced authorized nuclear pharmacist.**
2201 ~~demonstrated adequate prior experience as:~~

Formatted: Indent: Left: 0", First line: 0"

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

2202
2203
2204
2205
2206

~~7C4.3.1~~ An ~~individual identified as an authorized nuclear pharmacist on a license issued by the NRC or Agreement State, a permit issued under an NRC or Agreement State broad scope license before October 25, 2005, are not required to comply with the training requirements of 7C1 through 7C3.~~ ~~authorized nuclear pharmacist identified on a current facility license or permit, either on:~~

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

2207
2208

~~(1) A specific license or equivalent permit that authorizes medical use or the practice of pharmacy issued by the Department, an Agreement State, Licensing State, or NRC; or~~

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

2209
2210

~~(2) A permit issued under a Department, Agreement State, Licensing State, or NRC-specific license of broad scope that is authorized to permit the use of radioactive material;~~

Formatted: Font: 10 pt

2211

~~or~~

Formatted: Font: 10 pt

Formatted: Font: 10 pt

2212
2213

~~7C3.2 Is an experienced nuclear pharmacist who was identified before October 25, 2005 (and thus need not comply with the requirements of 7C2) either on:~~

Formatted: Font: 10 pt

2214

~~(1) An NRC or Agreement State license; or~~

Formatted: par2

2215
2216

~~(2) A permit issued under an NRC or Agreement State broad scope license that authorizes the practice of nuclear pharmacy.~~

Formatted: Font: 10 pt

2217
2218
2219
2220

~~7C4.2 Individuals not required to comply with the training requirements of 7C1 through 7C3 may serve as preceptors for, and supervisors of, applicants seeking authorization on licenses for the same uses for which these individuals are authorized.~~

Formatted: Font: 10 pt

Formatted: Indent: Left: 0.5"

Formatted: Font: 10 pt, Not Highlight

Comment [JJ63]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

Formatted: Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

2221

~~7C4~~ Training and experience required by Appendix 7C shall have been obtained:

2222

~~7C4.1 Within the 7 years preceding the date of license application; or~~

2223

~~7C4.2 Through documented subsequent continuing education and experience.~~

2224
2225
2226

~~7C5~~ To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by NRC at <http://www.nrc.gov/materials/miau/med-use/toolkit/spec-board-cert.html>), a specialty board shall require that each candidate for certification:

2227
2228
2229

~~7C5.1 Have graduated from a pharmacy program accredited by the American Council on Pharmaceutical Education (ACPE) or have passed the Foreign Pharmacy Graduate Examination Committee (FPGEC) examination;~~

2230

~~7C5.2 Hold a current, active license to practice pharmacy;~~

2231
2232
2233

~~7C5.3 Provide evidence of having acquired at least 4000 hours of training/experience in nuclear pharmacy practice (academic training may be substituted for no more than 2000 hours of the required training and experience); and~~

2234
2235
2236
2237
2238

~~7C5.4 Pass an examination, in nuclear pharmacy administered by diplomates of the specialty board, which assesses knowledge and competency in procurement, compounding, quality assurance, dispensing, distribution, health and safety, radiation safety, provision of information and consultation, monitoring patient outcomes, and research and development.~~

2239

DRAFT 2 –9/15/2011

PART 7, APPENDIX 7D: AUTHORIZED USER TRAINING FOR UPTAKE, DILUTION AND EXCRETION STUDIES (7.30 USES) ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE

The licensee shall require an authorized user of an unsealed radioactive material for the uses authorized under 7.30 to be a physician who has a current active State of Colorado license and:

7D1 ~~Has provided~~ **Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agreement State and who meets the requirements in paragraph 7D3.2 of this Appendix. NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>.**

7D1.1 To have its certification process recognized, a specialty board shall require that all candidates for certification to:

(1) Complete 60 hours of training in basic radionuclide handling techniques and radiation safety applicable to the medical use of unsealed radioactive materials for uptake, dilution, and excretion studies as described in 7D3.1(1) through 7D3.1(2)(f);

and

(2) Pass an examination, administered by diplomates of the specialty board, that assesses knowledge and competence in radiation safety, radionuclide handling, and quality control.

Evidence of current certification by a recognized specialty board (see 7D5); and

~~7D1.2 Written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 7.30;~~

~~(1) Each preceptor authorized user supervising the experiential training required by Appendix 7D shall meet the requirements of Appendix 7D, Appendix 7E or Appendix 7F, or equivalent Agreement State or NRC requirements.~~

or

7D2 Is an authorized user under Appendix 7E, Appendix 7F, or equivalent Agreement State or NRC requirements; or 7D3

or

7D3 Has satisfied the following criteria:

~~7D23.1~~ **Has provided written attestation(s), signed by a preceptor authorized user, that the individual has satisfactorily completed 60 hours of training and experience including a minimum of 8 hours of classroom and laboratory training, in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive materials for uptake, dilution, and excretion studies. The training and experience must include:**

(1) Classroom and laboratory training in the following areas:

(a) Radiation physics and instrumentation;

(b) Radiation protection;

Formatted: Indent: Hanging: 0.5"

Formatted: Indent: Left: 0", First line: 0", Tab stops: 0", Left + Not at 0.5"

DRAFT 2 –9/15/2011

- 2278 (c) Mathematics pertaining to the use and measurement of radioactivity;
- 2279 ~~(d)~~ Chemistry of radioactive material for medical use; and
- 2280 (e) Radiation biology;
- 2281 and
- 2282 (2) Work experience **under the supervision of an authorized user who meets the**
- 2283 **requirements of 7D4, 7D, 7E, 7F, or equivalent Agreement State or NRC**
- 2284 **requirements**, involving:
- 2285 (a) Ordering, receiving, and unpacking radioactive materials safely and
- 2286 performing the related radiation surveys;
- 2287 (b) Performing quality control procedures on instruments used to determine the
- 2288 activity of dosages and performing checks for proper operation of survey
- 2289 meters;
- 2290 (c) Calculating, measuring, and safely preparing patient or human research
- 2291 subject dosages;
- 2292 (d) Using administrative controls to prevent a misadministration involving the use
- 2293 of unsealed radioactive material;
- 2294 (e) Using procedures to contain spilled radioactive material safely and using
- 2295 proper decontamination procedures; and
- 2296 (f) Administering dosages to patients or human research subjects;

Comment [JJ64]: Correction of misnumbering / typographical errors.

Formatted: Indent: Left: 1", First line: 0"

Formatted: Font: 10 pt, Not Highlight

- 2297 **and**
- 2298 7D**23.2** Has provided written attestation(s), signed by a preceptor authorized user **who meets**
- 2299 **the requirements of 7D4, Appendix 7D, Appendix 7E, or Appendix 7F, or equivalent**
- 2300 **Agreement State or NRC requirements**, that the individual has **satisfactorily**
- 2301 **completed the requirements in 7D1.1(1) or 7D3.1, and has** achieved a level of
- 2302 competency sufficient to function independently as an authorized user for the medical
- 2303 uses authorized under 7.30.

2304 **and**

2305 **7D4 Meets the following recentness of training requirements:**

2306 **7D4.1 The training and experience required by Appendix 7D shall have been obtained**

2307 **within the 7 years preceding the date of license application or amendment request;**

2308 **or**

Comment [JJ65]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

Formatted: par2

Formatted: Indent: Hanging: 0.5"

2309 **7D4.2 The individual must have had related, documented, continuing education and**

2310 **experience since the required training and experience was obtained.**

2311 **or**

2312 **7D**35** Meets the following requirements for an experienced authorized user for 7.30 uses:**Has

2313 ~~demonstrated adequate prior experience as:~~

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

2314
2315
2316
2317
2318
2319
2320
2321
2322
2323

2324

2325

2326
2327

2328

2329

2330
2331

2332
2333

2334
2335
2336
2337

2338

2339

2340

2341
2342
2343

2344
2345
2346

2347
2348

2349
2350

~~7D35.1~~ An individual identified as an authorized user for the medical use of radioactive material on a license issued by the NRC or Agreement State, a permit issued under an NRC or Agreement State broad scope license that authorizes medical use before October 25, 2005, who perform only those medical uses for which they were authorized on that date are not required to comply with the training requirements of 7D1 through 7D4. authorized user identified on a current facility license or permit under Appendix 7E or Appendix 7F (and also meets the requirements specified in 7E3.1.7), or under equivalent Agreement State or NRC requirements, and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 7.30;

~~or~~

~~7D3.2~~ An experienced authorized user for uptake, dilution and excretion studies who:

~~(1)~~ Was identified before October 25, 2005 (and thus need not comply with the requirements of 7D2) either on:

~~(a)~~ An NRC or Agreement State license;

~~or~~

~~(b)~~ A permit issued under an NRC or Agreement State broad scope license that authorizes medical use or the practice of nuclear pharmacy;

~~(2)~~ Performs only those medical uses for which the authorized user identified in accord with 7D3.2(1) was authorized on October 25, 2005.

~~7D5.2~~ Individuals not required to comply with the training requirements of 7D1 through 7D4 may serve as preceptors for, and supervisors of, applicants seeking authorization on licenses for the same uses for which these individuals are authorized.

~~7D4~~ Training and experience required by Appendix 7D shall have been obtained:

~~7D4.1~~ Within the 7 years preceding the date of license application; or

~~7D4.2~~ Through documented subsequent continuing education and experience.

~~7D5~~ To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by NRC at <http://www.nrc.gov/materials/miau/med-use/toolkit/spec-board-cert.html>), a specialty board shall require that each candidate for certification:

~~7D5.1~~ Complete 60 hours in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive materials for uptake, dilution, and excretion studies (including the topics specified in 7D2.1); and

~~7D5.2~~ Pass an examination, administered by diplomates of the specialty board, which assesses knowledge and competence in radiation safety, radionuclide handling, and quality control.

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Indent: Left: 1"

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Indent: Left: 0.5"

Comment [JJ66]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par1

PART 7, APPENDIX 7E: AUTHORIZED USER TRAINING FOR IMAGING AND LOCALIZATION STUDIES (7.32 USES) ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE

The licensee shall require an authorized user of an unsealed radioactive material for the uses authorized under 7.32 to be a physician who has a current active State of Colorado license and:

7E1 ~~Has provided:~~ Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agreement State and who meets the requirements in paragraph 7E3.2 of this Appendix. NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>.

7E1.1 To have its certification process recognized, a specialty board shall require all candidates for certification to:

(1) Complete 700 hours in basic radionuclide handling techniques and radiation safety applicable to the medical use of unsealed radioactive materials for imaging and localization studies as described in 7E3.1(1) through 7E3.1(2)(g);

and

(2) Pass an examination, administered by diplomates of the specialty board, which assesses knowledge and competence in radiation safety, radionuclide handling, and quality control;

Evidence of current certification by a recognized specialty board (see 7E5); and

7E1.2 Written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 7.30 and 7.32;

(1) Each preceptor authorized user supervising the experiential training required by Appendix 7E shall meet the requirements of this Appendix 7E, or Appendix 7F, and also the requirements specified in 7E2.1(2)(g), or equivalent Agreement State or NRC requirements.

or

7E2 Is an authorized user under Appendix 7F and meets the requirements in 7E3.1(2)(g), or equivalent Agreement State or NRC requirements;

or

7E3 Has satisfied the following criteria:

7E23.1 Has ~~provided written attestation(s), signed by a preceptor authorized user, that the individual has~~ satisfactorily completed 700 hours, including a minimum of 80 hours of classroom and laboratory training in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive materials for imaging and localization studies. The training must include at a minimum:

(1) At least 80 hours of Classroom and laboratory training in the following areas:

(a) Radiation physics and instrumentation;

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

Formatted: par2, Indent: Left: 1", First line: 0", Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.5" + Indent at: 0.75", Tab stops: 1.25", Left

Formatted: Font: Not Italic

Formatted: par2, Tab stops: 1.25", Left

Formatted: Indent: Left: 1", First line: 0", Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.5" + Indent at: 0.75", Tab stops: 1.25", Left + Not at 1.5"

Formatted: Font: 10 pt

Formatted: Indent: Hanging: 0.5"

Formatted: Font: 10 pt

Formatted: Indent: Left: 0", First line: 0", Tab stops: 0", Left + Not at 0.5"

DRAFT 2 –9/15/2011

- 2388 (b) Radiation protection;
- 2389 (c) Mathematics pertaining to the use and measurement of radioactivity;
- 2390 (d) Chemistry of radioactive material for medical use; and
- 2391 (e) Radiation biology;
- 2392 and
- 2393 (2) Work experience **under the supervision of an authorized user who meets the**
- 2394 **requirements of 7E5, 7E, or 7F and 7E3.1(2)(g), or equivalent Agreement**
- 2395 **State or NRC requirements**, involving:
- 2396 (a) Ordering, receiving, and unpacking radioactive materials safely and
- 2397 performing the related radiation surveys;
- 2398 (b) Performing quality control procedures on instruments used to determine the
- 2399 activity of dosages and performing checks for proper operation of survey
- 2400 meters;
- 2401 (c) Calculating, measuring, and safely preparing patient or human research
- 2402 subject dosages;
- 2403 (d) Using administrative controls to prevent a misadministration involving the use
- 2404 of unsealed radioactive material;
- 2405 (e) Using procedures to contain spilled radioactive material safely and using
- 2406 proper decontamination procedures; and
- 2407 (f) Administering dosages to patients or human research subjects;
- 2408 (g) Eluting generator systems appropriate for preparation of radioactive drugs for
- 2409 imaging and localization studies, measuring and testing the eluate for
- 2410 radiochemical purity, and processing the eluate with reagent kits to
- 2411 prepare labeled radioactive drugs;

2412 and

2413 7E23.2 Has provided written attestation(s), signed by a preceptor authorized user **who meets**

2414 **the requirements of 7E5, Appendix 7E, or Appendix 7F and 7E3.1(2)(g), or**

2415 **equivalent Agreement State or NRC requirements**, that the individual has

2416 **satisfactorily completed the requirements in 7E1.1 or 7E3, and has** achieved a level

2417 of competency sufficient to function independently as an authorized user for the medical

2418 uses authorized under 7.30 and 7.32.

2419 and

2420 **7E4 Meets the following recentness of training requirements:**

2421 **7E4.1 The training and experience required by Appendix 7E shall have been obtained**

2422 **within the 7 years preceding the date of license application or amendment request;**

2423 or

Formatted: Indent: Left: 0", First line: 0"

Formatted: Font: 10 pt, Not Highlight

Comment [JJ67]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

DRAFT 2 –9/15/2011

2424 **7E4.2 The individual must have had related, documented, continuing education and**
2425 **experience since the required training and experience was obtained.**

Formatted: par2

2426 or

Formatted: Indent: Hanging: 0.5"

2427 **7E3.5 Meets the following requirements for an experienced authorized user for 7.32 uses:**Has
2428 **demonstrated adequate prior experience as:**

Formatted: Font: 10 pt

2429 **7E5.3.1 An individual identified as an authorized user for the medical use of radioactive**
2430 **material on a license issued by the NRC or Agreement State, a permit issued under**
2431 **an NRC or Agreement State broad scope license that authorizes medical use**
2432 **before October 25, 2005, who perform only those medical uses for which they were**
2433 **authorized on that date are not required to comply with the training requirements**
2434 **of 7E1 through 7E4.**authorized user identified on a current facility license or permit
2435 under Appendix 7F (and also meets the requirements specified in 7E2.1(2)(g)), or under
2436 equivalent Agreement State or NRC requirements, and has provided written
2437 attestation(s), signed by a preceptor authorized user, that the individual has achieved a
2438 level of competency sufficient to function independently as an authorized user for the
2439 **medical uses authorized under 7.30 and 7.32; or**

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

2440 **7E3.2 An experienced authorized user for imaging and localization studies who:**

Formatted: Font: 10 pt

Formatted: Font: 10 pt

2441 **(1) Was identified before October 25, 2005 (and thus need not comply with the**
2442 **requirements of 7E2) either on:**

Formatted: Font: 10 pt

2443 **(a) An NRC or Agreement State license; or**

Formatted: Font: 10 pt

2444 **(b) A permit issued under an NRC or Agreement State broad scope license that**
2445 **authorizes medical use or the practice of nuclear pharmacy;**

Formatted: Indent: Left: 1"

Formatted: Font: 10 pt

2446 **(2) Performs only those medical uses for which the authorized user identified in accord**
2447 **with 7E3.2(1) was authorized on October 25, 2005.**

Formatted: Font: 10 pt

2448 **7E5.2 Individuals not required to comply with the training requirements of 7E1 through**
2449 **7E4 may serve as preceptors for, and supervisors of, applicants seeking**
2450 **authorization on licenses for the same uses for which these individuals are**
2451 **authorized.**

Formatted: Indent: Left: 0.5"

Formatted: Font: 10 pt, Not Highlight

2452 **7E4 Training and experience required by Appendix 7E shall have been obtained:**

Comment [JJ68]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

2453 **7E4.1 Within the 7 years preceding the date of license application; or**

Formatted: Not Highlight

2454 **7E4.2 Through documented subsequent continuing education and experience.**

Formatted: Font: 10 pt, Not Highlight

2455 **7E5 To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by**
2456 **NRC at <http://www.nrc.gov/materials/miau/med-use/toolkit/spec-board-cert.html>), a specialty**
2457 **board shall require that each candidate for certification:**

Formatted: Font: Not Bold

Formatted: Font: 10 pt

Formatted: Font: 10 pt

2458 **7E5.1 Complete 700 hours in basic radionuclide handling techniques applicable to the medical use of**
2459 **unsealed radioactive materials for imaging and localization studies (including the topics specified**
2460 **in 7E2.1); and**

Formatted: Font: 10 pt

2461 **7E5.2 Pass an examination, administered by diplomates of the specialty board, which assesses**
2462 **knowledge and competence in radiation safety, radionuclide handling, and quality control.**
2463

DRAFT 2 –9/15/2011

PART 7, APPENDIX 7F: AUTHORIZED USER TRAINING FOR DIAGNOSTIC OR THERAPEUTIC USE OF UNSEALED RADIOACTIVE MATERIAL REQUIRING A WRITTEN DIRECTIVE (7.36.2 USES) ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE

The licensee shall require an authorized user of an unsealed radioactive material for the uses authorized under 7.36.2 to be a physician who has a current active State of Colorado license and:

7F1 ~~Has provided:~~ **Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agreement State and who meets the requirements in paragraph 7F2.1(2)(f) and 7F2.2 of this Appendix. NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>.**

7F1.1 **To have its certification process recognized, a specialty board shall require all candidates for certification to:**

- (1) Successfully complete residency training in a radiation therapy or nuclear medicine training program or a program in a related medical specialty. These residency training programs must include 700 hours of training and experience as described in 7F2.1(1) through 7F2.1(2)(e). Eligible training programs must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education, the Royal College of Physicians and Surgeons of Canada, or the Committee on Post-Graduate Training of the American Osteopathic Association;**

and

- (2) Pass an examination, administered by diplomates of the specialty board, which tests knowledge and competence in radiation safety, radionuclide handling, quality assurance, and clinical use of unsealed radioactive material for which a written directive is required;**

~~Evidence of current certification by a recognized specialty board (see 7F5); and~~

~~7F1.2 Written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 7.36;~~

- ~~(1) Each preceptor authorized user supervising the experiential training required by Appendix 7F shall meet the requirements of this Appendix 7F, including experience in administering dosages in the same dosage category or categories listed in 7F2.1(3), or equivalent Agreement State or NRC requirements.~~

or

7F2 **Has satisfied the following criteria:**

7F2.1 ~~Has provided written attestation(s), signed by a preceptor authorized user, that the individual has~~ satisfactorily completed 700 hours **of training and experience, including a minimum of 200 hours of classroom and laboratory training**, in basic radionuclide handling techniques applicable to the medical use of unsealed radioactive material requiring a ~~medical~~ **written** directive. ~~The training must include:~~

- (1) At least 200 hours of c**Classroom and laboratory training in the following areas:

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25", Tab stops: 1.25", Left + Not at 0.5" +
1.5"

Formatted: Font: 10 pt, Not Highlight

Formatted: Indent: Left: 1", Hanging: 0.25",
Tab stops: 1.25", Left + Not at 0.5" + 1.5"

Formatted: Indent: Hanging: 0.5"

DRAFT 2 –9/15/2011

- 2505 (a) Radiation physics and instrumentation;
- 2506 (b) Radiation protection;
- 2507 (c) Mathematics pertaining to the use and measurement of radioactivity;
- 2508 (d) Chemistry of radioactive material for medical use; and
- 2509 (e) Radiation biology;
- 2510 and
- 2511 (2) Work experience, **under the supervision of an authorized user who meets the**
2512 **requirements of 7F4, or 7F, or equivalent Agreement State or NRC**
2513 **requirements. A supervising authorized user, who meets the requirements**
2514 **in 7F2.1, must also have experience in administering dosages in the same**
2515 **dosage category or categories (i.e., 7F2.1(2)(f)) as the individual requesting**
2516 **authorized user status. The work experience must involveing:**
- 2517 (a) Ordering, receiving, and unpacking radioactive materials safely and
2518 performing the related radiation surveys;
- 2519 (b) Performing quality control procedures on instruments used to determine the
2520 activity of dosages and performing checks for proper operation of survey
2521 meters;
- 2522 (c) Calculating, measuring, and safely preparing patient or human research
2523 subject dosages;
- 2524 (d) Using administrative controls to prevent a misadministration involving the use
2525 of unsealed radioactive material;
- 2526 (e) Using procedures to contain spilled radioactive material safely and using
2527 proper decontamination procedures;
- 2528 and
- 2529 **(f) Administering dosages of radioactive drugs to patients or human**
2530 **research subjects involving a minimum of 3 cases in each of the following**
2531 **categories for which the individual is requesting authorized user status:**
- 2532 ~~(3) Has administered dosages of radioactive drugs to patients or human research~~
2533 ~~subjects:~~
- 2534 ~~(a) That include a minimum of 3 cases in each of the following categories for~~
2535 ~~which the individual is requesting authorized user status;~~
- 2536 (i) Oral administration of less than or equal to 1.22 GBq (33 mCi) of Na
2537 I-131 for which a written directive is required; ~~and~~
- 2538 (ii) Oral administration of greater than 1.22 GBq (33 mCi) of Na I-131
2539 for which a written directive is required [experience with at least
2540 3 cases in 7F2.1(23)(fa)(ii) also satisfies the requirement in
2541 category 7F2.1(23)(fa)(i)]; ~~and~~

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

2542 (iii) Parenteral administration of any beta emitter, or a photon-emitting
2543 radionuclide with a photon energy less than 150 keV, for which a
2544 written directive is required;

2545 and/or

2546 (iv) Parenteral administration of any other radionuclide for which a
2547 written directive is required;

2548 and

2549 (b) ~~Provided that the experience required by 7F2.1(3) may be obtained~~
2550 ~~concurrently with the supervised work experience required by 7F2.1(2);~~

2551 7F2.2 Has provided written attestation(s), ~~signed by a preceptor authorized user,~~ that the
2552 individual has **satisfactorily completed the requirements in 7F1.1 and 7F2.1(2)(f) or**
2553 **7F2.1, and has** achieved a level of competency sufficient to function independently as an
2554 authorized user for the medical uses authorized under 7.36. **The written attestation**
2555 **must be signed by a preceptor authorized user who:**

2556 (1) **Meets the requirements in 7F4, Appendix 7F, or equivalent NRC or Agreement**
2557 **State requirements; and**

2558 (1)(2) **The preceptor authorized user, who meets the requirements in 7F2.1 must**
2559 **have experience in administering dosages in the same dosage category or**
2560 **categories (i.e., 7F2.1(2)(f)) as the individual requesting authorized user status.**

2561 and

2562 **7F3 Meets the following recentness of training requirements:**

2563 **7F3.1 The training and experience required by Appendix 7F shall have been obtained:**
2564 **within the 7 years preceding the date of license application or amendment request;**

2565 or

2566 **7F3.2 The individual must have had related, documented, continuing education and**
2567 **experience since the required training and experience was obtained.**

2568 or

2569 **7F4.3 Meets the following requirements for an experienced authorized user for 7.36.2 uses:** ~~Has~~
2570 ~~demonstrated adequate prior experience as:~~

2571 **7F4.3.1 An individual identified as an authorized user for the medical use of radioactive**
2572 **material on a license issued by the NRC or Agreement State, a permit issued under**
2573 **an NRC or Agreement State broad scope license that authorizes medical use**
2574 **before October 25, 2005, who perform only those medical uses for which they were**
2575 **authorized on that date are not required to comply with the training requirements**
2576 **of 7F1 through 7F3.** ~~authorized user identified on a current facility license or permit under~~
2577 ~~Appendix 7F for uses listed in Appendix 7F, or under equivalent Agreement State or NRC~~
2578 ~~requirements, and has provided written attestation(s), signed by a preceptor authorized~~
2579 ~~user, that the individual has achieved a level of competency sufficient to function~~
2580 ~~independently as an authorized user for the medical uses authorized under 7.36;~~

Formatted: Tab stops: 4.12", Left

Comment [JJ69]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

Formatted: Indent: Hanging: 0.5"

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

2581
2582
2583
2584
2585
2586
2587
2588
2589
2590
2591
2592
2593
2594
2595
2596
2597
2598
2599
2600
2601
2602
2603
2604
2605
2606
2607
2608
2609

~~or~~

~~7F3.2 An experienced authorized user for use of unsealed radioactive material who:~~

~~(1) Was identified before October 25, 2005 (and thus need not comply with the requirements of 7F2) either on:~~

~~(a) An NRC or Agreement State license; or~~

~~(b) A permit issued under an NRC or Agreement State broad scope license that authorizes medical use or the practice of nuclear pharmacy;~~

~~(2) Performs only those medical uses for which the authorized user identified in accord with 7F3.2(1) was authorized on October 25, 2005.~~

~~**7F4.2 Individuals not required to comply with the training requirements of 7F1 through 7F3 may serve as preceptors for, and supervisors of, applicants seeking authorization on licenses for the same uses for which these individuals are authorized.**~~

~~**7F4 Training and experience required by Appendix 7F shall have been obtained:**~~

~~7F4.1 Within the 7 years preceding the date of license application; or~~

~~7F4.2 Through documented subsequent continuing education and experience.~~

~~**7F5 To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by NRC at <http://www.nrc.gov/materials/miau/med-use/toolkit/spec-board-cert.html>), a specialty board shall require that each candidate for certification:**~~

~~7F5.1 Successfully complete residency training in a radiation therapy or nuclear medicine training program or a program in a related medical specialty that includes 700 hours of training and experience as described in 7F2.1. Eligible training programs must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or Royal College of Physicians and Surgeons of Canada, or the Committee on Post-Graduate Training of the American Osteopathic Association; and~~

~~7F5.2 Pass an examination, administered by diplomates of the specialty board, which tests knowledge and competence in radiation safety, radionuclide handling, quality assurance, and clinical use of unsealed byproduct material.~~

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Comment [JJ70]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

Formatted: Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par1

DRAFT 2 –9/15/2011

PART 7, APPENDIX 7G: AUTHORIZED USER TRAINING FOR THE ORAL ADMINISTRATION (7.36) OF SODIUM IODIDE I-131 REQUIRING A WRITTEN DIRECTIVE IN QUANTITIES LESS THAN OR EQUAL TO 1.22 Gbq I-131 (33 mCi) SODIUM IODIDE ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE (7.36.3 USES)

The licensee shall require an authorized user ~~of~~ for the oral administration ~~of sodium iodide I-131 requiring a written directive in quantities of less than or equal to 1.22 GBq (33 mCi), of Na I-131 for which a written directive is required~~ to be a physician who has a current active State of Colorado license and:

7G1 ~~Has provided:~~ **Is certified by a medical specialty board whose certification process includes all of the requirements in 7G3.1 and 7G3.1(2) of this Appendix and whose certification process has been recognized by the NRC or an Agreement State and who meets the requirements in paragraph 7G3.1(3) of this Appendix. NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>.**

~~7G1.1 Evidence of current certification by a recognized medical specialty board (see 7G5); and~~

~~7G1.2 Written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user for the medical uses of unsealed radioactive materials using Na I-131 authorized under 7.36;~~

~~(1) Each preceptor authorized user supervising the experiential training required by Appendix 7G shall meet the requirements of Appendix 7G, or Appendix 7F (including experience in administering dosages in the same dosage category or categories listed in 7F2.1(3)), or Appendix 7H, or equivalent Agreement State or NRC requirements.~~

or

7G2 **Is an authorized user under Appendix 7F for uses listed in 7F2.1(2)(f)(i) or 7F2.1(2)(f)(ii), Appendix 7H, or equivalent NRC or Agreement State requirements;**

or

7G3 Has satisfied the following criteria:

7G3.1 ~~Has provided written attestation(s), signed by a preceptor authorized user, that the individual has satisfactorily completed~~ **80 hours of classroom and laboratory** training, ~~in basic radionuclide handling techniques~~ applicable to the medical use of sodium iodide **I-131** for procedures requiring a written directive, ~~including:~~

(1) ~~At least~~ **The** 80 hours of classroom and laboratory training **must include in the** following areas:

- (a) Radiation physics and instrumentation;
- (b) Radiation protection;
- (c) Mathematics pertaining to the use and measurement of radioactivity;
- (d) Chemistry of radioactive material for medical use; and

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Indent: Hanging: 0.5"

Formatted: Font: 10 pt, Not Bold

DRAFT 2 –9/15/2011

(e) Radiation biology;

and

- (2) **Has work experience under the supervision of an authorized user who meets the requirements of 7G5, or Appendix 7F, Appendix 7G, Appendix 7H or equivalent Agreement State or NRC requirements. A supervising authorized user, who meets the requirements in 7F2.1, must also have experience in administering dosages as specified in 7F2.1(2)(f)(i) or 7F2.1(2)(f)(ii) as the individual requesting authorized user status. The work experience must involve:**

Formatted: Font: 10 pt, Not Highlight

(a) Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;

(b) Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters;

(c) Calculating, measuring, and safely preparing patient or human research subject dosages;

(d) Using administrative controls to prevent a misadministration involving the use of unsealed radioactive material;

(e) Using procedures to contain spilled radioactive material safely and using proper decontamination procedures;

and

(f) Administering dosages to patients or human research subjects that includes at least 3 cases involving the oral administration of less than or equal to 1.22 gigabecquerels (33 millicuries) of sodium iodide I-131;

~~(3) Has administered dosages of radioactive drugs to patients or human research subjects:~~

~~(a) That include a minimum of 3 cases involving the oral administration of less than or equal to 1.22 GBq (33 mCi) of Na I-131; and~~

~~(b) Provided that the experience required by 7G2.1(3) may be obtained concurrently with the supervised work experience required by 7G2.1(2);~~

and

7G2.2(3) Has provided written attestation(s), signed by a preceptor authorized user, that the individual has completed the requirements of 7G3.1 and 7G3.1(2), and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses of unsealed radioactive materials using Na I-131 authorized under 7.36.3. The written attestation must be signed by a preceptor authorized user who:

Formatted: Indent: Left: 0.5", Hanging: 0.5", No bullets or numbering, Tab stops: 1.5", Left + Not at 1.25"

(a) Meets the requirements in 7G5, Appendix 7F, Appendix 7G, or Appendix 7H, or equivalent NRC or Agreement State requirements;

Formatted: Font: 10 pt, Not Highlight

and

DRAFT 2 –9/15/2011

2688 (4)(b) The preceptor authorized user, who meets the requirements in
2689 7F2.1, must have experience in administering dosages as specified in
2690 7F2.1(2)(f)(i) or 7F2.1(2)(f)(ii).

2691 and

2692 7G4 Meets the following recentness of training requirements:

2693 7G4.1 The training and experience required by Appendix 7G shall have been obtained
2694 within the 7 years preceding the date of license application or amendment request;

2695 or

2696 7G4.2 The individual must have had related, documented, continuing education and
2697 experience since the required training and experience was obtained.

2698 or

2699 7G5.3 Meets the following requirements for an experienced authorized user for 7.36.3 uses: Has
2700 demonstrated adequate prior experience as:

2701 7G5.3.1 An individual identified as an authorized user for the medical use of radioactive
2702 material on a license issued by the NRC or Agreement State, a permit issued under
2703 an NRC or Agreement State broad scope license that authorizes medical use
2704 before October 25, 2005, who perform only those medical uses for which they were
2705 authorized on that date are not required to comply with the training requirements
2706 of 7G1 through 7G4, authorized user identified on a current facility license or permit
2707 under Appendix 7F for uses listed in 7F2.1(3), under Appendix 7H for uses listed in
2708 7H2.1(3), or under equivalent Agreement State or NRC requirements, and has provided
2709 written attestation(s), signed by a preceptor authorized user, that the individual has
2710 achieved a level of competency sufficient to function independently as an authorized user
2711 for the medical uses of unsealed radioactive materials using Na I-131 authorized under
2712 7.36;

2713 or

2714 7G3.2 An experienced authorized user for the medical use of unsealed radioactive materials
2715 using Na I-131 who:

2716 (1) Was identified before October 25, 2005 (and thus need not comply with the requirements of
2717 7G2) either on:

2718 (a) An NRC or Agreement State license; or

2719 (b) A permit issued under an NRC or Agreement State broad scope license that
2720 authorizes medical use or the practice of nuclear pharmacy; and

2721 (2) Performs only those medical uses for which the authorized user identified in accord
2722 with 7G3.2(1) was authorized on October 25, 2005.

2723 7G5.2 Individuals not required to comply with the training requirements of 7G1 through
2724 7G4 may serve as preceptors for, and supervisors of, applicants seeking
2725 authorization on licenses for the same uses for which these individuals are
2726 authorized.

Formatted: Indent: Left: 1.5", Numbered +
Level: 1 + Numbering Style: a, b, c, ... + Start
at: 1 + Alignment: Left + Aligned at: 0.5" +
Indent at: 0.75"

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Indent: Left: 0"

Comment [JJ71]: The term "or amendment
request" is added for clarity, since many additions of
authorized users occur during license amendment
requests as well as during license applications.

Formatted: Indent: Left: 0"

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Indent: Hanging: 1"

Formatted: Font: 10 pt

Formatted: par3, Indent: Left: 1", Tab stops:
1.06", Left

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Comment [JJ72]: Additional language added to
be compatible with 10 CFR 35.57 (c). This provision
effectively allows or clarifies that experienced
individuals who are "grandfathered" may serve as
preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

Formatted: Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: Not Bold

DRAFT 2 –9/15/2011

2727 ~~7G4~~ Training and experience required by Appendix 7G shall have been obtained:

Formatted: Font: 10 pt

2728 ~~7G4.1~~ Within the 7 years preceding the date of license application; or

Formatted: Font: 10 pt

2729 ~~7G4.2~~ Through documented subsequent continuing education and experience.

Formatted: Font: 10 pt

2730 ~~7G5~~ To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by
2731 NRC at <http://www.nrc.gov/materials/miau/med-use/toolkit/spec-board-cert.html>), for purposes of
2732 Appendix 7G, a medical specialty board shall require that each candidate for certification to meet
2733 all of the requirements of 7G2.
2734

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

PART 7, APPENDIX 7H: AUTHORIZED USER TRAINING FOR THE ORAL ADMINISTRATION OF SODIUM IODIDE I-131 REQUIRING A WRITTEN DIRECTIVE IN QUANTITIES (7.36) OF GREATER THAN 1.22 GBq (33 mCi) (7.36.4 USES) SODIUM IODIDE ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE

Formatted: Not Highlight

Formatted: Font: 10 pt

The licensee shall require an authorized user ~~foref~~ the oral administration of **sodium iodide I-131** requiring a written directive in quantities greater than 1.22 GBq (33 mCi), ~~of Na I-131 for which a written directive is required~~ to be a physician who has a current active State of Colorado license and:

7H1 ~~Has provided:~~ **Is certified by a medical specialty board whose certification process includes all of the requirements in 7H3.1, and 7H3.1(2) and whose certification has been recognized by the NRC or an Agreement State, and who meets the requirements in paragraph 7H3.2 of this Appendix. NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>.**

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

~~7H1.1 Evidence of current certification by a recognized medical specialty board (see 7H5); and~~

~~7H1.2 Written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user for the medical uses of unsealed radioactive materials using Na I-131 in activities greater than 1.22 GBq (33 mCi) authorized under 7.36;~~

~~(1) Each preceptor authorized user supervising the experiential training required by Appendix 7H shall meet the requirements of Appendix 7H, or Appendix 7F (including experience in administering dosages in the same dosage category or categories listed in 7F2.1(3)), or equivalent Agreement State or NRC requirements.~~

or

Formatted: Indent: Hanging: 0.5"

7H2 **Is an authorized user under Appendix 7F for uses listed in 7F2.1(2)(f)(ii), or equivalent NRC or Agreement State requirements;**

Formatted: Font: Not Bold

or

7H3 Has satisfied the following criteria:

~~7H23.1~~ ~~Has provided written attestation(s), signed by a preceptor authorized user, that the individual has~~ satisfactorily completed **80 hours of classroom and laboratory** training, ~~in basic radionuclide handling techniques~~ applicable to the medical use of sodium iodide **I-131** for procedures requiring a written directive, ~~including:~~

(1) ~~The~~ **At least** 80 hours of classroom and laboratory training ~~in the following areas~~ **must include:**

- (a) Radiation physics and instrumentation;
- (b) Radiation protection;
- (c) Mathematics pertaining to the use and measurement of radioactivity;
- (d) Chemistry of radioactive material for medical use; and

DRAFT 2 –9/15/2011

- 2773 (e) Radiation biology;
- 2774 and
- 2775 (2) **Has** ~~W~~work experience, **under the supervision of an authorized user who meets**
2776 **the requirements of 7H5, Appendix 7F, Appendix 7H or equivalent**
2777 **Agreement State or NRC requirements. A supervising authorized user,**
2778 **who meets the requirements in 7F2.1, must also have experience in**
2779 **administering dosages as specified in 7F2.1(2)(f)(ii). The work experience**
2780 **must involve**ing;
- 2781 (a) Ordering, receiving, and unpacking radioactive materials safely and
2782 performing the related radiation surveys;
- 2783 (b) Performing quality control procedures on instruments used to determine the
2784 activity of dosages and performing checks for proper operation of survey
2785 meters;
- 2786 (c) Calculating, measuring, and safely preparing patient or human research
2787 subject dosages;
- 2788 (d) Using administrative controls to prevent a misadministration involving the use
2789 of unsealed radioactive material;
- 2790 (e) Using procedures to contain spilled radioactive material safely and using
2791 proper decontamination procedures;
- 2792 and
- 2793 (3f) **Administering** ~~Has administered~~ dosages of radioactive drugs to patients
2794 or human research subjects, **that includes at least 3 cases involving the oral**
2795 **administration of greater than 1.22 gigabecquerels (33 millicuries) of**
2796 **sodium iodide I-131;**
- 2797 ~~(a) That include a minimum of 3 cases involving the oral administration of~~
2798 ~~greater than 1.22 GBq (33 mCi) of Na I-131; and~~
- 2799 ~~(b) Provided that the experience required by 7H2.1(3) may be obtained~~
2800 ~~concurrently with the supervised work experience required by 7H2.1(2);~~
- 2801 and
- 2802 ~~7H2.2~~ (3) Has provided written attestation(s), ~~signed by a preceptor authorized user,~~ that the
2803 individual has **completed the requirements of 7H3.1(1) and 7H3.1(2), and has**
2804 **achieved a level of competency sufficient to function independently as an authorized user**
2805 **for the medical uses of unsealed radioactive materials using Na I-131 in activities greater**
2806 **than 1.22 GBq (33 mCi) authorized under 7.36.4. The written attestation must be**
2807 **signed by a preceptor authorized user who;**
- 2808 (1) **Meets the requirements in 7H5, Appendix 7F, or Appendix 7H, or equivalent**
2809 **NRC or Agreement State requirements;**
- 2810 and

DRAFT 2 –9/15/2011

2811 (2) The preceptor authorized user, who meets the requirements in 7F2.1 must have
2812 experience in administering dosages as specified in 7F2.1(2)(f)(ii).

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25", Tab stops: 1.25", Left + Not at 1.5"

2813 and

Formatted: Indent: Left: 0", First line: 0"

2814 7H4 Meets the following recentness of training requirements:

2815 7H4.1 The training and experience required by Appendix 7H shall have been obtained
2816 within the 7 years preceding the date of license application or amendment request;

Comment [JJ73]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

2817 or

Formatted: upar2

2818 7H4.2 The individual must have had related, documented, continuing education and
2819 experience since the required training and experience was obtained.

Formatted: Indent: Left: 0", First line: 0"

2820 or

Formatted: Font: 10 pt

2821 ~~7H5.3 Meets the following requirements for an experienced authorized user for 7.36.4 usesHas~~
2822 ~~demonstrated adequate prior experience as:~~

Formatted: Font: 10 pt

2823 ~~7H3.5.1 An individual identified as an authorized user for the medical use of radioactive~~
2824 ~~material on a license issued by the NRC or Agreement State, a permit issued under~~
2825 ~~an NRC or Agreement State broad scope license that authorizes medical use~~
2826 ~~before October 25, 2005, who perform only those medical uses for which they were~~
2827 ~~authorized on that date are not required to comply with the training requirements~~
2828 ~~of 7H1 through 7H4, authorized user identified on a current facility license or permit~~
2829 ~~under Appendix 7H, under Appendix 7F for uses listed in 7F2.1(3), or under equivalent~~
2830 ~~Agreement State or NRC requirements, and has provided written attestation(s), signed by~~
2831 ~~a preceptor authorized user, that the individual has achieved a level of competency~~
2832 ~~sufficient to function independently as an authorized user for the medical uses of~~
2833 ~~unsealed radioactive materials using Na I-131 in activities greater than 1.22 GBq (33~~
2834 ~~mCi) authorized under 7.36;~~

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

2835 ~~or~~

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par3, Indent: Left: 1", Tab stops: 0.31", Left

Formatted: Font: 10 pt, Not Highlight

Comment [JJ74]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

Formatted: Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: Not Bold

Formatted: Font: 10 pt

2836 ~~7H3.2 An experienced authorized user for the medical use of unsealed radioactive materials~~
2837 ~~using Na I-131 in activities greater than 1.22 GBq (33 mCi) who:~~

2838 ~~(1) Was identified before October 25, 2005 (and thus need not comply with the requirements of~~
2839 ~~7H2) either on:~~

2840 ~~(a) An NRC or Agreement State license; or~~

2841 ~~(b) A permit issued under an NRC or Agreement State broad scope license that authorizes~~
2842 ~~medical use or the practice of nuclear pharmacy; and~~

2843 ~~(2) Performs only those medical uses for which the authorized user identified in accord with~~
2844 ~~7H3.2(1) was authorized on October 25, 2005.~~

2845 ~~7H5.2 Individuals not required to comply with the training requirements of 7H1 through~~
2846 ~~7H4 may serve as preceptors for, and supervisors of, applicants seeking~~
2847 ~~authorization on licenses for the same uses for which these individuals are~~
2848 ~~authorized.~~

2849 ~~7H4 Training and experience required by Appendix 7H shall have been obtained:~~

DRAFT 2 –9/15/2011

2850 ~~7H4.1 Within the 7 years preceding the date of license application; or~~

Formatted: Font: 10 pt

2851 ~~7H4.2 Through documented subsequent continuing education and experience.~~

Formatted: Font: 10 pt

2852 ~~7H5~~ To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by
2853 NRC at <http://www.nrc.gov/materials/miau/med-use/toolkit/spec-board-cert.html>) for purposes of
2854 Appendix 7H, a medical specialty board shall require that each candidate for certification to meet
2855 all of the requirements of 7H2.
2856

DRAFT 2 –9/15/2011

PART 7, APPENDIX 7I: AUTHORIZED USER TRAINING FOR THE PARENTERAL ADMINISTRATION (7.36) OF UNSEALED RADIOACTIVE MATERIAL REQUIRING A WRITTEN DIRECTIVE (7.36.5 USES) ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE

The licensee shall require an authorized user for parenteral administration of unsealed radioactive material for which a written directive is required to be a physician who has a current active State of Colorado license and:

7I1 Is an authorized user under Appendix 7F for uses listed in 7F2.1(2)(f)(iii) or 7F2.1(2)(f)(iv), or equivalent NRC or Agreement State requirements;

or

7I2 Is an authorized user under Appendix 7K, Appendix 7M, or equivalent NRC or Agreement State requirements and who meets the requirements in 7I4;

or

7I3 Is certified by a medical specialty board whose certification process has been recognized by the NRC, or an Agreement State under Appendix 7K or Appendix 7M, and who meets the requirements in paragraph 7I4 of this section.

Has provided:

~~7I4.1 Evidence of current certification by a recognized medical specialty board (see 7I5); and~~

~~7I4.2 Written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user for parenteral administration of unsealed radioactive material for which a written directive authorized under 7.36;~~

~~(1) Each preceptor authorized user supervising the experiential training required by Appendix 7I shall meet the requirements of Appendix 7I, or Appendix 7F (including experience in administering dosages in the same dosage category or categories listed in 7F2.1(3)), or equivalent Agreement State or NRC requirements.~~

or

7I4.2 Has satisfied the following criteria:

~~7I4.2.1 Has provided written attestation(s), signed by a preceptor authorized user, that the individual has satisfactorily completed 80 hours of classroom and laboratory training in basic radionuclide handling techniques applicable to parenteral administrations, for which requiring a written directive is required, of any beta emitter, or any photon-emitting radionuclide with a photon energy less than 150 keV, and/or parenteral administration of any other radionuclide for which a written directive is required. including:~~

~~(1) At least 80 hours of eThe training must include classroom and laboratory training in the following areas:~~

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Not Highlight

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Normal (Web)

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt, Not Highlight

Formatted: Font: (Default) Arial, 10 pt

Formatted: Indent: Left: 0"

Formatted: Indent: Left: 0", First line: 0"

DRAFT 2 –9/15/2011

- 2895 (a) Radiation physics and instrumentation;
- 2896 (b) Radiation protection;
- 2897 (c) Mathematics pertaining to the use and measurement of radioactivity;
- 2898 (d) Chemistry of radioactive material for medical use;
- 2899 and
- 2900 (e) Radiation biology;
- 2901 and
- 2902 (2) **Has work experience under the supervision of an authorized user who meets**
- 2903 **the requirements of 7F, Appendix 7F, Appendix 7I, or equivalent**
- 2904 **Agreement State or NRC requirements, in the parenteral administration, for**
- 2905 **which a written directive is required, of any beta emitter, or any photon-**
- 2906 **emitting radionuclide with a photon energy less than 150 keV, and/or**
- 2907 **parenteral administration of any other radionuclide for which a written**
- 2908 **directive is required. A supervising authorized user, who meets the**
- 2909 **requirements in 7F, must have experience in administering dosages as**
- 2910 **specified in 7F2.1(2)(f)(iii) and/or 7F2.1(2)(f)(iv). The work experience must**
- 2911 **involveing:**
- 2912 (a) Ordering, receiving, and unpacking radioactive materials safely and
- 2913 performing the related radiation surveys;
- 2914 (b) Performing quality control procedures on instruments used to determine the
- 2915 activity of dosages and performing checks for proper operation of survey
- 2916 meters;
- 2917 (c) Calculating, measuring, and safely preparing patient or human research
- 2918 subject dosages;
- 2919 (d) Using administrative controls to prevent a misadministration involving the use
- 2920 of unsealed radioactive material;
- 2921 (e) Using procedures to contain spilled radioactive material safely and using
- 2922 proper decontamination procedures;
- 2923 and
- 2924 (3) **Has (f) Administering dosages of radioactive drugs to patients or human research**
- 2925 **subjects that include:**
- 2926 (ai) **At least 3 cases involving the Pparenteral administration, for**
- 2927 **which a written directive is required, of any beta emitter, or any**
- 2928 **photon-emitting radionuclide with a photon energy less than 150**
- 2929 **keV;**
- 2930 and/or
- 2931 (bii) **At least 3 cases involving the Pparenteral administration of any**
- 2932 **other radionuclide, for which a written directive is required;**

Formatted: Indent: Left: 0", First line: 0"

Formatted: Font: 10 pt

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

2933 and

Formatted: Indent: Left: 0", First line: 0"

2934 712.2 (3) Has provided written attestation(s); signed by a preceptor authorized user, that the
2935 individual has **completed the requirements in 712 or 713, and has** achieved a level of
2936 competency sufficient to function independently as an authorized user for the parenteral
2937 administration of unsealed radioactive materials **requiring a written directive** authorized
2938 **under 7.36. The written attestation must be signed by a preceptor authorized user**
2939 **who:**

(a) **Meets the requirements in 716, Appendix F, or Appendix I, or equivalent**
NRC or Agreement State requirements;

Formatted: Indent: Left: 1.5", Hanging: 0.5",
No bullets or numbering, Tab stops: 1.5", Left
+ Not at 1.25"

Formatted: Font: 10 pt

2942 and

(b) **Meets the requirements in Appendix 7F must have experience in**
administering dosages as specified in 7F2.1(2)(f)(iii) and/or
7F2.1(2)(f)(iv).

Formatted: Indent: Left: 1.5"

Formatted: Font: 10 pt

2946 and

Formatted: Indent: Left: 0"

2947 715 Meets the following recentness of training requirements:

2948 715.1 The training and experience required by Appendix 7I shall have been obtained within
2949 the 7 years preceding the date of license application or amendment request;

Comment [JJ75]: The term "or amendment
request" is added for clarity, since many additions of
authorized users occur during license amendment
requests as well as during license applications.

2950 or

2951 715.2 The individual must have had related, documented, continuing education and
2952 experience since the required training and experience was obtained.

Formatted: Indent: Left: 0"

2953 or

2954 716.3 Meets the following requirements for an experienced authorized user for 7.36.5 uses: Has
2955 demonstrated adequate prior experience as:

Formatted: Font: 10 pt

2956 713.1 An individual identified as an authorized user for the medical use of radioactive
2957 material on a license issued by the NRC or Agreement State, a permit issued under
2958 an NRC or Agreement State broad scope license that authorizes medical use
2959 before October 25, 2005, who perform only those medical uses for which they were
2960 authorized on that date are not required to comply with the training requirements
2961 of 711 through 715, authorized user identified on a current facility license or permit under
2962 Appendix 7I, Appendix 7F for uses listed in 7F2.1(3), Appendix 7K, or Appendix 7M, or
2963 under equivalent Agreement State or NRC requirements, and has provided written
2964 attestation(s), signed by a preceptor authorized user, that the individual has achieved a
2965 level of competency sufficient to function independently as an authorized user for the
2966 parenteral administration of unsealed radioactive materials authorized under 7.36;

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

2967 or

Formatted: Font: 10 pt

Formatted: par2

2968 713.2 An experienced authorized user for the parenteral administration of unsealed radioactive
2969 materials who:

Formatted: Font: 10 pt

2970 (1) Was identified before October 25, 2005 (and thus need not comply with the requirements of
2971 712) either on:

Formatted: Font: 10 pt

Formatted: par2

DRAFT 2 –9/15/2011

2972 (a) An NRC or Agreement State license; or

2973 (b) A permit issued under an NRC or Agreement State broad scope license that authorizes

2974 medical use or the practice of nuclear pharmacy; and

2975 (2) Performs only those medical uses for which the authorized user identified in accord with

2976 713.2(1) was authorized on October 25, 2005.

2977 **716.2. Individuals not required to comply with the training requirements of 711 through 714**

2978 **may serve as preceptors for, and supervisors of, applicants seeking authorization**

2979 **on licenses for the same uses for which these individuals are authorized.**

2980 ~~714 Training and experience required by Appendix 71 shall have been obtained:~~

2981 ~~714.1 Within the 7 years preceding the date of license application; or~~

2982 ~~714.2 Through documented subsequent continuing education and experience.~~

2983 ~~715 To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by~~

2984 ~~NRC at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>) for purposes of~~

2985 ~~Appendix 71, a medical specialty board shall require that each candidate for certification to meet~~

2986 ~~all of the requirements of 712.~~

2987

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Indent: Left: 0.5"

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Comment [JJ76]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

Formatted: Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: Not Bold

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

PART 7, APPENDIX 7J: AUTHORIZED USER **TRAINING** FOR USE OF SEALED SOURCES FOR
DIAGNOSIS (7.40 **USES**) **ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE**

The licensee shall require an authorized user of a diagnostic sealed source for use in a device authorized under 7.40 to be a physician, dentist or podiatrist who has a current active State of Colorado license and:

Formatted: Font: 10 pt

7J1 ~~Has provided~~ **Is certified by evidence of current certification by a recognized a medical specialty board whose certification process includes all of the requirements in 7J2 and 7J3, and whose certification process has been recognized by the NRC or an Agreement State. (see 7J5); NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>.**

Formatted: Font: 10 pt

Formatted: Font: 10 pt

or

Formatted: par1

7J2 Has satisfied the following criteria:

Formatted: Font: 10 pt

7J2.1 Has ~~satisfactorily~~ completed **8 hours of classroom and laboratory** training in basic radionuclide handling techniques specifically applicable to the use of the device.;
~~including:~~

(1) ~~At least 8 hours of classroom and laboratory training in the following areas~~ **The training must include:**

- (a) Radiation physics and instrumentation;
- (b) Radiation protection;
- (c) Mathematics pertaining to the use and measurement of radioactivity;
- (d) Radiation biology;

and

Formatted: Indent: Left: 0", First line: 0"

7J3(2) Has completed ~~T~~ training in the use of the device for the uses requested.

~~7J2.2 Has provided written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user of a diagnostic sealed source for use in a device authorized under 7.40.~~

(1) ~~Each preceptor authorized user supervising the experiential training required by Appendix 7J shall meet the requirements of Appendix 7K or Appendix 7L, or equivalent Agreement State or NRC requirements.~~

and

7J4 Meets the following recentness of training requirements:

7J4.1 The training and experience required by Appendix 7J shall have been obtained within the 7 years preceding the date of license application or amendment request;

or

Comment [JJ77]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

DRAFT 2 –9/15/2011

7J4.2 The individual must have had related, documented, continuing education and experience since the required training and experience was obtained.

Formatted: Indent: Left: 0"

or

Formatted: Indent: Hanging: 0.5"

7J53 Meets the following requirements for an experienced authorized user for 7.40 usesHas demonstrated adequate prior experience as:

Formatted: Font: 10 pt

7J53.1 An individual identified as an authorized user for the medical use of radioactive material on a license issued by the NRC or Agreement State, a permit issued under an NRC or Agreement State broad scope license that authorizes medical use before October 25, 2005, who perform only those medical uses for which they were authorized on that date are not required to comply with the training requirements of 7J1 through 7J4, authorized user identified on a current facility license or permit under this Appendix 7J for uses listed in Appendix 7J, or under equivalent Agreement State or NRC requirements, and has provided written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user of a diagnostic sealed source for use in a device authorized under 7.40;

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

or

Formatted: Font: 10 pt

7J3.2 An experienced authorized user of a diagnostic sealed source for use in a device authorized under 7.40 who:

Formatted: Font: 10 pt

(1) Was identified before October 25, 2005 (and thus need not comply with the requirements of 7J2) either on:

Formatted: Font: 10 pt

Formatted: par2

(a) An NRC or Agreement State license; or

Formatted: Font: 10 pt

(b) A permit issued under an NRC or Agreement State broad scope license that authorizes medical use or the practice of nuclear pharmacy; and

Formatted: Font: 10 pt

Formatted: Indent: Hanging: 1"

(2) Performs only those medical uses for which the authorized user identified in accord with 7J3.2(1) was authorized on October 25, 2005.

Formatted: Font: 10 pt

7J5.2 Individuals not required to comply with the training requirements of 7J1 through 7J4 may serve as preceptors for, and supervisors of, applicants seeking authorization on licenses for the same uses for which these individuals are authorized.

Formatted: Font: 10 pt

Formatted: par3, Indent: Left: 1"

Formatted: Font: 10 pt, Not Highlight

7J54 Training and experience required by Appendix 7J shall have been obtained:

Comment [JJ78]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

7J4.1 Within the 7 years preceding the date of license application; or

Formatted: Not Highlight

7J4.2 Through documented subsequent continuing education and experience.

Formatted: Font: 10 pt, Not Highlight

7J5 To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by NRC at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>) for purposes of Appendix 7J, a medical specialty board shall require that each candidate for certification to meet all of the requirements of 7J2.1(1).

Formatted: Font: Not Bold

Formatted: Font: 10 pt

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

**PART 7, APPENDIX 7K: AUTHORIZED USER TRAINING FOR THE USE OF MANUAL
BRACHYTHERAPY SOURCES USE (7.42 USES) ADEQUATE RADIATION SAFETY
TRAINING AND EXPERIENCE**

The licensee shall require an authorized user of a manual brachytherapy source for the uses authorized under 7.42 to be a physician who has a current active State of Colorado license and:

Formatted: Font: 10 pt

7K1 ~~Has provided:~~ Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agreement State, and who meets the requirements in paragraph 7K2.3 of this Appendix. NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>.

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

7K1.1 To have its certification process recognized, a specialty board shall require all candidates for certification to:

(1) Successfully complete a minimum of 3 years of residency training in a radiation oncology program approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Committee on Post-Graduate Training of the American Osteopathic Association; and

Formatted: Numbered + Level: 1 +
Numbering Style: 1, 2, 3, ... + Start at: 1 +
Alignment: Left + Aligned at: 1" + Indent at:
1.25", Tab stops: 1.25", Left + Not at 1.5"

(2) Pass an examination, administered by diplomats of the specialty board, that tests knowledge and competence in radiation safety, radionuclide handling, treatment planning, quality assurance, and clinical use of manual brachytherapy;

~~meet the requirements of 10 CFR 35.490(a)(1) and 10 CFR 35.490(a)(2). NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>. Evidence of current certification by a recognized specialty board (see 7K5); and~~

7K1.2 ~~Written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user of an manual brachytherapy source for the uses authorized under 7.42;~~

~~(1) Each preceptor authorized user supervising the experiential training required by Appendix 7K shall meet the requirements of Appendix 7K, or equivalent Agreement State or NRC requirements.~~

Formatted: Indent: Hanging: 0.5"

or

7K2 Has satisfied the following criteria:

7K2.1 Has ~~provided written attestation(s), signed by a preceptor authorized user, that the individual has~~ satisfactorily completed ~~700 total hours in~~ a structured educational program in **basic** radionuclide handling techniques applicable to the medical use of manual brachytherapy sources, ~~that includes:~~

(1) ~~At least~~ 200 hours of classroom and laboratory training in the following areas:

(a) Radiation physics and instrumentation;

(b) Radiation protection;

DRAFT 2 –9/15/2011

- 3098 (c) Mathematics pertaining to the use and measurement of radioactivity;
- 3099 (d) Radiation biology;
- 3100 and
- 3101 (2) 500 hours of supervised work experience, **under the supervision of an authorized**
- 3102 **user who meets the requirements in 7K4, Appendix 7K, or equivalent NRC**
- 3103 **or Agreement State requirements at a medical institution,** involving:
- 3104 (a) Ordering, receiving, and unpacking radioactive materials safely and
- 3105 performing the related radiation surveys;
- 3106 (b) Checking survey meters for proper operation;
- 3107 (c) Preparing, implanting, and removing brachytherapy sources;
- 3108 (d) Maintaining running inventories of material on hand;
- 3109 (e) Using administrative controls to prevent a misadministration involving the use
- 3110 of unsealed radioactive material;
- 3111 (f) Using emergency procedures to control radioactive material;

Formatted: Indent: Left: 0", First line: 0"

Formatted: Font: 10 pt

- 3112 **and**
- 3113 **7K2.2 (3) Or he** **has completed** 3 years of supervised clinical experience in radiation oncology,
- 3114 **under the supervision of** an authorized user who meets the requirements **in 7K4, of this**
- 3115 **Appendix 7K, or equivalent Agreement State or NRC requirements,** provided that the
- 3116 **experience:**

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.5"

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

- 3117 (a) Is part of a formal training program approved by the Residency Review
- 3118 Committee of the Accreditation Council for Graduate Medical Education
- 3119 or Royal College of Physicians and Surgeons of Canada or the Council
- 3120 on Postdoctoral Training of the American Osteopathic Association;

3121 and

- 3122 (b) May be obtained concurrently with the supervised work experience required
- 3123 by 7K2.1(2).

Formatted: Indent: Left: 0", First line: 0"

3124 **and**

- 3125 **7K2.32** Has provided written attestation(s), signed by a preceptor authorized user **who meets**
- 3126 **the requirements in 7K4, Appendix 7K, or equivalent Agreement State or NRC**
- 3127 **requirements,** that the individual has **satisfactorily completed the requirements in**
- 3128 **7K1, or paragraphs 7K2.1 and 7K2.2, and has** achieved a level of competency
- 3129 sufficient to function independently as an authorized user of manual brachytherapy
- 3130 sources for the medical uses authorized under 7.42.

Formatted: Font: 10 pt

Formatted: Font: 10 pt

3131 **and**

3132 **7K3 Meets the following recentness of training requirements:**

DRAFT 2 –9/15/2011

3133 7K3.1 The training and experience required by Appendix 7K shall have been obtained:
3134 within the 7 years preceding the date of license application or amendment request;

Comment [JJ79]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

3135 or

Formatted: Indent: Hanging: 0.5"

3136 7K3.2 The individual must have had related, documented, continuing education and
3137 experience since the required training and experience was obtained.

3138 or

Formatted: Font: 10 pt

3139 ~~7K4.3~~ Meets the following requirements for an experienced authorized user for 7.42 uses:Has
3140 demonstrated adequate prior experience as:

Formatted: Font: 10 pt

3141 ~~7K4.3.1~~ An individual identified as an authorized user for the medical use of radioactive
3142 material on a license issued by the NRC or Agreement State, a permit issued under
3143 an NRC or Agreement State broad scope license that authorizes medical use
3144 before October 25, 2005, who perform only those medical uses for which they were
3145 authorized on that date are not required to comply with the training requirements
3146 of 7K1 through 7K3, authorized user identified on a current facility license or permit
3147 under Appendix 7K for uses listed in Appendix 7K, or under equivalent Agreement State
3148 or NRC requirements, and has provided written attestation(s), signed by a preceptor
3149 authorized user, that the individual has achieved a level of competency sufficient to
3150 function independently as an authorized user of an manual brachytherapy source for the
3151 uses authorized under 7.42;

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

3152 or

Formatted: Font: 10 pt

3153 ~~7K3.2~~ An experienced authorized user of an manual brachytherapy source for the uses
3154 authorized under 7.42 who:

Formatted: Font: 10 pt

3155 ~~(1)~~ Was identified before October 25, 2005 (and thus need not comply with the
3156 requirements of 7K2) either on:

Formatted: Font: 10 pt

3157 ~~(a)~~ An NRC or Agreement State license; or

Formatted: Font: 10 pt

3158 ~~(b)~~ A permit issued under an NRC or Agreement State broad scope license that
3159 authorizes medical use or the practice of nuclear pharmacy;

Formatted: Font: 10 pt

Formatted: Indent: Left: 1"

Formatted: Font: 10 pt

3160 ~~(2)~~ Performs only those medical uses for which the authorized user identified in accord with
3161 7K3.2(1) was authorized on October 25, 2005.

Formatted: Indent: Left: 0.5", First line: 0",
Tab stops: 0.94", Left + Not at 1"

Formatted: Not Highlight

3162 ~~7K4.2~~ Individuals not required to comply with the training requirements of 7K1 through
3163 7K3 may serve as preceptors for, and supervisors of, applicants seeking
3164 authorization on licenses for the same uses for which these individuals are
3165 authorized.

Formatted: Font: 10 pt

Formatted: Indent: Left: 0.5"

Formatted: Font: 10 pt, Not Highlight

3166 ~~7K4~~ Training and experience required by Appendix 7K shall have been obtained:

Comment [JJ80]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

3167 ~~7K4.1~~ Within the 7 years preceding the date of license application; or

Formatted: Not Highlight

3168 ~~7K4.2~~ Through documented subsequent continuing education and experience.

Formatted: Font: 10 pt, Not Highlight

3169 ~~7K5~~ To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by
3170 NRC at <http://www.nrc.gov/materials/miau/med-use/toolkit/spec-board-cert.html>); a specialty
3171 board shall require that each candidate for certification:

Formatted: Font: 10 pt

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

- 3172 ~~7K5.1 Successfully complete a minimum of 3 years of residency training in a radiation oncology program~~
3173 ~~approved by the Residency Review Committee of the Accreditation Council for Graduate Medical~~
3174 ~~Education or Royal College of Physicians and Surgeons of Canada, or the Committee on Post-~~
3175 ~~Graduate Training of the American Osteopathic Association; and~~
- 3176 ~~7K5.2 Pass an examination, administered by diplomates of the specialty board, which tests knowledge~~
3177 ~~and competence in radiation safety, radionuclide handling, quality assurance, and clinical use of~~
3178 ~~manual brachytherapy.~~
3179

Formatted: par1

DRAFT 2 –9/15/2011

PART 7, APPENDIX 7L: AUTHORIZED USER TRAINING FOR OPHTHALMIC USE OF STRONTIUM-90 (7.42 USES) ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE

The licensee shall require an authorized user of an Strontium-90 source for ophthalmic radiotherapy authorized under 7.42 to be a physician who has a current active State of Colorado license and:

Formatted: Font: 10 pt

7L1 Is an authorized user under Appendix 7K or equivalent NRC or Agreement State requirements; and has provided written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user of strontium-90 for ophthalmic radiotherapy uses authorized under 7.42;

~~(1) Each preceptor authorized user supervising the experiential training required by Appendix 7L shall meet the requirements of Appendix 7K or Appendix 7L, or equivalent Agreement State or NRC requirements.~~

Formatted: par1

or

Formatted: Indent: Hanging: 0.5"

7L2 Has satisfied the following criteria:

7L2.1 Has satisfactorily completed 24 hours of classroom and laboratory training in basic radionuclide handling techniques specifically applicable to the medical use of strontium-90 for ophthalmic radiotherapy, including:

(1) **The training must include** At least 24 hours of classroom and laboratory training in the following areas:

- (a) Radiation physics and instrumentation;
- (b) Radiation protection;
- (c) Mathematics pertaining to the use and measurement of radioactivity;
- (d) Radiation biology;

and

Formatted: Indent: Left: 0", First line: 0"

(2) ~~Has satisfactorily completed~~ Supervised clinical training in ophthalmic radiotherapy under the supervision of an authorized user at a medical institution, clinic, or private practice that includes the use of strontium-90 for the ophthalmic treatment of five individuals, ~~that~~ **This supervised clinical training must involve** includes:

- (a) Examination of each individual to be treated;
- (b) Calculation of the dose to be administered;
- (c) Administration of the dose; and
- (d) Follow-up and review of each individual's case history;

and

Formatted: Indent: Left: 0", First line: 0"

DRAFT 2 –9/15/2011

3215 7L2.2 (3) Has provided written attestation(s), signed by a preceptor authorized user **who**
3216 **meets the requirements in 7L4, Appendix 7K, Appendix 7L, or equivalent NRC or**
3217 **Agreement State requirements**, that the individual has **satisfactorily completed the**
3218 **requirements of 7L2 and has** achieved a level of competency sufficient to function
3219 independently as an authorized user of strontium-90 for ophthalmic radiotherapy uses
3220 authorized under 7.42.

3221 and

3222 7L3 Meets the following recentness of training requirements:

3223 7L3.1 The training and experience required by Appendix 7L shall have been obtained
3224 within the 7 years preceding the date of license application or amendment request;

3225 or

3226 7L3.2 The individual must have had related, documented, continuing education and
3227 experience since the required training and experience was obtained.

3228 or

3229 7L43 Meets the following requirements for an experienced authorized user for 7.42 ophthalmic
3230 radiotherapy uses: ~~Has demonstrated adequate prior experience as:~~

3231 7L34.1 An individual identified as an authorized user for the medical use of radioactive
3232 material on a license issued by the NRC or Agreement State, a permit issued under
3233 an NRC or Agreement State broad scope license that authorizes medical use
3234 before October 25, 2005, who perform only those medical uses for which they were
3235 authorized on that date are not required to comply with the training requirements
3236 of 7L1 through 7L3, authorized user identified on a current facility license or permit under
3237 this Appendix 7L for uses listed in Appendix 7L, or under equivalent Agreement State or
3238 NRC requirements, and has provided written attestation(s), signed by a preceptor
3239 authorized user, that the individual has achieved a level of competency sufficient to
3240 function independently as an authorized user of strontium-90 for ophthalmic radiotherapy
3241 uses authorized under 7.42;

3242 or

3243 7L3.2 An experienced authorized user of strontium-90 for ophthalmic radiotherapy uses
3244 authorized under 7.42 who:

3245 (1) Was identified before October 25, 2005 (and thus need not comply with the requirements of
3246 7L2) either on:

3247 (a) An NRC or Agreement State license; or

3248 (b) A permit issued under an NRC or Agreement State broad scope license that authorizes
3249 medical use or the practice of nuclear pharmacy; and

3250 (2) Performs only those medical uses for which the authorized user identified in accord with
3251 7L3.2(1) was authorized on October 25, 2005.

3252 7L4.2 Individuals not required to comply with the training requirements of 7L1 through
3253 7L3 may serve as preceptors for, and supervisors of, applicants seeking

Comment [JJ81]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

Formatted: par2

Formatted: Indent: Hanging: 0.5"

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: par2

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Indent: Left: 0.5"

Formatted: Font: 10 pt, Not Highlight

DRAFT 2 –9/15/2011

3254 authorization on licenses for the same uses for which these individuals are
3255 authorized.

3256 ~~7L4 Training and experience required by Appendix 7L shall have been obtained:~~

3257 ~~7L4.1 Within the 7 years preceding the date of license application; or~~

3258 ~~7L4.2 Through documented subsequent continuing education and experience.~~
3259

Comment [JJ82]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are “grandfathered” may serve as preceptors for others.

(NRC RATS 2009-1; Compatibility=B)

Formatted: Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

PART 7, APPENDIX 7M: AUTHORIZED USER TRAINING FOR USE OF SEALED SOURCES IN REMOTE AFTERLOADER UNITS, TELETHERAPY UNITS, AND GAMMA STEREOTACTIC RADIOSURGERY UNITS (7.48 USES) ADEQUATE RADIATION SAFETY TRAINING AND EXPERIENCE

The licensee shall require an authorized user of a sealed source for use in a device authorized under 7.48 to be a physician who has a current active State of Colorado license and:

7M1 Is certified by a medical specialty board whose certification process has been recognized by the NRC or an Agreement State and who meets the requirements in paragraph 7M2.3 and 7M3 of this Appendix, NRC recognized specialty boards are posted on the NRC website at <http://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>. Has provided:

7M1.1 To have its certification process recognized, a specialty board shall require all candidates for certification to:

(1) Successfully complete a minimum of 3 years of residency training in a radiation therapy program approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Committee on Post-Graduate Training of the American Osteopathic Association;

and

(1) Pass an examination, administered by diplomats of the specialty board, which tests knowledge and competence in radiation safety, radionuclide handling, treatment planning, quality assurance, and clinical use of stereotactic radiosurgery, remote afterloaders and external beam therapy;

Evidence of current certification by a recognized specialty board (see 7M5); and

7M1.2 Written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user for each type of the therapeutic medical unit for which the individual is requesting authorized user status for the medical uses authorized under 7.48;

(1) Each preceptor authorized user supervising the experiential training required by Appendix 7M shall meet the requirements of this Appendix 7M, or equivalent Agreement State or NRC requirements.

or

7M2 Has satisfied the following criteria:

7M2.1 Has provided written attestation(s), signed by a preceptor authorized user, that the individual has satisfactorily completed 700 total hours in a structured educational program in basic radionuclide handling techniques applicable to the medical use of sealed sources in a therapeutic medical unit remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units, that includes:

(1) At least 200 hours of classroom and laboratory training in the following areas:

(a) Radiation physics and instrumentation;

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Tab stops: 1.25", Left + Not at 1.5"

Formatted: Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 1" + Indent at: 1.25", Tab stops: 1.25", Left + Not at 1.5"

Formatted: par2

Formatted: Indent: Hanging: 0.5"

DRAFT 2 –9/15/2011

- 3299 (b) Radiation protection;
- 3300 (c) Mathematics pertaining to the use and measurement of radioactivity;
- 3301 (d) Radiation biology;
- 3302 and
- 3303 (2) 500 hours of supervised work experience, **under the supervision of an authorized**
- 3304 **user who meets the requirements in 7M5, Appendix 7M, or equivalent**
- 3305 **Agreement State or NRC requirements at a medical institution, involving:**
- 3306 (a) Reviewing full calibration measurements and periodic spot checks;
- 3307 (b) Preparing treatment plans and calculating treatment doses and times;
- 3308 (c) Using administrative controls to prevent a misadministration involving the use
- 3309 of **unsealed**-radioactive material;
- 3310 (d) Implementing emergency procedures to **be** followed in the event of the
- 3311 abnormal operation of the medical unit or console;
- 3312 (e) Checking and using survey meters; and
- 3313 (f) Selecting the proper dose and how it is to be administered;

3314 **and**

3315 **7M2.2 Has completed 3 years of supervised clinical experience in radiation therapy, under**

3316 **an authorized user who meets the requirements in 7M5, Appendix 7M, or**

3317 **equivalent Agreement State or NRC requirements, as part of a formal training**

3318 **program approved by the Residency Review Committee for Radiation Oncology of**

3319 **the Accreditation Council for Graduate Medical Education or the Royal College of**

3320 **Physicians and Surgeons of Canada or the Committee on Postdoctoral Training of**

3321 **the American Osteopathic Association. This experience may be obtained**

3322 **concurrently with the supervised work experience required by paragraph 7M2.1(2)**

3323 **of this section;**

3324 **and**

3325 7M2.32 **Has provided written attestation(s), ~~signed by a preceptor authorized user,~~ that the**

3326 **individual has satisfactorily completed ~~the requirements of 7M1 or 7M2.1 and 7M2.2,~~**

3327 **and 7M3, and has achieved a level of competency sufficient to function**

3328 **independently as an authorized user of each type of therapeutic medical unit for**

3329 **which the individual is requesting authorized user status. The written attestation**

3330 **must be signed by a preceptor authorized user who meets the requirements in**

3331 **7M5, Appendix 7M, or equivalent Agreement State or NRC requirements for an**

3332 **authorized user for each type of therapeutic medical unit for which the individual is**

3333 **requesting authorized user status;**

3334 **and**

3335 **7M3 Has received training in device operation, safety procedures, and clinical use for the type(s) of**

3336 **use for which authorization is sought, ~~that:~~ This training requirement may be satisfied by:**

Formatted: Font: 10 pt

Formatted: Indent: Left: 0.5"

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Font: 10 pt

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0", First line: 0"

DRAFT 2 –9/15/2011

3337 (1) Includes:

3338 (a) Hands-on device operation;

3339 (b) Safety procedures;

3340 (c) Clinical use; and

3341 (d) Treatment planning system operation; and

3342 (2) Is provided by either:

3343 **7M3.1(a)** Satisfactorily completing a vendor training program;

3344 or

3345 **7M3.2(b)** By receiving training Being supervised by an **authorized user** or authorized medical

3346 physicist, **as appropriate, who is** authorized for the type(s) of use for which the

3347 individual is seeking authorization;

3348 ~~7M2.3 Or has completed 3 years of supervised clinical experience in radiation therapy, under~~

3349 ~~the supervision of an authorized user who meets the requirements of this Appendix 7M,~~

3350 ~~or equivalent Agreement State or NRC requirements, provided that the experience:~~

3351 (1) Is part of a formal training program approved by the Residency Review Committee of

3352 the Accreditation Council for Graduate Medical Education or Royal College of

3353 Physicians and Surgeons of Canada, or the Committee on Post-Graduate

3354 Training of the American Osteopathic Association; and

3355 (2) May be obtained concurrently with the supervised work experience required by

3356 7M2.4(2); and

3357 7M2.4 Has provided written attestation(s), signed by a preceptor authorized user, that the

3358 individual has achieved a level of competency sufficient to function independently as an

3359 authorized user for each type of the therapeutic medical unit for which the individual is

3360 requesting authorized user status for the medical uses authorized under 7.48.

3361 and

3362 **7M4 Meets the following recentness of training requirements:**

3363 **7M4.1 The training and experience required by Appendix 7M shall have been obtained**

3364 **within the 7 years preceding the date of license application or amendment request;**

3365 or

3366 **7M4.2 The individual must have had related, documented, continuing education and**

3367 **experience since the required training and experience was obtained.**

3368 or

3369 **7M53 Meets the following requirements for an experienced authorized user, for 7.48 uses, Has**

3370 **demonstrated adequate prior experience as:**

Formatted: par3

Formatted: par3, Indent: Left: 1"

Comment [JJ83]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

Formatted: Indent: Left: 0.5", Hanging: 0.5", Tab stops: Not at 0.5"

Formatted: Indent: Hanging: 0.5", Tab stops: Not at 0.5"

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

Formatted: Font: 10 pt, Not Highlight

Formatted: Font: 10 pt

DRAFT 2 –9/15/2011

3371
3372
3373
3374
3375
3376
3377
3378
3379
3380
3381
3382

~~7M53.1~~ An individual identified as an authorized user for the medical use of radioactive material on a license issued by the NRC or Agreement State, a permit issued under an NRC or Agreement State broad scope license that authorizes medical use before October 25, 2005, who perform only those medical uses for which they were authorized on that date are not required to comply with the training requirements of 7M1 through 7M4. authorized user identified on a current facility license or permit under Appendix 7M for uses listed in Appendix 7M, or under equivalent Agreement State or NRC requirements, and has provided written attestation(s), signed by a preceptor authorized user, that the individual has achieved a level of competency sufficient to function independently as an authorized user for each type of the therapeutic medical unit for which the individual is requesting authorized user status for the medical uses authorized under 7.48;

Formatted: Font: 10 pt
Formatted: Font: 10 pt, Not Highlight
Formatted: Font: 10 pt
Formatted: Font: 10 pt, Not Highlight
Formatted: Font: 10 pt

3383

~~or~~

Formatted: Font: 10 pt
Formatted: Indent: Hanging: 0.5"
Formatted: Font: 10 pt

3384
3385

~~7M3.2~~ An experienced authorized user of the therapeutic medical unit authorized under 7.48 who:

3386
3387

~~(1) Was identified before October 25, 2005 (and thus need not comply with the requirements of 7M2) either on:~~

Formatted: Font: 10 pt

3388

~~(a) An NRC or Agreement State license; or~~

Formatted: Font: 10 pt

3389
3390

~~(b) A permit issued under an NRC or Agreement State broad scope license that authorizes medical use or the practice of nuclear pharmacy;~~

Formatted: Font: 10 pt
Formatted: Indent: Left: 1"

3391
3392

~~(2) Performs only those medical uses for which the authorized user identified in accord with 7M3.2(1) was authorized on October 25, 2005.~~

Formatted: Font: 10 pt

3393
3394
3395
3396

~~7M5.2~~ Individuals not required to comply with the training requirements of 7M1 through 7M4 may serve as preceptors for, and supervisors of, applicants seeking authorization on licenses for the same uses for which these individuals are authorized.

Formatted: Font: 10 pt, Not Highlight
Formatted: Font: 10 pt
Formatted: Font: 10 pt, Not Highlight
Formatted: par3, Indent: Left: 1"

3397

~~7M54~~ Training and experience required by Appendix 7M shall have been obtained:

3398

~~7M54.1~~ Within the 7 years preceding the date of license application; or

3399

~~7M54.2~~ Through documented subsequent continuing education and experience.

Comment [JJ84]: Additional language added to be compatible with 10 CFR 35.57 (c). This provision effectively allows or clarifies that experienced individuals who are "grandfathered" may serve as preceptors for others.
(NRC RATS 2009-1; Compatibility=B)

3400
3401
3402

~~7M5~~ To be recognized by an Agreement State or the U.S. Nuclear Regulatory Commission (posted by NRC at <http://www.nrc.gov/materials/miau/med-use/toolkit/spec-board-cert.html>), a specialty board shall require that each candidate for certification:

Formatted: Not Highlight
Formatted: Font: 10 pt, Not Highlight
Formatted: Font: 10 pt
Formatted: Font: 10 pt
Formatted: Font: 10 pt

3403
3404
3405
3406

~~7M5.1~~ Successfully complete a minimum of 3 years of residency training in a radiation therapy program approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or Royal College of Physicians and Surgeons of Canada, or the Committee on Post-Graduate Training of the American Osteopathic Association;

3407
3408
3409
3410

~~7M5.2~~ Pass an examination, administered by diplomates of the specialty board, which tests knowledge and competence in radiation safety, radionuclide handling, treatment planning, quality assurance, and clinical use of stereotactic radiosurgery, remote afterloaders and external beam therapy.

DRAFT 2 –9/15/2011

3411 **PART 7, APPENDIX 7N: NUCLEAR MEDICINE TECHNOLOGIST (NMT) ADEQUATE RADIATION**
3412 **SAFETY TRAINING AND EXPERIENCE**

Comment [JJ85]: There is no equivalent section to Appendix N in 10 CFR Part 35. The NRC does not recognize nuclear medicine technologists in regulation or guidance. The CRCPD has not finalized SSRCR Part Z for training requirements for NMTs, and therefore the current section is not being changed significantly.

3413 **The licensee shall require the nuclear medicine technologist using radioactive materials under the**
3414 **supervision of an authorized user to be an individual who:**

3415 **7N1** Has provided:

3416 7N1.1 Evidence of:

3417 (1) Current registration with The American Registry of Radiologic Technologists with
3418 competency in Nuclear Medicine (ARRT(N));

3419 or

3420 (2) Current certification by The Nuclear Medicine Technology Certification Board in
3421 Nuclear Medicine (CNMT);

3422 or

3423 (3) Being board-eligible to take the CNMT or ARRT(N) examination;

3424 or

3425 (4) Current certification by a recognized specialty board (see 7N5);

3426 and

Formatted: Indent: Left: 0.5"

3427 7N1.2 Has provided written attestation(s), signed by a preceptor authorized user, that the
3428 individual has achieved a level of competency sufficient to function independently as a
3429 nuclear medicine technologist;

3430 (1) Each preceptor authorized user supervising the experiential training required by
3431 Appendix 7N shall meet the requirements of Appendix 7N, or equivalent
3432 Agreement State or NRC requirements.

3433 or

Formatted: Indent: Hanging: 0.5"

3434 **7N2** Has satisfied the following criteria:

3435 7N2.1 Has provided written attestation(s), signed by a preceptor authorized user, that the
3436 individual has satisfactorily completed 80 hours in a structured educational program in
3437 basic radionuclide handling techniques applicable to the medical use of unsealed
3438 radioactive materials, including:

3439 (1) Classroom and laboratory training in the following areas:

3440 (a) Radiation physics and instrumentation;

3441 (b) Radiation protection;

3442 (c) Mathematics pertaining to the use and measurement of radioactivity;

3443 (d) Chemistry of radioactive material for medical use; and

DRAFT 2 –9/15/2011

- 3444 (e) Radiation biology; and
- 3445 (2) Work experience, involving:
- 3446 (a) Ordering, receiving, and unpacking radioactive materials safely and
- 3447 performing the related radiation surveys;
- 3448 (b) Quality Control checking of instruments used to determine the activity of
- 3449 dosages and performing checks for proper operation of survey meters;
- 3450 (c) Calculating, measuring, and safely preparing patient or human research
- 3451 subject dosages;
- 3452 (d) Using administrative controls to prevent a misadministration involving the use
- 3453 of unsealed radioactive material;
- 3454 (e) Using procedures to contain spilled radioactive material safely and using
- 3455 proper decontamination procedures; and
- 3456 (f) Administering dosages to patients or human research subjects;

3457 7N2.2 Has provided written attestation(s), signed by a preceptor authorized user, that the

3458 individual has achieved a level of competency sufficient to function independently as a

3459 nuclear medicine technologist;

3460 or

Formatted: Indent: Hanging: 1"

3461 **7N3** Has demonstrated adequate prior experience as:

3462 7N3.1 A full-time nuclear medicine technologist for a minimum of two years performing during the

3463 past five-year period under the supervision of an authorized user and has provided

3464 written attestation(s), signed by a preceptor authorized user, that the individual has

3465 achieved a level of competency sufficient to function independently as a nuclear medicine

3466 technologist;

3467 or

Formatted: Indent: Hanging: 0.5"

3468 7N3.2 An experienced nuclear medicine technologist working at a facility holding a Department

3469 license before October 25, 2005 (and thus need not comply with the requirements of

3470 7N2);

3471 **7N4 Meets the following recentness of training requirements:** ~~Training and experience required by~~

3472 ~~Appendix 7N shall have been obtained.~~

3473 7N4.1 **The training and experience required by Appendix 7N shall have been obtained**

3474 ~~W~~within the 7 years preceding the date of license application **or amendment request;**

Comment [JJ86]: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

3475 or

3476 7N4.2 **The individual must have had related,** ~~Through~~ documented, ~~subsequent~~ continuing

3477 education and experience **since the required training and experience was obtained.**

3478 **7N5** To be recognized by the Department, a specialty board shall require that each candidate for

3479 certification as a nuclear medicine technologist satisfactorily complete a certification process that

3480 includes all of the training requirements in 7N2.1.

DRAFT 2 –9/15/2011

3481 **PART 7, APPENDIX 7O: RADIATION THERAPY TECHNOLOGIST (RTT) ADEQUATE RADIATION**
3482 **SAFETY TRAINING AND EXPERIENCE**

3483 **The licensee shall require the radiation therapy technologist using radioactive materials under the**
3484 **supervision of an authorized user to be an individual who:**

3485 **7O1** Has provided:

3486 7O1.1 Evidence of:

- 3487 (1) Current registration with The American Registry of Radiologic Technologists with
3488 competency in Radiation Therapy;
- 3489 or
- 3490 (2) Current certification by a recognized specialty board (see 7O5);
- 3491 or
- 3492 (3) Being board-eligible to take the ARRT(T) examination;
- 3493 or
- 3494 (4) Having successfully completed a training program in radiation therapy which has
3495 resulted in a certificate, associate degree, or baccalaureate degree in a
3496 radiologic technology program that complies with the requirements of the Joint
3497 Review Committee on Education in Radiologic Technology (consult the
3498 *Essentials and Guidelines of an Accredited Educational Program for the*
3499 *Radiation Therapy Technologist*, Joint Review Committee on Education in
3500 Radiologic Technology, 1988);

3501 and

3502 7O1.2 Written attestation(s), signed by a preceptor authorized user, that the individual has
3503 achieved a level of competency sufficient to function independently as a radiation therapy
3504 technologist;

- 3505 (1) Each preceptor authorized user supervising the experiential training required by
3506 Appendix 7O shall meet the requirements of Appendix 7O, or equivalent
3507 Agreement State or NRC requirements.

3508 or

3509 **7O2** Has satisfied the following criteria:

3510 7O2.1 Has provided written attestation(s), signed by a preceptor authorized user, that the
3511 individual has satisfactorily completed 80 hours in a structured educational program in
3512 basic radionuclide handling techniques applicable to the medical use of unsealed
3513 radioactive materials, including:

3514 (1) Classroom and laboratory training in the following areas:

3515 (a) Radiation physics and instrumentation;

3516 (b) Radiation protection;

Comment [JJ87]: There is no equivalent section to Appendix O in 10 CFR Part 35. The NRC does not recognize radiation therapy technologists in regulation or guidance. The CRCPD has not finalized SSRCR Part Z for training requirements for Radiation Therapy Technologists, and therefore the current section is not being changed significantly.

Formatted: Indent: Left: 0.5"

Formatted: Indent: Hanging: 0.5"

DRAFT 2 –9/15/2011

- 3517 (c) Mathematics pertaining to the use and measurement of radioactivity;
3518 (d) Radiation biology;
3519 and
3520 (2) Work experience, involving:
3521 (a) Ordering, receiving, and unpacking radioactive materials safely and
3522 performing the related radiation surveys;
3523 (b) Assisting the authorized user in simulating the patient for treatment;
3524 (c) Preparing the patient for treatment;
3525 (d) Implementing treatment plans as prescribed by the authorized user;
3526 (e) Providing written documentation of treatment setup and patient treatments;
3527 (f) Quality control checks to determine that devices used to deliver the radiation
3528 doses are in compliance with institutional standards and performing
3529 checks for proper operation of survey meters;
3530 (g) Preparing or assisting in the preparation of sources, and implantation and
3531 removal of sealed sources;
3532 (h) Delivering doses to patients or human research subjects under the
3533 supervision of the authorized user;
3534 (i) Maintaining running inventories of radioactive material on hand;
3535 (j) Using administrative controls to prevent a misadministration involving the use
3536 of radioactive material; and,
3537 (k) Properly implementing emergency procedures;
3538 702.2 Has provided written attestation(s), signed by a preceptor authorized user, that the
3539 individual has achieved a level of competency sufficient to function independently as a
3540 radiation therapy technologist;
3541 or
3542 **703** Has demonstrated adequate prior experience as:
3543 703.1 A full-time radiation therapy technologist for a minimum of two years performing during the
3544 past five-year period under the supervision of an authorized user and has provided
3545 written attestation(s), signed by a preceptor authorized user, that the individual has
3546 achieved a level of competency sufficient to function independently as a radiation therapy
3547 technologist;
3548 or
3549 703.2 An experienced radiation therapy technologist working at a facility holding a Department
3550 license before October 25, 2005 (and thus need not comply with the requirements of
3551 702);

Formatted: Indent: Left: 1"

Formatted: Indent: Hanging: 1"

Formatted: Indent: Hanging: 0.5"

DRAFT 2 –9/15/2011

3552 **704** ~~Meets the following recentness of training requirements:~~ Training and experience required by
3553 ~~Appendix 7O shall have been obtained:~~

3554 704.1 ~~The training and experience required by Appendix 7O shall have been obtained~~
3555 ~~W~~within the 7 years preceding the date of license application ~~or amendment request;~~

3556 or

3557 704.2 ~~The individual must have had related,~~ Through documented, ~~subsequent~~ continuing
3558 education and experience ~~since the required training and experience was obtained.~~

Comment [JJ88]: JJ 6/21/2011: The term "or amendment request" is added for clarity, since many additions of authorized users occur during license amendment requests as well as during license applications.

3559 **705** To be recognized by the Department, a specialty board shall require that each candidate for
3560 certification as a radiation therapy technologist satisfactorily complete a certification process that
3561 includes all of the training requirements in 702.1.

3562

3563 **EDITOR'S NOTES**

3564 6 CCR 1007-1 has been divided into smaller sections for ease of use. Versions prior to 4/1/07 and rule
3565 history are located in the first section, 6 CCR 1007-1. Prior versions can be accessed from the History link
3566 that appears above the text in 6 CCR 1007-1. To view versions effective on or after 4/1/07, Select the
3567 desired part of the rule, for example 6 CCR 1007-1 Part 1 or 6 CCR 1007-1 Parts 8 - 10.

3568 **History**

3569 *[For history of this section, see Editor's Notes in the first section, 6 CCR 1007-1]*